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Abstract 
Heparan sulphate (HS) plays crucial roles during the genesis and resolution of inflammation 
by sequestration, stabilization and presentation of proinflammatory cytokines and growth 
factors.  The interaction between many of these factors and HS is critically dependent on the 
variable distribution of anionic 6-O-sulphated glucosamine residues within the structure of 
HS.  The pattern of 6-O-sulphation is generated during HS biosynthesis by HS-6-O-
sulphotransferases (HS6STs) but can be modified later by cell-surface HS-6-O-
endosulphatases (SULFs).  This study was designed to examine the potential contribution of 
these enzyme families to renal fibrosis following chronic inflammation.   
Initial experiments showed that the fibrogenic cytokine TGF-β induced SULF2 expression by 
renal tubular epithelial cells. Immortalized renal tubular epithelial cells were transfected to 
constitutively overexpress either HS6ST1 or SULF2 in order to examine the effect of these 
enzymes on cytokine function.  Cells which overexpressed HS6ST1 showed increased 
binding of FGF2 compared to mock transfected control cells; this FGF2 binding correlated 
with increased pERK expression and enhanced cell proliferation.  The requirement for HS for 
these processes was validated by inhibition of FGF2 binding with soluble HS, heparin or 
heparitinase III, whilst the importance of HS sulphation for increased binding was 
demonstrated after treatment of the cells with chlorate. Structural analysis of 
35
S-labelled HS 
from HS6ST1 overexpressing cells demonstrated an increase in mono-6-O-sulphated 
disaccharides accompanied by a decrease in 2-O-sulphated iduronic acid. By contrast, SULF2 
transfectants showed reduced FGF2 binding, ERK activation and proliferation. Structural 
analysis of 
35
S-labelled HS from these cells showed a 50% reduction in 6-O-sulphation with a 
parallel increase in mono-2-O-sulfated iduronic acid. 
The significance of the in vitro study for renal fibrosis was then examined using a murine 
unilateral ureteric obstruction (UUO) model.  Immunochemical analysis of UUO kidney 
sections showed a significant increase in expression of epitopes containing N- and 6-O 
sulphated HS around the renal tubules.  This change was accompanied by a 5-fold increase in 
expression of the SULF1 gene.  In summary, this study suggests that modulation of the 
expression of sulphate at the 6-O position in HS plays a significant role in the progression of 
chronic renal fibrosis by alteration of the biological activity of fibrogenic growth factors. 
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1.1 Background to this study 
This thesis addresses the role of heparan sulphate (HS) in the etiology of chronic 
renal allograft rejection.  The main reason for losing a transplanted kidney is 
chronic rejection which is a complex process that involves inflammation and ends in 
graft dysfunction.  Infiltrating leucocytes, endothelial and epithelial cells, cytokines 
and chemokines all play key role in this process.  Heparan sulphate is ubiquitously 
expressed on all mammalian cell surfaces and the extracellular matrix.  Heparan 
sulphate can interact with many factors of relevance to graft failure.  The sulphation 
of heparan sulphate plays a crucial role in determining its biological activity.  
Sulphation of heparan sulphate is a multi-step process which is performed 
specifically by different modifying enzymes.  Loss or gain of sulphation affects the 
binding, binding affinity and signalling pathway of growth factor-receptor 
interactions.  Better understanding of the roles of heparan sulphate in allograft 
dysfunction might help in improving and maintaining long term allograft survival. 
1.2 Transplantation and inflammatory response 
Allogenic transplantation initiates a complex and multi-level immune response 
which recognizes the non-self organ in an initial step that precedes graft damage 
and rejection. Renal transplantation may result in severe inflammatory response 
because of ischemia–reperfusion injury despite recipient-donor major 
histocompatibility complex (MHC) matching (Ysebaert et al., 2000).  Graft damage 
can be classified into several levels depending on time and type of immune 
response.   
1.3 Transplant rejection 
Organ allogenic transplantation is the final therapy for end-stage organ failure.  
Many organs can be transplanted including kidney, liver, heart and pancreas.  The 
first successful human kidney transplant operation took place in 1954 between 
identical twin brothers in Boston, USA and was performed by Dr. J Murray 
(Murray, 2002).  Organ transplantation is now performed more routinely between 
genetically different recipients and donors.  Although cross-matching tests are 
performed before transplantation, several anti-mitotic and immunosuppressive drugs 
need to be given to recipients in order to avoid rejection.  The transplanted organ is 
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susceptible to different types of rejection depending on time of rejection, 
mechanisms and mediators involved (Terasaki, 2003). 
1.3.1 Hyperacute rejection 
Hyperacute rejection occurs minutes after transplantation, and is usually mediated 
by pre-formed anti-donor human leucocyte antigen (HLA)-specific antibodies 
(Kissmeyer-Nielsen et al., 1966; Sumitran-Holgersson, 2001).  These antibodies 
recognize graft antigens and activate the complement system.  Due to cross 
matching and tissue typing of major histocompatibility molecules (MHC) and ABO, 
this type of rejection is limited nowadays. 
1.3.2 Acute rejection 
Acute allograft rejection takes place weeks after transplantation due to mismatching 
between recipient anti-HLA antibodies and donor tissues.  Acute renal allograft 
rejection is considered both a T cell-mediated (cellular response) and an antibody-
mediated process (humoral response) (Le Moine et al., 2002; Terasaki, 2003).  
Graft cells are exposed to a specific T-cell mediated immune response initiated by 
the release of a range of pro-inflammatory cytokines such as interferon-γ (IFN-γ), 
interleukin-2 (IL-2) and IL-4.  After recognizing allograft antigens, CD4
+ 
T cells 
can differentiate into Th1, Th2 or Th17 subsets which secrete pro-inflammatory 
cytokines that stimulate additional activities such as T cell proliferation and 
antibody secretion.  These activities consistently lead to an inflammatory response, 
leukocyte infiltration and tissue damage (Flach et al., 1998).   
The humoral response produces alloantibodies against mismatched MHC 
molecules, ABO antigens and endothelial cells (Win and Pettigrew, 2010).  
Antibodies against donor tissue are involved in acute and chronic rejection 
(Terasaki and Cai, 2008). 
1.3.3 Chronic rejection (CR) 
Chronic allograft rejection constitutes the primary cause of graft loss which often 
occurs even in cases of high compatibility between donor and recipient.  Chronic 
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rejection takes place months or years after transplantation due to the effect of 
factors which lead to a loss of graft function.  
Recognition of donor antigens leads to a severe reaction towards graft cells and 
causes decreased long-term survival.  The incidence of acute rejection and 
intratubular infiltration of T cells constitutes one of the most serious reasons for CR 
(Robertson et al., 2004).  Graft damage is usually accompanied by T cell infiltration 
and proinflammatory cytokine secretion (Waaga et al., 2000).   
Chronic renal rejection constitutes the end stage of chronic vascular, glomerular and 
interstitial inflammation.  Tubules and the interstitium form about 90% of the 
kidney volume, which correlates with kidney function (Nath, 1998).  A transplanted 
graft undergoing chronic rejection displays features similar to what is seen in wound 
healing.  These include epithelial cell proliferation, collagen deposition, tubular 
atrophy (TA) and interstitial fibrosis (IF) which lead finally to the loss of graft 
function (Racusen et al., 2002; Cornell and Colvin, 2005; Solez et al., 2007).  In 
addition to tubulointerstitial fibrosis, loss of nephrons and intimal thickening of 
small arteries has been observed (Gourishankar and Halloran, 2002).  Renal fibrosis 
is divided into three phases: the induction, inflammation and post-inflammatory 
phase as summarized in table 1.1 (Strutz and Neilson, 2003).  
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 Table 1.1, Mechanisms of fibrosis (table adapted from Strutz et al., 2003). 
1.3.3.1 Induction phase 
In the induction phase, the main feature is the infiltration of mononuclear cells into 
the interstitial space.  These cells can be located either between tubular epithelial 
cells or between the epithelial cells and the tubular basement membrane causing 
tubulitis (Ivanyi and Olsen, 1995).  The level of infiltration is correlated with renal 
function in many diseases (Alexopoulos et al., 1990).  T cell influx is supported by 
a variety of chemokines and proinflammatory cytokines which are secreted by renal 
epithelial cells.  For example, the expression of TNF-α and IL-1 is upregulated in 
glomerular inflammatory diseases and interstitial fibrosis (Strutz and Neilson, 
1994).  
1.3.3.2 Inflammatory phase 
The basic feature of this phase is the secretion of profibrotic cytokines by infiltrated 
cells leading to matrix synthesis and graft fibrosis.  Various cytokines have been 
shown to promote fibrogenic mechanisms during chronic rejection.  These include 
angiotensin II, fibroblast growth factor 2 (FGF2) and TGF-β along with additional 
cytokines such as platelet derived growth factor (PDGF) and epidermal growth 
factor (EGF) (Strutz and Neilson, 2003).   
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The most important factor in chronic rejection is TGF-β.  This plays significant 
roles in stimulation of epithelial mesenchymal transformation (EMT), 
transformation of fibroblasts to myofibroblasts and synthesis of extracellular matrix 
(ECM) proteins such as fibronectin and collagen-I.  An experimental model of 
TGF-β transgenic mice developed glomerulosclerosis and interstitial fibrosis (Kopp 
et al., 1996).  A high concentration of TGF-β is always accompanied by fibrosis in 
solid organs such as kidney, liver and lung (Border and Noble, 1994).  TGF-β gene 
expression is increased in acute rejection and chronic allograft nephropathy 
(Pribylova-Hribova et al., 2006).  One important cytokine is angiotensin II which 
induces TGF-β synthesis in renal epithelial cells and fibroblasts (Eddy, 2000).  
Angiotensin II has the capability to induce ECM proteins such as collagen in 
interstitial fibrosis in vitro (Ruiz-Ortega and Egido, 1997).   
In addition, FGF2 constitutes an important mitogen for renal fibroblasts.  Induction 
of FGF2 produces glomerulosclerosis and interstitial fibrosis in rats (Kriz et al., 
1995).  
1.3.3.3 Post-inflammatory phase 
In this phase the inflammatory process is limited to a few areas whereas matrix 
synthesis and deposition is still in progress.  The main feature is the proliferation of 
interstitial fibroblasts.  The origin of fibroblasts in the kidney has been a matter of 
controversy.  There is strong evidence that these cells originate from bone marrow 
derived precursors (Pereira et al., 1998; Abe et al., 2001).  However, some of these 
cells are derived from resident renal epithelial cells which are undergoing 
mesenchymal transition (Ng et al., 1998; Lan, 2003).  It has been demonstrated that 
about 12% of fibroblasts originate from bone marrow, 30% are derived as a 
consequence of EMT in mice kidney, about 35% from endothelial to mesenchymal 
cell transformation and the remaining are thought to originate from resident 
fibroblasts or other mesenchymal cells (Kalluri and Neilson, 2003; Zavadil and 
Bottinger, 2005).  Fibrogenesis continues during this phase by various mechanisms 
including ongoing stimulation of fibroblasts by an autocrine loop between 
fibroblasts and cytokines (Lonnemann et al., 1995).  Interaction between epithelial 
cells and fibroblasts may provide an additional driver of the fibrogenesis process.   
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Several factors have been shown to play a major role in the etiology of tubular 
atrophy/interstitial fibrosis (TA/IF) including TGF-β, tumor necrosis factor-α (TNF-
α) and FGF2 (Mohamed et al., 2000; Waaga et al., 2000).  TGF-β is upregulated 
during renal rejection; indeed TGF-β plays a major role in the induction of EMT in 
the kidney in association with FGF2 which stimulates the proliferation of renal 
fibroblasts (Robertson et al., 2001; Strutz et al., 2001).  Furthermore, FGF2 
expression has been increased in fibrotic kidney particularly in interstitial and 
tubular cells (Strutz et al., 2000; Strutz et al., 2002).  FGF2 stimulates the release of 
latent TGF-β from proximal tubules (Phillips et al., 1997).  In turn TGF-β 
stimulates the synthesis and secretion of FGF2 from cortical fibroblasts (Strutz et 
al., 2001).  The main pathology in chronic rejection is tubulointerstitial fibrosis (IF) 
in association with loss of nephrons and intimal thickening of small arteries 
(Gourishankar and Halloran, 2002).  This fibrosis results mainly from the effect of 
fibroblasts which in turn, result from epithelial cells undergoing EMT (Lan, 2003).   
1.3.3.4 Epithelial mesenchymal transition (EMT)  
Epithelial mesenchymal transition is a process that involves transformation of 
polarized epithelial cells into migratory mesenchymal cells.  Epithelial cells loose 
many of their phenotyping features such as polarity and exhibit reduced expression 
of E-cadherin.  At the same time these cells acquire a new mesenchymal phenotype 
such as spindle-shaped morphology and become more isolated and motile, invasive 
and more resistant to apoptosis with increased production of ECM molecules 
(Kalluri and Neilson, 2003; Klymkowsky and Savagner, 2009).  At the end of EMT, 
newly transformed cells migrate through the underlying basement membrane and 
accumulate in the interstitial spaces of tissues (Okada et al., 1996).  
The EMT process is crucial for biological activities such as embryonic 
development, wound healing and tissue repair (type-I EMT), (Acloque et al., 2009).  
Another kind of EMT is involved in cancer progression and metastasis (type-III 
EMT) (Brabletz et al., 2001; Thiery, 2002; Fidler and Poste, 2008).  In fibrosis, 
epithelial cells undergo type-II EMT and become fibroblasts after chronic 
inflammation accompanied with the effects of several cytokines.  Endothelial cells 
can also undergo type-II EMT in the heart and kidney (Zeisberg et al., 2007a; 
Zeisberg et al., 2008).  For example, endothelial cells from microvasculature were 
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shown to undergo mesenchymal transformation (EndMT) during fibrosis (Potenta et 
al., 2008). 
EMT is induced by stimulation by several factors which lead to the expression of 
specific proteins on the cell surface, activation of transcription factors, production 
of ECM degradation enzymes and expression of cytoskeletal proteins (Kalluri and 
Weinberg, 2009).  Several antigens have been used to characterize type-II EMT.  
These include fibroblast-specific protein 1 (FSP1), α-smooth muscle actin (α-SMA) 
and collagen-I (Strutz et al., 1995; Zeisberg et al., 2003).   
FSP1 is considered a typical marker of EMT in fibrogenesis (Iwano et al., 2002).  
FSP1 (also known as S100A4 in human), a member of Ca
+2
 binding S100 family, is 
considered a cytoskeletal marker for EMT (Rygiel et al., 2010).  This marker is 
expressed early in epithelial cells undergoing EMT.  It has been shown that more 
than one third of FSP1, in transgenic mice, is produced in EMT-derived cells in 
kidney or liver fibroblasts (Iwano et al., 2002; Zeisberg et al., 2007b).  α-SMA also 
constitutes a marker which is normally expressed in vascular smooth muscles and 
myoepithelial cells (Gabbiani et al., 1981).  In type-II EMT, α-SMA is generally 
associated with myofibroblasts (Zeisberg and Neilson, 2009).  
1.3.3.5 Renal epithelial cells in chronic rejection 
Renal epithelial cells play pivotal roles in renal function in both health and disease.  
These cells are found in the lining layer of tubules, collecting ducts and urinary 
tracts.  There is strong evidence that proximal tubular epithelial cells constitute a 
source of FGF2 and TGF-β (Phillips et al., 1997; Jones et al., 1999).  In 
fibrogenesis, epithelial cells are exposed to the effects of proteinuria and cytokines.   
Increased tubular expression of adhesion molecules such as intracellular adhesion 
molecule-1 (ICAM-1) and/or vascular cell adhesion molecule-1 (VCAM-1) is 
correlated with interstitial infiltrates in the context of inflammatory response and 
renal fibrosis (Roy-Chaudhury et al., 1996).  Stimulation of renal epithelial cells 
with IFN-γ induces the expression of MHC-II molecules (Wuthrich et al., 1990).  
Tubular epithelial cells are able to stimulate T cells by expressing MHC-II 
molecules and thereafter, working as antigen presenting cells (Banu and Meyers, 
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1999).  MHC-II expression was shown to localize specifically in areas of 
mononuclear infiltration and damage (Halloran et al., 1988; Wuthrich et al., 1989).   
Activated fibroblasts are essential effectors in renal fibrogenesis.  These cells can be 
converted to contractile myofibroblasts which express α-SMA (Okada et al., 1997).   
Epithelial cells have the ability to synthesize chemoattractants such as RANTES 
(Regulated on Activation Normal T Cell Expressed and Secreted) and monocyte 
chemoattractant protein-1 (CCL2) which facilitate macrophage infiltration into the 
tubulointerstitial space (Remuzzi and Bertani, 1998).  By production of these 
factors, epithelial cells are an essential component in the pathogenesis of renal 
inflammation and fibrosis (Phillips et al., 1997).   
1.4 The extracellular matrix  
Renal fibrosis is characterized by excessive deposition and accumulation of 
extracellular matrix components such as collagen, fibronectin, laminin and 
proteoglycans (Eddy, 2000).  Cytokines involved in chronic renal dysfunction are 
also involved in generating ECM components such as TGF-β (Creely et al., 1992).  
ECM components are generated by cytokine-stimulated mesangial cells, fibroblasts 
and tubular epithelial cells (Okada et al., 2000).  The increase in collagens and 
fibronectin is also accompanied by increased proteoglycan secretion following 
stimulation of keratocytes with TGF-β (Funderburgh et al., 2001). 
1.5 Heparan sulphate proteoglycans (HSPG) 
Proteoglycans are complex molecules composed of central domains called core 
proteins which are covalently attached to one or more oligosaccharide chains of 
glycosaminoglycan (GAGs).  The core protein has crucial role in determining 
proteoglycan functions and regulation of activities such as cell adhesion and HS 
shedding (Bernfield et al., 1999; Saoncella et al., 1999).  Depending on the core 
proteins and GAG chains, proteoglycans are divided into three major groups: 
chondroitin/dermatan sulphate proteoglycans (CSPGs), heparin /heparan sulphate 
proteoglycans (HSPGs) and keratan sulphate proteoglycans (KSPGs).  
CS-GAGs are composed of galactosamine (GalN) and either glucuronic or iduronic 
acid (IdoA) whereas the basic component of HS is glucosamine (GlcN) and 
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glucuronic/iduronic acid.  KS is composed of disaccharide units of glucosamine and 
galactose (Gal) (Gallagher et al., 1990).  
HSPGs are categorized in three subfamilies:  
The first group contains membrane spanning proteoglycans such as syndecans, 
betaglycans and CD44.  The second group contains membrane associated 
proteoglycans such as glypicans, whereas the third group contains extracellular 
matrix (secreted) proteoglycans such as agrin, collagen XVIII and perlecan (Jackson 
et al., 1991; Bishop et al., 2007).   
 
Figure 1.1.  Model of proteoglycan structure.  Syndecans have trans-membrane core 
proteins with HS- or CS-GAG chains.  Glypicans have GPI core protein with only 
HS-GAG chains whereas perlecan is a secreted HSPG.  Figure adapted from (Lin, 
2004)   
HSPG consist of a core protein and 2-3 covalently attached GAG chains.  Core 
proteins generally determine the localization of HSPG on cell surface or ECM.  
Syndecans and glypicans constitute two major groups of core proteins on cell 
surfaces (Figure 1.1).  Syndecans consist of 4 family members (syndecans 1-4) 
which are expressed differentially in mature tissues.  Syndecan 1, for instance, is 
abundant in epithelial cells whereas syndecan 2 is highly expressed in endothelial 
cells and fibroblasts (Bernfield et al., 1992; Gotte, 2003).   
Syndecans usually bind three GAG chains close to the N termini. These chains, in 
the case of syndecans 2 and 3 for instance, are exclusively HS-GAGs whereas they 
may have CS as well in case of syndecans 1 and 4, (Figure 1.1), (Shworak et al., 
1994; Rapraeger and Ott, 1998).   
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In contrast, glypicans are cell-surface glycosylphosphatidylinositol (GPI) bound 
proteoglycans with six different mammalian members (1-6) and one Drosophila 
homologue (Lander et al., 1996; Bandtlow and Zimmermann, 2000).  All glypicans 
share a distinctive structure of 14 conserved cysteine residues mainly located in the 
extracellular domain and exclusively substituted with HS chains (Chen and Lander, 
2001).  
Heparan sulphate is found on GBM as ECM components such as perlecan, agrin 
and collagen XVIII (Noonan and Hassell, 1993; Groffen et al., 1998; Halfter et al., 
1998).  HS is also found at the cell surface of leucocytes, endothelial and epithelial 
cells in different types such as glypicans, syndecans, betaglycans and CD44 (Carey, 
1997; Filmus and Selleck, 2001; Eickelberg et al., 2002).  Betaglycan, a receptor for 
TGF-β, is mainly found in cortical renal interstitium and on microvascular 
endothelial cells (Eickelberg et al., 2002).  Syndecans 1, 2, and 4 are generally 
expressed at basolateral surfaces of vascular endothelial cells (Bernfield et al., 
1992; Rosenberg et al., 1997).  Syndecan 1 and 4 are expressed in kidney with 
various distribution pattern; syndecan 1 for instance, is predominant on basolateral 
surface of the renal epithelial cells (Cook et al., 1996) whereas syndecan 4 is mainly 
found on endothelial cells (Kim et al., 1994). 
1.6 Heparan sulphate (HS) 
HS proteoglycans (HSPGs) are located on cell surfaces and extracellular matrices 
(ECM) in all mammalian cells.  HS concentration may reach up to 200 µg/ml within 
a thin proteoglycan layer including 50-90% of endothelial cell surfaces (Ali et al., 
2003).  HS synthesis undergoes a series of steps before reaching its final and 
functional form. 
1.6.1 Initiation 
HS synthesis is initiated after binding xylose from uridine-diphospho-D-xylose 
(UDP-Xylose) to a core protein serine by UDP-xylosyltransferase in Golgi 
apparatus.  Then a molecule of galactose is transferred to the xylose by UDP-
Galactosyl (UDP-Gal) transferase I followed by another galactose by UDP-Gal 
transferase II.  The final saccharide (glucoronic acid) of the linkage is added by 
UDP-Glucuronic acid (UDP-GlcA) transferase I (Esko and Zhang, 1996; Kitagawa 
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et al., 1998).  Following synthesis of this tetrasaccharide linkage, the HS chain is 
ready to be extended by the addition of repeated glucuronic acid and glucosamine 
units. 
1.6.2 Elongation and polymerization 
HS is synthesized as a repeating disaccharide unit composed of N-
acetylglucosamine (GlcNAc) and glucuronic acid (GlcA) joined by 1-4 linkage 
tetrasaccharides (Kjellen and Lindahl, 1991).  Elongation of the GAG chain occurs 
by adding GlcNAc and GlcA to the linkage region by the GlcNAc transferase I 
enzyme and GlcA transferase II enzyme respectively (Lind et al., 1998; McCormick 
et al., 2000).  These enzymes are products of tumor (exostoses) suppressor genes 
EXT1 and EXT2 and constitute a part of a hetero-oligomeric complex in the Golgi 
apparatus that is responsible of HS chain polymerase activity (Munro, 1998; Wei et 
al., 2000).  In the case of addition of GalNAc (instead of GlcNAc) to the 
tetrasaccharide linkage, a chondroitin sulphate (CS) chain will be created.  GAG 
chains can reach a total length of between 30-200 saccharides (Kjellen and Lindahl, 
1991).  
Humans with mutations in either gene of EXT1 or EXT2 suffer from benign bone 
tumours known as exostoses.  Mutation in EXT1 and EXT2 results in neonatal 
lethality at gastrulation due to lack of organized mesoderm and extracellular 
embryonic tissue (Forsberg and Kjellen, 2001), whereas partial mutation of EXT1 
was found to cause truncated HS chains (30% of normal length) and consequent 
biological activity (McCormick et al., 1998; Lin et al., 2000; Kitagawa et al., 2001).  
1.6.3 Modification 
HS modification is not random but a controlled and specific process.  Each enzyme 
affects its substrate in a way that allows the next step to take place (Kusche-
Gullberg and Kjellen, 2003).  HS structure is modified by a range of enzymes 
beginning with N-deacetylase N-sulphotransferase enzyme (NDST) which replaces 
the N-acetyl group of GlcNAc with sulphate groups from nucleotide sulphate 3’-
phosphoadenosine-5’phosphosulphate (PAPS) donors creating a highly sulphated 
domain (GlcNS), (Orellana et al., 1994).  The PAPS is a general sulphate donor 
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which is located in the cytoplasm and transferred to the Golgi compartment by 
nucleotide transporters.  This vital molecule is synthesized by the act of PAPS 
synthetase 1 and 2 (ATP sulphurylase/APS kinase) which combines adenosine 
triphosphate (ATP) with the adenosinephosphosulphate (APS) kinase enzyme 
(Venkatachalam et al., 1998). 
D-glucuronic acid residues adjacent to GlcNS are epimerized to L-iduronic acid 
(IdoA) residues by the C5 epimerase enzyme (Li et al., 1997).  Additional sulphate 
groups to IdoA and/or GlcA at 2-O position are added by heparan sulphate 2-O 
sulphotransferase (HS2ST).  Further sulphation takes place by transferring sulphate 
groups to 6-0 position of GlcNAc and GlcNS by heparan sulphate 6-O 
sulphotransferase (HS6ST) and, to a lesser extent, to the 3-O position by heparan 
sulphate 3-O sulphotransferase (HS3ST), (Lindahl et al., 1998), (Figure 2.1). 
Polymerization and modification of the HS chain results in a more mature and 
complicated HS structure.  This structure contains three types of sequences: non-
sulphated regions with N-Acetyl (NA), mixed regions with N-sulphated (NS) and 
NA (NA/NS), and N-sulphated regions NS (Gallagher et al., 1992).  NS domains 
extend from 2-9 disaccharides which are flanked by 16-18 disaccharides of NA/NS 
domains.   
Variation of HS structure is attributed, in addition to HS chain length, to the content 
of O-sulphation imposed on N-sulphated regions (Lyon and Gallagher, 1998).  It 
has been suggested that NA domains at the beginning of HS chains (contiguous 
with the protein linkage) provide a “flexible non-interactive arm” with more free 
rotational freedom.  This may help in HS interaction with extracellular and cell 
surface proteins and ligands (Turnbull and Gallagher, 1991; Lyon et al., 1994a).   
1.6.4 HS modifying enzymes 
The HS chain undergoes a series of modification following chain polymerization.  
Modification reactions are performed by four sulphotransferase enzymes and an 
epimerase.  The modifying enzymes are generally expressed in a tissue specific and 
developmentally regulated pattern.  Except for HS2ST and C5 epimerase, 
sulphotransferase enzymes have several isoforms which catalyze the same reaction 
but with different chemical contexts. 
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Figure 1.2. Heparan sulphate modifying.  The NDST enzyme removes acetyl and 
adds sulphate group to the GlcNAc.  HS2ST transfers S group to the GlcA/IdoA 
whereas HS6ST and HS3ST transfer S groups the 6-O and 3-O positions of 
glucosamine respectively, figure adapted from Esko et al. (Esko and Selleck, 2002) 
1.6.4.1 NDST  
The NDST enzyme has 4 mammalian isoforms (1, 2, 3 and 4) with similar sequence 
homology of 65-80% and different tissue expression (Aikawa et al., 2001; Esko and 
Selleck, 2002).  The sulphotransferase domain of NDST1 contains two highly 
conserved structural motifs which have the ability to interact with PAPS (Kakuta et 
al., 1999).  The NDST enzyme catalyzes the first modification reaction in HS 
structure in the Golgi compartment by removing N-acetyl from glucosamine 
residues and transferring sulphate group to the N position.  This modification was 
shown as a prerequisite for further N- sulphation and all additional modifications 
including C5 epimerization and O sulphation (Esko and Selleck, 2002; Bengtsson et 
al., 2003).  However, further studies have shown that epimerization or O-sulphation 
might take place in absence of N-sulphation.  This phenomenon was attributed to 
the presence of a complex of HS modifying enzymes known as GAGosome.  In this 
model, several biosynthetic enzymes work on the same polysaccharide substrate in a 
flexible manner (Esko and Selleck, 2002).  For example, HS synthesized by mice 
stem cells with a complete absence of N-sulphate groups was shown to have 6-O 
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sulphate groups; this rules out the requirement for a mandatory N-sulphation step 
for subsequent HS sulphation (Holmborn et al., 2004).   
NDST1 and 2 have a wide tissue distribution whereas NDST3 and 4 are expressed 
in a more restricted manner.  It has been shown that NDST3 and 4 are more 
abundant in human fetal liver, kidney or brain than NDST1 or NDST2 (Kusche and 
Lindahl, 1990; Toma et al., 1998; Aikawa et al., 2001).  These isoforms are also 
different in N-deacetylase/N-sulphotransferase activity.  For example, NDST1 has 
higher N-deacetylase activity than N-sulphotransferase activity compared to NDST2 
(Aikawa et al., 2001).  Additionally the isoform of NDST4 has weak deacetylase 
activity with high sulphotransferase activity, whereas NDST3 has the reverse 
properties (Aikawa et al., 2001). 
Cells overexpressing NDST exhibit an increase in N-sulphation. NDST2 
overexpressing cells express more N-sulphated groups and more extended NS 
domains compared to cells overexpressing NDST1, which are primarily involved in 
NA/NS domains (Pikas et al., 2000).  
Knock-out of NDST isoforms in experimental animal models produces different 
phenotypes.  Knock-out of NDST1 produces an increased incidence of lethality 
shortly after birth due to respiratory defects. However, mice with NDST2 knocked-
out are viable and fertile but have reduced connective-tissue-type mast cells, which 
play an important role in heparin synthesis (Forsberg et al., 1999; Fan et al., 2000).  
NDST1 is involved in several systems including the nervous system, digestive 
system and immune system.  In an inflammatory response, Wang et al. showed that 
disruption of NDST1 in endothelial cells reduced chemokine-mediated neutrophil 
infiltration (Wang et al., 2005).  Stimulation of endothelial cells with TNF-α and 
IFN-γ increased expression of NDST-1 at the mRNA level (Klein et al., 1992; 
Carter et al., 2003).   
1.6.4.2 GlcA C5 epimerase 
HS chain epimerization usually takes place after N sulphation, where D-glucuronic 
acid is converted into L-iduronic acid by C5 epimerase, which causes the carboxyl 
group (C5) of GlcA to locate below the hexose ring.  The absence of 2-OS at 
surrounding GlcA residues is necessary for this reaction (Jacobsson et al., 1984).   
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Epimerization of HS chains releases conformational forces which facilitate the 
binding of various factors and ligands to specific sites with the HS chain (Mulloy 
and Forster, 2000). 
Mice lacking the GlcA C5 epimerase enzyme exhibit neonatal lethality which sheds 
more light on the important role of this enzyme in modifying HS structure with 
consequent effect on biological and developmental biology (Li et al., 2003).  
1.6.4.3 HS2ST 
The HS2ST enzyme transfers sulphate groups to the 2-O position of GlcA/IdoA.  
No isoforms for this enzyme have been found.  The HS2ST transfers sulphates to 
substrate including GlcA/IdoA with GlcNS (IdoA-GlcNS), however, this does not 
include O-sulphated residues or that are adjacent to O-sulphated residues (IdoA-
GlcNS6S), (Kobayashi et al., 1996; Kobayashi et al., 1997).   
The 2-O sulphation usually occurs after the glucosamine N-sulphation.  The C5 
epimerase and HS2ST have a kind of interconnection between each other.  HS2ST 
has higher affinity to an iduronic acid than to glucuronic acid (Rong et al., 2001).  It 
has been shown that 50-90% of the 2-O sulphation occurs at the IdoA residue which 
increases along with NS domain length (Safaiyan et al., 2000).  
In 1998, Bullock et al. showed that homozygous mice with HS2ST knockout died 
during the neonatal period and exhibited bilateral renal agenesis as well as skeletal 
defects; these defects indicate significant role for HS2ST in HS regulation of 
morphogenesis during embryonic development (Bullock et al., 1998). 
1.6.4.4 HS6ST 
The HS6ST enzyme transfers sulphate groups to the 6-O position of glucosamine in 
the HS chain; this role has been described in many species including Drosophila, 
C.elegans and Zebrafish.   
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Figure 1.3. Disaccharide structure of heparan sulphate.  Repeated disaccharide units 
contain Glucuronic acid and N- Acetyl glucosamine.  
HS6ST has three isoforms which have specific substrates and different tissue 
distributions.  These isoforms generally transfer sulphate groups to the 6-O position 
of glucosamine substrates varying in concentration, level of sulphation and adjacent 
sulphated units (Habuchi et al., 2000).  Sulphate groups are generally transferred to 
substrates containing GlcNS-GlcA-GlcNS, GlcNS-IdoA-GlcNS and GlcA-GlcNS3S 
units with preference for targets containing IdoA in the presence or absence of 2-O 
sulphation (Smeds et al., 2003).  Habuchi et al showed that each isoform is more 
specific for hexuronic acid (GlcA or IdoA) adjacent to targeted GlcNS.  The 
HS6ST1 enzyme was found to catalyze the sulphation at residues containing 
GlcA/IdoA rather than 2-O sulphated residues.  HS6ST2 catalyzes sulphate 
transferase to different substrates depending on concentration.  For example GlcA-
GlcNS substrate is favored at a high concentration while IdoA-GlcNS is preferred at 
a low concentration (Habuchi et al., 2000).  HS6ST3 prefers substrates with higher 
amount of 2-O sulphation (Jemth et al., 2003), (Figure 1.3). 
In addition, the HS6ST isoforms express a variable pattern of tissue expression.  
Murine HS6ST1 and HS6ST2 are highly expressed in liver and brain respectively, 
whereas HS6ST3 is ubiquitously expressed (Habuchi et al., 2000).  Human HS6ST 
isoforms have an approximately similar tissue distribution.  HS6ST1, for instance, 
has an abundant distribution pattern (higher expression in liver), whereas HS6ST2 is 
highly expressed in brain, spleen, placenta and fetal kidney whereas HS6ST3 is 
ubiquitously expressed in many tissues (Habuchi et al., 2003; Smeds et al., 2003).  
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The HS6ST expression also varies during development stages; HS6ST1 expression 
in early mouse embryos is mainly high in neural tissue while in adult mouse this 
enzyme is mainly expressed in the liver (Sedita et al., 2004).   
Sulphation of HS glucosamine at the 6-O position plays a crucial role in the 
developmental process.  In Drosophila, for instance, disruption of HS6ST-RNA 
expression resulted in remarkable changes in fibroblast growth factor signalling in 
the tracheal epithelium and affected tracheal morphogenesis (Kamimura et al., 
2001) whereas null mutation of the gene encoding HS6ST in C.elegans produced 
defects in the nervous system (Bulow and Hobert, 2004).  Habuchi et al. showed 
that the high percentage of null HS6ST1 mice died between embryonic day 15.5 and 
the prenatal stage (Habuchi et al., 2007).  Additional studies show that mice with 
mutant HS6ST1 (homozygous) exhibited significant growth retardation, failure to 
thrive and lethality in early adulthood (Izvolsky et al., 2008).  Sulphation at the 6-O 
position has been involved in development of limbs in the chicken embryo (Nogami 
et al., 2004; Kobayashi et al., 2010).  HS6ST1 and HS6ST2 mutations were found 
to affect formation of Zebrafish muscles (Bink et al., 2003).  In humans, HS6ST 
mutations cause macular corneal dystrophy (Iida-Hasegawa et al., 2003). 
1.6.4.5 HS3ST 
The HS3ST enzyme transfers sulphate group to the 3-O position of glucosamine in 
the HS chain.  The sulphate group is transferred from PAPS to a substrate such as 
GlcNS or GlcNS6S (Habuchi et al., 2004).  So far, seven HS3ST isoforms have 
been identified (1, 2, 3A, 3B, 4, 5 and 6) with substrate preferences and more 
specific biological properties (Shukla et al., 1999; Shworak et al., 1999; Xu et al., 
2005).  Despite forming only about 1% of the total, sulphation at the 3-O position is 
crucial for significant biological activities.  Late modification of HS by HS3ST 
isoforms requires generally more specific substrates at various positions.  HS3ST2 
isoform adds sulphate group to GlcA2S-GlcNS and IdoA2S-GlcNS, while 
HS3OST-3A transfers sulphate group to IdoA2S-GlcNAc (Liu et al., 1999a).   
One pivotal role for 3-O sulphate is formation of the antithrombin-III (AT-III) 
binding site in HS.  HS3ST1 constitutes the predominant isoform involved in the 
transfer of 3-O sulphate to the AT-III-HS epitope (Liu et al., 1999b).  HS can 
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promote anticoagulation by interacting with AT-III which forms a protease inhibitor 
of pro-coagulant thrombin (Casu and Lindahl, 2001).  HS3ST3B participates in the 
construction of 3-O sulphated HS binding site of herpes simplex virus type-1 (HSV-
1) (Shukla et al., 1999).   
Importantly, the HS3ST1 gene is upregulated in rejected (failed) renal allografts 
compared to non-failed grafts.  This result suggests a potential role for HS3ST1 in 
the pathology of graft rejection, which is accompanied by novel sulphation 
modulation compared to normal organs or non-failed grafts (Einecke et al., 2010).  
HS3ST1 knockout mice show no haemostasis defects in coagulation, despite the 
crucial role of HS3ST1 in synthesis of the HS-AT-III binding site.  However, these 
mice do show retardation of intrauterine development (Shworak et al., 2002).   
1.6.5  HS sulphation 
HS polymerization and epimerization is crucial for the regulation of HS sulphation 
and diversity.  Availability of the sulphate donor PAPS constitutes an additional 
factor for the regulation of HS binding efficiency.  This is determined by the 
capacity of PAPS synthesizing enzymes and the PAPS transport system.  The 
concentration of PAPS in the intra-Golgi system is crucial for the sulphation 
patterns generated by HS modifying enzymes (Wlad et al., 1994; Abeijon et al., 
1997).  PAPS is synthesized in the cell cytoplasm and transferred to the Golgi 
compartment by two transporters PAPST1 and PAPST2 (Kamiyama et al., 2003; 
Kamiyama et al., 2006).   
The pattern of HS sulphation is different during carcinogenesis, development and 
inflammation (Feyzi et al., 1998; Jayson et al., 1998; Carter et al., 2003).  HS 
sulphation also exhibits tissue specificity; indeed, disaccharide analysis of HS 
chains shows that porcine liver has more heavy sulphated HS than the intestine 
(Jastrebova et al., 2010).  Interestingly, HS sulphation undergoes age-dependent 
modulations which are accompanied by changes in biological activity, including 
decreased ability to bind FGF2 (Huynh et al., 2012).  In addition, stimulation of 
endothelial cells with proinflammatory cytokines such as TNF-α and IFN-γ 
increases expression of the HS modifying enzyme NDST-1 (Klein et al., 1992; 
Carter et al., 2003).  Sections from acutely rejecting human renal biopsies showed 
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an increase in N-sulphation compared to normal kidney suggesting an important 
role for HS in regulating the inflammatory response (Ali et al., 2003).  Changes in 
HS expression were also observed in synovial endothelial cells and chemokine 
binding sites.  For example, syndecan 3 is expressed by synovial endothelial cells 
during normal and rheumatoid inflammatory conditions.  However, these cells 
express HS which selectively binds CXCL8 only during inflammation (Patterson et 
al., 2005).  
1.6.6 HS-protein interactions 
HS has polyanionic charges on GAG chains that play a crucial role in binding a 
wide range of proteins, cytokines and growth factors.  Many of these interactions 
are related to H bonds, van der Waals forces and hydrophobic interaction 
(Thompson et al., 1994).  These interactions allow HS to play an important role in 
many biological processes including cell adhesion, migration, differentiation, 
angiogenesis, coagulation, haemostasis, inflammation and proliferation (Wight et 
al., 1992; Bernfield et al., 1999; Tumova et al., 2000).   
The localization of HS on the cell surface enhances the binding of proteins such as 
growth factors and chemokines, as well as increasing their stability and activity 
(Lortat-Jacob et al., 1995; Sasisekharan et al., 1997).  Interaction between HS and 
FGF2 for instance, provides protection from thermal and pH denaturation.  Binding 
of HS-FGF2 may also restrict FGF2 diffusion and increase its concentration, which 
enhances its paracrine mode of activity (Mulloy and Rider, 2006) 
Heparin has been used as a highly sulphated model of HS in many studies for HS-
protein interactions.  Heparin has the same structure as HS, but with more heavily 
trisulphated disaccharides (Lindahl et al., 1998).  Most proteins interact with 
immobilized heparins via ionic interactions between amino acids such as lysine or 
arginine which are generally aligned in specific sequences.  Consensus sequences 
suggested for HS/heparin binding proteins include XBBBXXBX, XBBXBX and 
XBBBXXBBBXXBBX where B and X refer to basic and hydropathic amino acid 
respectively (Cardin and Weintraub, 1989). 
Interaction between cationic binding proteins and negatively charged heparins may 
indicate relatively nonspecific binding (Salmivirta et al., 1996; Lindahl and Kjellen, 
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1998).  Specific sequences in NA and NA/NS regions of HS provide selective 
binding domains for various proteins which interact with HS in a biological 
environment.  Additional factors may play roles in generating unique protein 
binding epitopes, including N-substitution pattern, HS chain length, the number of 
sulphated domains, the deposition of NS, NS/NA and NA regions, and combination 
between sulphate groups at N- and O- positions (Lindahl et al., 1998). 
A very well studied example of specific HS-protein interaction is between AT-III 
and HS/heparin.  Structural analysis revealed the requirement of a 3-O sulphate 
group containing pentasaccharide motif (Petitou et al., 2003).   
1.7 Chemokines 
Chemokines are chemotactic cytokines, a family of homologous proteins with 
molecular weight between 8-12 kD.  These proteins play significant roles in 
localizing immune cells to the site of tissue damage (inducible) during inflammation 
or in homing lymphocytes in nonpathological conditions (constitutive) (Rot and von 
Andrian, 2004).  Depending on the presence of cysteine residues (C), chemokines 
are classified into four families termed: CXC, CC, C and CX3C on the basis of the 
presence of amino acid X between cysteine residues near the N terminus (Zlotnik 
and Yoshie, 2000) .   
Chemokines signal via specific cell surface G-protein coupled receptors (GPCR); 
each has seven transmembrane domains (Murdoch and Finn, 2000).  Alternatively, 
GAGs bind to chemokines and have the capability to generate a signal through 
phosphotyrosine kinase (PTK), even in absence of GPCR.  For example CCL5 
could signal through HeLa cells stably transfected with CD4 in presence of GAGs 
even in the absence of GPCR, whereas these cells failed to signal in lacking of cell 
surface GAGs (Chang et al., 2002).   
Chemokines are expressed by a broad spectrum of cells and tissues.  CXCL8 and 
CCL2, for example, are secreted by leucocytes, fibroblasts, platelets, endothelial 
and epithelial cells.  This secretion is mainly maintained by pro-inflammatory 
cytokines such as TNF-α, IFN-γ, IL-1 and IL-2 (Ward et al., 1998; Hillyer et al., 
2003).  It has been shown that the CC chemokine family members CCL4 and CCL2 
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(MCP-1) are upregulated in tubular epithelial cells within rejected renal allografts 
(Robertson et al., 2000).  
1.7.1 Chemokine-HS interaction  
Chemokines are anchored and presented by HS on the cell surface in a way that 
controls their functions.  Chemokine-GAG binding domains have been identified by 
sequence alignment and mutagenesis experiments.  These domains consist of basic 
amino acids (B) and other amino acids (X).  The most abundant domain motif for 
chemokine-GAG binding is XBBXBX and XBBBXXBX (Hileman et al., 1998).  
For example, HS binding domain in CCL5 (BBXB) includes R44, K45 and R47 
which constitute the key HS-CCL5 binding epitope (Proudfoot et al., 2001). 
Interaction with HS can protect chemokines from degradation and induces 
oligomerization (a more active form of chemokines) (Webb et al., 1993; Hoogewerf 
et al., 1997).  This binding is also important for localization of chemokines on 
endothelial cell surfaces by preventing their displacement by rapid blood flow 
(Lortat-Jacob et al., 2002).   
HS sequesters chemokines at the site of generation, potentially leading to the 
formation of a chemokine gradient that can play an important role in leucocyte 
migration (Middleton et al., 2002).  HS also plays a significant role in chemokine 
transport across the endothelial cell layer (transcytosis).  CXCL8, for example, is 
involved in endothelial transcytosis, which is a heparan sulphate dependent process 
(Middleton et al., 1997).  Chemokine gradients influence neutrophil crawling in the 
extravascular lumen in vivo.  A macrophage inflammatory protein-2 (MIP-2, 
CXCL2) releasing gel attracted neutrophils to the vascular endothelia compared to 
endothelia from heparanase transgenic mice which express short HS chains.  This 
result suggests that an intravascular chemokine gradient is created along endothelial 
HS which induces neutrophil to crawl towards transmigration sites (Massena et al., 
2010). 
Chemokine-HS binding is necessary not only for chemokine protection and gradient 
formation but also for chemokine signalling.  HS binding to chemokine allows 
presentation to GPCRs and, thereafter, chemokine signalling (Hoogewerf et al., 
1997; Ali et al., 2000).  Mutant CCL7 with an inability to bind HS has a reduced 
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potential to stimulate transendothelial leucocyte migration in comparison to wild-
type chemokine in in vitro chemotaxis assay (Ali et al., 2005b).  An in vivo 
experiment showed that mutant CCL5 with reduced ability to bind HS is less 
effective in recruiting leucocytes (Proudfoot et al., 2003).  A non-heparin-binding 
CCL5 mutant (K45A), demonstrated a decreased ability to establish chemokine 
gradients affecting haptotactic leucocyte transendothelial migration (Ali et al., 
2002).  Furthermore, heparan sulphate facilitates chemokine transport from tissue to 
lumen.  For example, truncated CCL8 (1-63) with an inability to bind HS, failed to 
transport through the endothelium to the apical surface (Middleton et al., 1997).  
The interaction between chemokine and HS has been shown to affect allograft 
survival; inhibition of chemokine-HS interactions reduced transplant rejection in 
mice (Dai et al., 2010).   
The chemokine-HS interaction exhibits a level of selectivity that has been revealed 
by identifying the HS binding domain for a limited number of chemokines.  
Sulphate groups at N- and O- positions are involved in the HS binding site for 
chemokines such as CCL2, CCL7 and/or CCL8 (Schenauer et al., 2007).  Further 
studies using X-ray diffraction analysis of CCL5 mixed with heparin disaccharides, 
has shown that N- and 6-O sulphate groups are involved in CCL5-HS interaction 
(Shaw et al., 2004).  The binding site should contain at least 14 monosaccharides in 
order to allow CCL5 oligomerization which is necessary for affinitive binding and 
signalling (Rek et al., 2009). 
1.7.2 Leucocyte extravasation 
During the inflammatory response, leucocytes such as neutrophils migrate into 
tissues by penetrating the junctions between vascular endothelial cells or by the 
transcellular pathway.  Alternatively, naive lymphocytes can migrate across the high 
endothelial venules (HEV) in the absence of inflammation (Engelhardt and 
Wolburg, 2004).   
The first step in leucocyte migration is the binding of selectins which mediate 
attachment to the vascular endothelial wall in the direction of blood flow resulting 
in leucocyte tethering and rolling (Ley et al., 2007).  These cells are recruited to 
inflammatory sites by binding to three selectins namely: lymphocyte (L), platelet 
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(P) and endothelial (E) selectins (Lowe, 2003).  In the following step, leucocytes 
firmly adhere to the endothelial surface due to activation of integrins which interact 
with counter adhesion molecules such as ICAM-1 (Shimizu et al., 2008).  This 
interaction  leads to leucocyte arrest in a step that results in activation of a signalling 
cascade and leucocyte migration (Yadav et al., 2003).  In the third step, leucocytes 
begin to extravasate between or through the endothelial cells towards the tissue.  
Degradative enzymes, i.e. heparanases facilitate leucocyte release and increase the 
vascular permeability at the inflammatory endothelial sites (Edovitsky et al., 2006).   
Migration of circulating leucocytes towards inflamed tissue is mediated by 
chemokine-HS binding.  This interaction supports the formation of chemokine 
gradient on endothelial cell surface and ECM which is crucial for leucocyte 
activation and migration (Middleton et al., 2002; Yadav et al., 2003) 
 
Figure 1.4. Leucocyte extravasation. Leucocytes extravasation can be divided into 
three main steps. 1, leucocyte rolling involves the binding with selectins. 2, firm 
adhesion. 3, crawling.  4, diapedesis (transmigration). 
However, a recent report has shown that some effector T lymphocytes have the 
ability to transmigrate via inflamed barriers without surface deposited chemokine or 
even chemokine gradients (Shulman et al., 2012).  This mechanism requires 
adhesive integrin interaction with inflamed endothelial barriers without the need for 
integrin-activating chemokines (Figure 1.4). 
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1.8 Fibroblast growth factors (FGF) 
Fibroblast growth factors constitute a family of polypeptides recognized in both 
vertebrates and invertebrates.  In vertebrates the FGFs are categorized into 6 
subfamilies that share similar sequences, developmental and biochemical properties.  
The FGF1 sub family includes acidic and basic FGF members (FGF1 and FGF2 
respectively).  FGF8 subgroup members (FGF8, FGF17 and FGF18), for instance, 
have about 80% amino acid sequence similarity and receptor binding identity (Xu et 
al., 2000; Itoh and Ornitz, 2004).  FGF11, FGF12, FGF13 and FGF14 are not 
classified in subfamilies because they do not activate FGF receptors (Olsen et al., 
2003). 
1.8.1 FGF2 and renal fibrogenesis 
FGF2 is a single-chain polypeptide with a molecular weight of 18 kilo Daltons 
(kD).  FGF2 was first isolated from a kidney homogenate in 1985 (Baird et al., 
1985).  FGF2 is expressed at different sites in normal human kidney such as distal 
epithelial and vascular smooth muscle cells (Floege et al., 1999).  There is strong 
evidence that proximal tubular epithelial cells constitute the source of FGF2 and 
TGF-β (Phillips et al., 1996; Phillips et al., 1997).   
FGF2 plays crucial roles in biological activities such as cell proliferation and 
differentiation.  This factor stimulates the proliferation of mesangial, proximal 
epithelial and endothelial cells in vitro and in vivo (Zhang et al., 1991; Floege et al., 
1993; Klint and Claesson-Welsh, 1999) as well as the production of mesangial cell 
extracellular matrix (Floege et al., 1992).  FGF2 was found to increase the 
mitogenesis of smooth muscles and fibroblasts (Scholz et al., 2001).  Another 
example of the function of FGF2 is stimulation of the proliferation of smooth 
muscle cells in asthmatic inflammation (Bosse and Rola-Pleszczynski, 2008).   
TGF-β is upregulated during renal rejection; indeed TGF-β plays a major role in the 
induction of EMT in kidney in association with FGF2 (Robertson et al., 2001; 
Strutz et al., 2001).  FGF2 expression was upregulated in fibrotic kidney, 
particularly in interstitial and tubular cells.  Interestingly, FGF2 stimulated the 
proliferation of fibroblasts in kidney which indicates the importance of this cytokine 
in promoting EMT and renal fibrosis (Strutz et al., 2000; Strutz et al., 2002).  
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Recent reports examined tubular epithelial cells for the expression of syndecan-1 
and the heavily sulphated 10E4 epitope alongside FGF2 in renal allograft biopsies.  
The results show that tubular epithelial cells stained with syndecan-1 and 10E4 
antibody failed to stain to FGF2; which explains two levels of regulation for FGF2 
binding : the expression of syndecan-1 and sulphation motifs (Celie et al., 2012).   
1.8.2 FGF-HS interaction 
Interactions between HS and FGFs such as FGF1, FGF2, FGF8 and FGF18 have 
been extensively studied (Xu et al., 2000; Itoh and Ornitz, 2004; Kreuger et al., 
2005).  These interactions depend on HS structure and sequences attached to 
proteoglycans on cell surface (Allen and Rapraeger, 2003).   
HS interacts with growth factors via specific binding domains.  FGF1 binds to HS 
via a minimal binding site composed of a tetrasaccharide (Mach et al., 1993), 
whereas the minimal binding site for FGF2 is a hexasaccharide (Turnbull et al., 
1992).  The HS interaction with FGF is required for further high affinity binding 
with FGF specific receptor (FGFR) (Brickman et al., 1995).  For example, the 
FGF2-FGFR signalling requires the presence of the 6-O sulphate group which is 
necessary for FGF dimerization (Schlessinger, 1988).  This interaction enhances the 
affinity of FGFs for their receptors by forming a trimolecular complex including 
FGF, FGFR and HS.  This complex allows FGFR dimerization and phosphorylation 
which is necessary for FGFR activation and signalling (Rapraeger et al., 1991; 
Ornitz et al., 1995).  Further studies showed that formation of ternary complex is 
essential for FGF2 signalling (Ashikari-Hada et al., 2009), (Figure 1.5).  
Activation of FGFR leads to phosphorylation of the intracellular signalling pathway 
of mitogen activating phosphokinase (MAPK), which includes pathways of 
extracellular regulated kinase (ERK), p38 and c-Jun amino terminal kinase (JNK).  
Additional pathways were classified under the MAPK group for cell-specific 
signalling including phospholipase C, phosphoinositol 3 kinase (PI3K) and protein 
kinase B (Akt) (Dailey et al., 2005; Katz et al., 2007).  Crystal structure analysis has 
shown that FGF2 interacts with its specific receptor in presence of HS in a ternary 
complex FGF2-HS-FGFR (Pellegrini et al., 2000; Schlessinger et al., 2000).   
        General introduction 
27 
 
Sulphation at the O position is crucial for HS binding with fibroblast growth factors.  
Disruption of specific HS O-sulphotransferase genes during the embryonic stage 
resulted in significant developmental defects (Ashikari-Hada et al., 2004).  
Angiogenesis induced by FGF2 was inhibited in presence of 6-O desulphated 
heparins in chicken embryos (Lundin et al., 2000).  Furthermore, double knockout 
of HS6ST1 and HS6ST2 in murine embryonic fibroblasts exhibited a reduction of 
FGF4, FGF2 and FGF1 signalling pathways (Sugaya et al., 2008).  The role of 2-O 
and N- sulphate groups as an essential component in the epitope binding as well as 
the assembly of FGF-HS-FGFR complex was extensively studied (Allen et al., 
2001).   
 
Figure 1.5. The ternary complex of FGF-HS-FGFR. FGF and FGFR have been 
shown to have a positive charge that binds to negative charged heparin surfaces 
forming a sandwich model.  Figure adapted from (Johnson MS et al, 1999). 
Although the trimolecular FGF-HS-FGFR complex is required for complete 
activation of FGFR, a few cases have shown that FGFs can still bind and activate 
FGFR in absence of heparin/HS (Roghani et al., 1994).  Additionally, Lin et al. 
demonstrated that in the absence of HS, high levels of FGF can activate FGFR 
leading to dimerization and signalling (Lin et al., 1999).   
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1.8.3 FGF-HS binding epitope 
HS structural diversity is generated through biosynthesis of polysaccharide units.  
The nature of HS interaction with FGF2 has been a subject of intense study 
(Rapraeger et al., 1991; Friedl et al., 2001).  Several models have been suggested 
for FGF-HS-FGFR structure.   
Faham et al. were the first group to show that a tetrasaccharide structure of heparin 
is required for FGF2 binding using crystal diffraction.  The FGF-HS binding 
epitope contains UA2S-GlcNS6S-IdoA2S-GlcNS6S which interact specifically with 
Aspartic acid-28 (Asp), Arginine-121 (Arg), Lysine-126 (Lys) and Glutamine-135 
(Glu) on the FGF2 structure (XBBX), (Faham et al., 1996).  This result was 
confirmed using nuclear magnetic resonance (NMR) spectroscopy (Guglieri et al., 
2008).  Inclusion of an additional IdoA2S-GlcNS6S domain allowed additional 
binding to Lys-27, Asn-102 and Lys-136-144 (Faham et al., 1996).  Using 
selectively desulphated disaccharides, it was shown that 2-O sulphate is required for 
HS-FGF2 binding (Ishihara et al., 1994). 
Fragments involved in HS-FGF2 binding were revealed by using binding and 
elution techniques from FGF2 affinity chromatography columns (Habuchi et al., 
1992; Turnbull et al., 1992).  Further techniques were used to clarify the HS-FGF2 
structure, including x-ray diffraction to resolve crystal structures (Faham et al., 
1996; Schlessinger et al., 2000) and affinity analysis of oligosaccharides generated 
by enzymatically-modified heparin (Jemth et al., 2002; Ashikari-Hada et al., 2004).  
The crystal structure shows that FGF-HS binding is not just a neutralization of 
charge but it is also a specific reaction (Waksman and Herr, 1998).  
The essential components of the HS-FGF2 epitope are GlcA/IdoA-GlcNS-IdoA2S 
disaccharide domains (Guimond et al., 1993; Faham et al., 1996; Pye et al., 2000; 
Kreuger et al., 2001; Loo et al., 2001).  Initial experiments showed that five 
repeating disaccharides of IdoA2S-GlcNS were able to interact with FGF2 
(Turnbull et al., 1992).  However, the highest binding affinity was observed with 14 
dp (degree of polymerization) monosaccharides.  Interestingly, 6-O sulphate groups 
were found in the dp 14 fractions in small amounts.  For biological activity, 
including FGF-FGFR signalling, it was shown that at least 10 monosaccharides are 
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required, including the 6-O sulphate group (Maccarana et al., 1993; Tyrrell et al., 
1993; Ishihara et al., 1994).  A good example of the role of 2-O sulphate in FGF2 
binding was verified using a specific FGF2 octasaccharides with or without 2-O 
sulphate groups.  Addition of a 2-O sulphated tetrasaccharide resulted in binding of 
FGF2 (competing) and inhibition of FGFR activation and, thereafter, ERK 
phosphorylation, whereas in the absence of 2-O sulphates the tetrasaccharide did not 
inhibit the binding of FGF2 (Ashikari-Hada et al., 2009). 
It has been demonstrated that HS-FGF2 binding is correlated to the overall level of 
HS sulphation.  Heavily sulphated heparin oligosaccharides were shown to have 
more efficient domains compared to sulphated HS (Kreuger et al., 2006).  Charge 
distribution along HS chains is suggested to be the major requisite for HS-protein 
interaction and to a lesser extent the presence of specific saccharide sequences is 
required.  Accordingly, the importance of specific sulphation of HS with FGF-
FGFR binding and signalling was verified in previous reports (Stringer, 2006).  
However, this interaction is claimed not to depend on a definite sequence of 
monosaccharide domains or even the presence of a unique component.  (Kreuger et 
al., 2006; Lindahl, 2007).  Mulloy et al. have argued that high affinity GAG binding 
might require specific structural features of oligosaccharides but “does not depend 
on any single unique sequence, or even a very restricted set of sequences” (Mulloy 
and Rider, 2006).  
1.9 The Role of HS in the regulation of transplant rejection 
Heparan sulphate plays various roles in inflammation and fibrosis following kidney 
transplantation.  These roles depend to a large extent on HS structure, sulphation 
pattern and consequent biological activity.  
1.9.1 HS in kidney  
The kidney is composed of a large number of functional units called nephrons.  
Each nephron is composed of a glomerulus, proximal tubule, loop of Henle and 
distal tubule.  The glomerulus basement membrane (GBM), covered by a thin layer 
of epithelial cells, contains interacting ECM molecules such as collagens, laminins 
and HSPGs.  The GBM plays a key role in glomerular filtration by regulating the 
access of plasma molecules to the tubular system depending on size, shape and 
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charge.  The GBM has a negative charge, attributed to its content of HS, which 
forms a selective barrier for plasma proteins (Raats et al., 2000).  Therefore, 
negatively charged proteins will not be able to cross the barrier due to the negative 
charge of HS in the GBM (Kanwar and Farquhar, 1979).   
Glomerular endothelial cells have the capability to produce HS, dermatan sulphate 
and chondroitin sulphate (Kashihara et al., 1992).  Indeed, a study using in vitro 
bovine endothelial cells has shown that IL-1β increases HS expression by 
glomerular endothelial cells (Sorensson et al., 2003).  HS undergoes several 
modifications in patients with proteinuria such as masking by immune complexes, 
cleavage, HS depolymerization, or reduced production (Raats et al., 2000).  
Additionally, HS undergoes changes in sulphation patterns concerning N- and 6-O 
sulphate groups in systemic lupus erythematic nephropathy.  These changes were 
mainly observed in HS on the endothelium and in the GBM (Rops et al., 2007).  HS 
also facilitates leucocyte infiltration of the tubular epithelium, which causes 
tubulitis.  This role requires interaction between HS and chemokines, cytokines and 
L-selectins, leading to tubulitis-induced acute rejection (Robertson and Kirby, 2003; 
Ali et al., 2005a). 
1.9.2 HS in inflammation 
The immobilization of chemokines by HS leads to the establishment and 
maintenance of chemokine gradients which are important for leucocyte migration 
through various tissues and organs (Li et al., 2002).  Interestingly, the involvement 
of HS in chemokine transport across endothelial cell layers (transcytosis) sheds 
more light on the involvement of HS in the inflammatory response (Gotte et al., 
2005).  Wang et al. showed that decreased endothelial HS (knock-down of NDST1 
and NDST2) caused decreased neutrophil infiltration accompanied with impaired L-
selectin binding and reduced chemokine mediated transcytosis through vascular 
endothelium (Wang et al., 2005).   
IFN-γ is a proinflammatory cytokine which plays important roles in the immune 
response via activating and promoting cell mediated immune response including 
cytotoxic T cells, NK cells and macrophages (Dalton et al., 1993).  IFN-γ is also 
involved in tissue remodeling, matrix biosynthesis, cell adhesion and cell 
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differentiation and proliferation (Stark et al., 1998).  Binding of IFN-γ to HS 
provides protection to the cytokine but can modulate its activity (Lortat-Jacob, 
2006).  Further studies confirmed the role of HS in binding IFN-γ; addition of 
heparin was shown to block the interaction between endothelial cell HS and IFN-γ 
by competing with endogenous HS (Douglas et al., 1997).  The HS-IFN-γ binding 
sequence was reported to have NA domains flanked with NS domains (6-8 
saccharides) (Lortat-Jacob et al., 1995).  
1.9.3 Role of HS in chronic rejection 
Heparan sulphate is an essential co-receptor for binding and signalling of various 
cytokines and growth factors which are involved in the pathology of chronic 
inflammation of transplanted kidney such as IL-1, IFN-γ, TGF-β and FGFs (Ali et 
al., 2003).   
Acute rejection constitutes a major risk factor for chronic rejection (Waaga et al., 
1997).  HS undergoes changes in expression and sulphation according to its 
involvement in inflammatory responses.  HS plays significant roles in chronic 
rejection which are mediated via binding and presenting of factors such as IL-1, IL-
6, IL-4, TGF-β, IFN-γ and FGF2 (Phillips et al., 1996; Shirwan, 1999; Valles et al., 
1999; Waaga et al., 2000).   
TGF-β induces the production of ECM proteins such as collagen-I in rat tubular 
cells (Creely et al., 1992).  TGF-β also stimulates the production of fibronectin and 
HSPGs in rabbit tubular cells (Humes et al., 1993).  Furthermore, HS has the 
capability to bind and protect TGF-β from degradation leading to high concentration 
of the cytokine which is necessary for its activity (McCaffrey et al., 1994).  
Interestingly, selective desulphation of N-, 2-O or 6-O has been shown to affect 
negatively the TGF-β activity (Lyon et al., 1997).  
Recent reports have shown that HS sulphation is modulated in disease along with 
novel binding roles and activities.  In fibrogenic liver disease, HS modifying 
enzymes showed an increase in their expression at the mRNA level compared to 
normal tissue.  These enzymes included NDST1, sulphatase 1 and 2, HS3ST1, 
NDST2 and HS6ST1 (Tatrai et al., 2010).  Liver fibrosis changed HS expression 
and sulphation in order to accommodate novel interaction abilities with factors 
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involved in this process.  Increased levels of ECM molecules including collagen 
XVIII and perlecan were reported in chronic kidney rejection (Joosten et al., 2002).  
Fragments of perlecan (LG3) were increased in urine as an indicator of chronic 
kidney disease (O'Riordan et al., 2008); these fragments were also increased in 
patients serum accompanying with vascular rejection (Soulez et al., 2012).  Changes 
in HS expression levels were also reported in chronic inflamed synovium.  
Markedly increased expression of syndecans (1, 2 and 3) and glypican 4 was 
reported in chronic rheumatoid and psoriatic synovia compared to normal joint 
synovia (Patterson et al., 2008).   
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1.10 Hypothesis 
“The sulphation pattern of HS regulates fibrosis during renal allograft rejection 
by modulating the biological activity of growth factors”. 
1.11 Specific Aims 
This project aims to achieve the following objectives: 
1. To investigate the role of HS6ST1 on HS sulphation and regulation of 
biological activity of cytokines in renal epithelial cells. 
2. To study the effect of endosulphatase 2 (SULF2) expression on HS 
sulphation and regulation of biological activity of FGF2. 
3. To investigate changes in HS sulphation using an in vivo model of unilateral 
ureteral obstruction (UUO) in mouse kidney. 
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Chapter two 
2 General materials and methods
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2.1 Laboratory procedure  
All experiments were carried out under the safety policy of Newcastle University 
and the Institute of Cellular Medicine (ICM), in accordance with university rules of 
‘Safe Working with Biological Hazards’, ‘Safe Working with Chemicals in the 
laboratory’ and ‘A basic Guide for Radiation Workers’.  Experiments involving 
radioisotopes were approved prior to commencement in accordance with rules of 
‘Local Rules for the Use of Unsealed Sources of Radioactivity in the Medical 
School-Newcastle University’.  For experiments involving the use of potent 
carcinogens and toxins, a COSHH ‘Control of Substances Hazardous to Health’ a 
risk assessment was followed.  Tissue culture work was performed in compliance 
with regulations of BIO-COSHH class II risk assessment with guidelines produced 
in ICM.  Genetic modifications and mammalian cell transfection were approved by 
the Microbiological Hazards and Genetic Modification Safety Advisory Sub-
Committee. 
2.2 Culture media 
2.2.1 Dulbecco’s Modified Eagle Medium (DMEM) 
DMEM (Lonza) was supplemented with 100 IU/ml penicillin, 100µg/ml 
streptomycin, 2mM L-glutamine and 10% heat inactivated fetal calf serum FCS.  
This medium was used for supporting the growth of EAhy.926 cells. 
2.2.2 DMEM-ham’s F12 medium 
DMEM–Nutrient F12 Ham (DMEM-F12) (Lonza) supplemented with 10% heat 
inactivated fetal calf serum (FCS), 100IU/ml penicillin, 100µg/ml streptomycin and 
2mM of L-glutamine (Sigma-Aldrich).  This medium was used for growth of 
epithelial cell lines HK2, HKC8, CHO, CHO-745 and CHO-677. 
2.2.3 MCDB-131 medium 
MCDB-131 medium (Sigma-Aldrich) containing 1 ng/ml hydrocortisone (Sigma-
Aldrich) and 10 ng/ml human epidermal growth factor (EGF).  Complete media 
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were supplemented with 10% heat inactivated fetal calf serum (FCS), 100 IU/ml 
penicillin, 100 µg/ml streptomycin and 2mM of L-glutamine (Sigma-Aldrich).  
2.2.4 Propagation of cell lines 
Adherent cells in this study were grown in 25 and 75 cm
2
 flasks horizontally 
(Griener Bio-One) in humidified 37
o
C incubators with 5% CO2.  These cells were 
harvested every 2-3 days in a ratio of 1:3. 
2.3 Cell lines 
2.3.1 Human kidney (HK2) 
HK2 is a human kidney cell line immortalized from human proximal tubular cells 
(Ryan et al., 1994).  These cells were grown in DMEM-F12 complete medium in 
horizontal culture flasks.  The HK2 cells have adherent and epithelial morphology. 
2.3.2 Human kidney (HKC8) 
Human kidney proximal tubular epithelial cells (HKC8) were kindly provided by 
Dr. Lorrain Racusen (Racusen et al., 1997).  These cells were grown in complete 
medium of DMEM–F12. 
2.3.3 Human microvascular endothelial cell line (HMEC-1) 
This cell line was grown in MCDB-131 medium (Sigma Aldrich) containing 1 
ng/ml hydrocortisone (Sigma Aldrich) and 10 ng/ml human epidermal growth factor 
(EGF) as well as FCS 10% and penicillin-streptomycin as stated above. 
2.3.4 Chinese hamster ovary cells (CHO) 
CHO-K1 is a wild type Chinese hamster ovary cell line that was grown in complete 
DMEM-F12 media.  Additional mutant cell line known as CHO-745 was used.  
This mutant cell line is deficient of xylosyltransferase which is an essential enzyme 
for HS synthesis by transferring xylose to the core protein (serine) of HS which 
initiates the synthesis of GAG chains.  Mutant CHO-745 and CHO-677( a GAG 
mutant cell line) were grown in DMEM-F12 (Esko et al., 1985). 
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2.3.5 EAhy.926 
EAhy.926 is a hybrid cell line derived by fusion of human umbilical vein 
endothelial cells HUVEC with human lung carcinoma cell line thioguanine resistant 
clone A 549.  These cells have characteristics of differentiated endothelial cell 
functions such as haemostasis, inflammation and angiogenesis (Edgell et al., 1983).  
EAhy.926 cells were grown in complete medium of DMEM. 
2.4 Sub-culture work 
2.4.1 Adherent cells 
Cells were grown till 80% confluence when they were passaged by removing the 
medium and washed twice with sterile phosphate buffer saline (PBS; Sigma-
Aldrich). Cells were detached by incubating with pre-warmed EDTA-Trypsin 
(Sigma-Aldrich) for 2-3 minutes at 37
o
C.  Following this, the detached cells were 
neutralized by equal volume of complete medium and transferred to plastic 
universal tubes (SLS, North Shields, UK) for centrifugation at 500g for 5 minutes.  
Pellets were resuspended in complete medium and divided into 2-3 flasks. 
2.4.2 Cell counting and viability 
Cells were counted by using modified Neubauer haemocytometer (Reichert). After 
being resuspended, 10 µl of cell suspension were put in the counting chamber 
beneath the coverslip.  Cells were counted in at least two of the large squares and 
the total number was divided by two and multiplied by 1x10
4
 to obtain the final 
number in ml.  Cell viability was examined by mixing one volume of cell 
suspension with one volume of 0.2% trypan blue (Sigma-Aldrich) and dye-
excluding cells were counted as viable. 
2.4.3 Cryopreservation of cells in liquid nitrogen 
Cells were detached from 80% confluent flasks, spun down at 500g for 5 minutes 
and resuspended in 0.9ml of complete media, following this 0.1 ml of 
dimethylsulphoxide (DMSO, Sigma-Aldrich) was added at a final concentration of 
10%.  The cells were transferred into cryovials (Corning) and put in a freezing 
General materials and methods 
 
38 
 
vessel (Nalgene) which contains isopropranol.  Cells were then cooled in -80
o
C at 1
 
o
C/minute overnight and transferred to liquid nitrogen.  These cells were recovered 
by thawing at 37
o
C followed by incubation in 5-10 ml of complete medium for 24 
hours where medium was replaced with fresh medium to remove any remaining 
DMSO.  
2.4.4 Mycoplasma screening test 
Cell contamination with Mycoplasma may affect the cell metabolism, viability, 
proliferation and function.  MycoAlert kit (Lonza) was used for detection of 
mycoplasma enzymes that catalyze the conversion of adenosine diphosphate (ADP) 
to adenosine triphosphate (ATP). This conversion can be measured by 
bioluminescent reaction due to interaction between MycoAlert substrate and ATP.  
The MycoAlert protocol depends on mixing of 100 µl of supernatant media with 
100 µl MycoAlert reagent and the first reading was taken after 5 minutes (A), 10 
minutes later the second reading was taken (B). Results were calculated by dividing 
B/A, and result with less than 1 considered as negative whereas results more than 1 
was considered as mycoplasma positive.  No positive Mycoplasma results were 
noticed in this project.  However, in case of positive results, cells will be discarded 
or treated with mycoplasma removal agent (MRA, Serotec) until free of infection. 
2.5 General Molecular Biology 
2.5.1 RNA isolation  
In order to avoid RNA degradation caused by RNase contamination, RNA isolation 
was carried out under strict rules of high decontamination.  These included 
decontaminating bench, racks, micropipettes, gloves and other equipment with 
RNase-ZAP (Sigma-Aldrich) followed with alcohol.  Cells were grown till 70-80% 
confluency, washed with PBS and incubated with 1ml RNAzol B reagent (Sigma-
Aldrich) for 5 minutes (approximately 1x10
7
cells).  RNAzol B allows cell lysis and 
solubilization by forming complexes of RNA, water and thiocyanate.  Cells were 
removed by scrapers into 1.7 ml Eppendorf tubes and left at room temperature for 5 
minutes.  200 µl (1:5 RNAzol) of pre-chilled chloroform (denatures the protein) was 
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added and tubes were shaken vigorously for 15 seconds, left on ice 2-3 minutes and 
centrifuged for 15 minutes at 12000 g in 4
o
C centrifuge.  The upper aqueous layer 
was gently removed to 1.7 ml Eppendorf tube and mixed well with equal volume of 
propan2-ol (Isopropranol, BDH LTD, UK) and left on ice for 10 minutes.  Tubes 
were then centrifuged at 12,000g for 10 minutes. Following that, the supernatant 
was removed and pellets were washed with 1ml of 75% ethanol by centrifugation 
for 5 minutes at 7500g.  Supernatant was removed and pellets were left to air-dry.  
The RNA was finally reconstituted in 50 µl diethyl pyrocarbonate (DEPC) treated 
water.  
2.5.2 Nucleotide quantification 
RNA/DNA was quantified by spectrophotometer (Biophotometer, Nanodrop).  One 
drop (1 µl) of nucleotide was measured at O.D of 260/280 and 230/260.  The 
260/280 value gives a good clue of the purity of RNA/DNA whereas 260/230 ratio 
gives an idea about the nucleotide contents. Values of 260/280 more than 2 were 
considered for good quality and samples were used for further steps.  In case of 
260/280 value less than 1.8 RNA/DNA sample was discarded and the whole 
procedure was repeated. 260/280 values lower than 1.8 indicate the presence of 
proteins, phenol or other contaminants. 
2.5.3 RNA separation by gel electrophoresis 
To examine its integrity, each RNA sample was run on a 0.8 % Agarose gel with 
ethidium bromide (final concentration 0.5µg/ml).  This gel was electrophoresed in 
tris-acetate EDTA (TAE) buffer (0.004M Tris-acetate and 0.001M EDTA, pH 8.0) 
and visualized by UV light.  Intact subunits (no smears) of 28s and 18s with a ratio 
of 2:1 respectively were considered as a good clue of RNA integrity. 
2.5.4 Synthesis of cDNA 
Complementary DNA (cDNA) is synthesized from RNA by reverse transcription to 
produce a single strand of DNA.  cDNA was obtained from RNA using Superscript 
III reverse transcriptase (Invitrogen).  Each tube contained 5 µg RNA with 1µl oligo 
dT12-18 primer/random hexameres and 1 µl of dNTP (10mM) in a total volume of 13 
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µl.  Tubes were incubated at 65oC for 5 minutes.  The mix was chilled at 4oC for 
one minute and centrifuged briefly.  A master mix of 6 µl was added to each tube (4 
µl of 5x First Strand buffer, 1 µl of DTT and 1 µl of Superscript III enzyme) and 
mixed by gentle pipetting. Tubes were incubated at 50
o
C for 50 minutes followed 
by 15 minutes at 70
o
C before cooling. Incubations were performed in PCR thermal 
cycler (Hybaid). 
2.5.5 Transformation 
The cDNA encoding the human HS6ST1 gene (contained in pCR-Blunt II-Topo 
plasmid) was purchased from Geneservice.  This plasmid was cut in order to be 
ligated to pcDNA3.1/Zeo+.  Both plasmids were digested with Pst I and BamH I 
resulting in cohesive ends 
2.5.5.1 Bacterial culture  
Escherichia coli (E.coli) were grown in Luria-Bertani (LB) broth (10g/L Bacto-
tryptone, 5g/L Bacto-yeast extract, 10g/l sodium chloride and pH:7; Sigma-Aldrich) 
in different sizes such as universal tubes or glass conical flasks.  In case of plasmid-
containing bacteria, antibiotics in accordance to the plasmid were added to prevent 
other clones from growing.  In this study, ampicillin (100µg/ml) or kanamycin 
(50µg/ml) were used for plasmids containing SULF2 or HS6ST1 genes 
respectively.  Bacteria were cryopreserved for longer use by mixing 0.5ml of 
bacteria broth with 0.5ml of 40 % glycerol (Sigma-Aldrich) in cryovials and kept in 
-80
o
C. 
Agar plates including ampicillin were also prepared for growing of bacteria after 
transformation.  Antibiotics were necessary to allow only transformed bacteria to 
grow. 
2.5.5.2 Competent Cells 
Competent cells were made with XL1-Blue, DH5-α or JM83 clones.  Bacteria were 
grown in LB overnight.  The next day, 5 ml of bacteria was inoculated in 200 ml of 
LB and grown in orbital shaking incubator at 37
o
C till OD550 was 0.500.  In the 
following step, cells were chilled at 4
o
C for 15 minutes, gently mixed with 50 ml of 
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10 mM CaCl2 and incubated on ice for 10 minutes.  Pellets were resuspended in 
50ml of cold 75mM CaCl2 and kept on ice for 35 minutes.  Tubes were spun down 
for 15 minutes in cold centrifuge, pellets were suspended in 3 ml of pre-cold 75mM 
CaCl2 and the resulting content was transferred to a tube containing 0.488 ml of 
100% sterile glycerol.  Finally, competent bacteria were aliquoted into sterile 1.5 ml 
tubes and kept in -80
o
C. 
2.5.5.3 Transformation of competent bacteria 
Plasmids containing the DNA of interest were transformed into competent bacteria 
in order to obtain a higher quantity of DNA by bacterial growth.  In this study DNA 
insert was ligated in a proper mammalian vector and vector/insert (i.e. HS6ST1-
pcDNA3.1/zeo+) was initially transformed into competent cells (DH5-α).  First, 10-
100ng of plasmid DNA (vector/insert) was incubated with 100µl of competent 
bacteria (DH5-α) on ice for 30 minutes.  The mix was heat-shocked by exposing to 
temperature of 42
o
C for 90 seconds in water bath followed by ice cooling for 5 
minutes.  In the following step, cells were incubated with 20ml LB in shaking 
incubator at 37
o
C/150 rpm for 2 hours.  The universals were then centrifuged for 5 
minutes at 400g and the pellets were gently resuspended in 200 µl of LB medium 
and spread on LB agar plates (35 g/L of LB Agar) supplied with proper antibiotic.  
For each experiment, a series of control tubes was included which contained 
negative and positive controls (Table 2.1). 
 
Table 2.1. Agar plates distribution in transformation.  
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The plates were incubated overnight at 37
o
C upside down.  Transformed bacteria 
growing on dishes with antibiotics (Dish-3) were considered positive.  For large 
amounts of DNA, individual colonies were picked up and grown in an antibiotic-
containing LB broth in shaking incubator (150 rpm) at 37
o
C overnight.   
2.5.5.4  DNA precipitation 
DNA precipitation was carried out to increase the DNA concentration for some 
experiments.  Sodium acetate (3M) was added to the DNA to reach a final 
concentration of (0.3M) and mixed well with 2 volumes of 100% ethanol.  The mix 
was cooled at -80
o
C for 20 minutes and centrifuged at 15000 g for 10 minutes.  
DNA pellet was washed with 70% cold ethanol and centrifuged for additional 5 
minutes at the same speed.  The supernatant was removed and the remaining DNA 
was air-dried and reconstituted in the appropriate volume of DEPC treated water. 
2.5.5.5   Restriction enzyme digestions 
Restriction enzymes were used in this study depending on the sequence of the 
plasmid in use.  Restriction enzymes can cleave DNA in a sequence specific 
manner.  Plasmid sequence was restriction-mapped using the Invitrogen web site 
and the restriction enzymes were chosen as needed.  Mostly, two restriction 
enzymes were chosen with unique restriction sites for both of the insert and the 
vector.  One unit of an enzyme is the activity that cleaves 1μg of Lambda-DNA at 
37
o
C in one hour.  For each digestion reaction, 1μg of plasmid DNA, 2μl of 10X 
buffer (Promega), 0.2 µl of BSA and 1 µl  (5 units) of  restriction enzyme were 
added in a 20 µl final volume reaction and mixed gently by pipetting.  Tubes were 
incubated at 37
o
C for 2-3 hours according to the manufacturer’s instructions 
(Promega).  For pcDNA3.1/Zeo+ and HS6ST1, both were cut using Pst I and BamH 
I that resulted in cohesive ends.  
PstI: 5’-CTGCA G-3’ 
      BamHI: 5’-G  GATCC-3’ 
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2.5.5.6 Ligation Reaction 
DNA coding HS6ST1 was cut using Pst I and BamH I enzymes and run on an 
agarose gel (1%) alongside the vector.  The insert-DNA was then cut out of the gel 
and purified.  The vector pcDNA3.1/Zeo+ was also digested with restriction 
enzymes Pst I and BamH, run on agarose gel and purified as stated above.  The 
DNAs of the insert and the vector were ligated using T4 DNA ligase kit (Invitrogen) 
following instructions related to cohesive ends.  The molar ratio of the insert to the 
vector was 6:1 respectively. Ligated fragments were tested by digesting with Pst I 
and BamH I enzymes and then loaded on 1% agarose gel to visualize the band sizes.  
Concentration of insert-DNA was calculated according to the equation: 
Insert mass (ng) = 6 x 
                  
                  
 x vector mass (ng) 
2.5.5.7 Gel Electrophoresis 
Agarose gel electrophoresis was carried out to visualize DNA products such as after 
conventional PCR or following digestion with restriction enzymes.  This technique 
depends on separation of DNA products upon their sizes compared to DNA ladder 
100bp (Promega) or 1kbp ladder (Fermentas).  The gel is immersed in a TAE buffer 
where an electric field is applied that allows DNA fragments to migrate towards the 
positive electrode (according to their negative charges).  A definite weight of 
agarose (w/v), depending on the final concentration required, was dissolved in 50 
ml of TAE buffer and boiled in a microwave.  The gel was left to cool at room 
temperature when ethidium bromide (0.5µg/ml) was added.  Gels were prepared 
with different concentrations between (0.7-1.5%) depending on sizes of DNA 
fragments.  
2.5.5.8 Gel Extraction 
DNA fragments were excised out of the gel and purified following the protocol of 
QIAquick Gel Extraction Kit (Qiagen).  After being electrophoresed, DNA 
fragments were cut out of the gel using a sterile scalpel.  The gel-slice containing 
the DNA fragment was weighed (mg) and completely dissolved in a binding 
solution (QG Buffer) at 50
o
C for 10 minutes.  The dissolving mixture was prepared 
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where 3 volumes (3µl) of QG buffer were mixed with one volume (1mg) of the gel-
slice considering that each 1µl of the solution approximately equals to 1mg of gel-
slice.  The mixture was applied to spin column and washed twice with membrane 
Wash Solution.  In the final step, DNA was eluted using DEPC treated water and 
stored at -20
o
C.   
2.5.5.9   DNA extraction 
According to the amount of DNA required, mini, midi or maxi prep kits were used 
(Qiagen).  DNA was isolated from bacteria following the manufacturer’s 
instructions (www.qiagen.com/handbooks).  The reaction depends basically on lysis 
of bacteria under alkaline conditions and adsorbing of DNA to silica in presence of 
high salt buffer.  Transformed bacteria were grown overnight with appropriate 
antibiotic.  The cells were centrifuged and pellets were lysed and neutralized in 
presence of RNase.  Samples were then purified by application of the supernatant to 
spin columns (silica membrane).  The tubes were centrifuged and washed by PB 
buffer to remove endonucleases.  High salt was removed by washing with PE buffer 
and plasmid DNA was eluted in nuclease free water.  DNA was then quantified and 
stored at -20
o
C. 
2.5.6 DNA transfection 
Transfection is a common procedure used to insert a foreign DNA into eukaryotic 
cells.  The DNA is cloned in a vector with the ability to replicate. The plasmid is a 
double stranded DNA that contains specific promoter with an antibiotic resistance, 
origin of replication, and cloning sites with different restriction sites.  
Transfection is classified into two main types, stable and transient.  In transient 
transfection, the DNA does not integrate in the genome but transfected cells are able 
to express the gene of interest for several days.  In stable transfection the translated 
DNA is integrated into the genome where it can replicate during cell division. 
In this study, stable transfectants were generated by introducing the plasmid with a 
gene of interest into mammalian cells.  Followed by antibiotic selection, single 
clones were picked and expanded.  
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The transfection depends on introducing the HS6ST1gene (Gene services) cloned in 
pcDNA3.1/zeo+ (Invitrogen) into the HK2 cells.  The cells were grown to 60% 
confluence in six-well plates by using lipid-based transfection reagents (Effectene, 
Qiagen).  One day before transfection, cells were seeded in 100 mm dishes and 
incubated under normal conditions.  At the day of transfection cells were confluent 
by around 70%.  For 100 mm dish, 2μg of DNA was dissolved in TE buffer with EC 
buffer in 300 µl (Table 2.2).  DNA was mixed with enhancer at a ratio 1:8.  The 
mixture was left 5-10 minutes at room temperature and 100 µl of Effectene reagent 
was added, mixed well and left at room temperature for additional 5-10 minutes.  
Afterwards, cells were washed with PBS and fresh growth medium was added (7 
ml).  Finally 3 ml of growth medium (DMEM-F12) was added to DNA-Effectene 
complex and the whole mix was added to the dish and incubated at 37
o
C with 5% 
CO2 for 48 hours.  Cells were then passaged at 1:5 to 1:10 ratio and antibiotic 
(Zeocin, Invitrogen) was added at a final concentration of 400 µg/ml.  Antibiotic-
containing media was changed at 2-3 days.  Colonies were picked and transferred 
into 48 well plates and grown to confluency before transferring to larger wells or 
flasks.   
2.5.6.1 Optimization of transfection procedure 
Transfection procedure was optimized using several ratios of Effectene Reagent 
(ER) to DNA.  Best efficiency was noticed at 1: 50 ratio of DNA (µg) and Effectene 
reagent (µl) respectively. 
 
Table 2.2. Transfection reagent optimization (Qiagen). 
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2.5.6.2 Transfection efficiency 
Cells were transfected with green fluorescent plasmid (GFP) (Invitrogen) at the 
same time and under the same condition as the gene of interest such as DNA 
concentration and DNA/ER ratio.  These cells were examined by flow cytometry 
after 24 hours in order to estimate the efficiency of transfection.  Briefly, GFP 
transfected cells were washed with PBS twice, detached by EDTA-Trypsin and 
centrifuged at 500g for 5 minutes.  Pellets were resuspended in 2 % BSA-PBS and 
examined by flow cytometry against wild type cells.  Cells that expressed GFP were 
considered as positively transfected and the ratio of these cells to the whole number 
of cells was considered as the transfection efficiency. 
2.5.6.3 Antibiotic killing curve 
Zeocin (Invitrogen) is a copper-chelated glycopeptides antibiotic which is isolated 
from culture broth of Streptomyces verticillus mutant.  At a toxic level, Zeocin can 
bind to cell DNA and cleave it causing cell death. HK2 cells were seeded in six-well 
plates (in duplicates) till 20% confluent where different concentrations of Zeocin 
were added as follows: 0, 50, 100, 200, 400 and 600 µg/ml in complete media.  The 
cells were left to grow in 37
o
C, 5% CO2 and media including antibiotic was 
changed every two days. The cell confluency was assessed every day for 7-8 days, 
floating cells were considered as dead.  The lowest concentration of antibiotic 
where cells were completely dead was considered as the toxic dose (400µg/ml).  
Negative control included cells grown in absence of antibiotics. 
2.5.7  DNA sequencing and alignment 
Plasmid was supplied from Invitrogen (DNA3.1/zeo+) and cut with BamHI and PstI 
which have unique restriction sites, at 929 bp and 961bp respectively (Figure 2.1).  
HS6ST1 gene was supplied from Geneservice on pCR-Blunt II-TOPO plasmid 
transformed into bacteria with kanamycin selection antibiotic. HS6ST1 was 
digested using PstI and BamHI which produce cohesive ends. The insert (HS6ST1) 
and the vector (pcDNA3.1zeo+) were ligated using T4 DNA ligase (Invitrogen).  
Resultant vector-insert was sequenced (Geneservice) and aligned with HS6ST1 in 
PubMed (see appendices).   
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Figure 2.1. Drawing of the plasmid vector (pcDNA3.1/zeo+) and HS6ST1 insert. 
2.5.8 Conventional PCR  
The polymerase chain reaction (PCR) is used to amplify a target DNA.  This 
reaction requires the presence of oligo nucleotide primers with specific sequence 
that binds at the beginning of the targeted sequence to be amplified.  DNA needs to 
be denatured into two single chains by increasing temperature up to 94
o
C which is 
carried out by thermal cycler.  Temperature between 50-60
o
C is required for primer 
annealing to the denatured DNA whereas 72
o
C is required for the Taq polymerase 
extension (polymerization).  Therefore a DNA polymerase chain reaction requires a 
thermal cycler, oligo nucleotide primers, dNTP and DNA polymerase enzymes with 
optimal conditions.  For primers to anneal to the single stranded DNA, the thermal 
cycler will bring the temperature down to 50-60 
o
C according to the optimum 
temperature of primer annealing.  Taq DNA polymerase enzyme is derived from 
Thermus aquaticus which is active at high temperatures.  PCR experiments were 
performed using ready master mix (VHBio) with primers for house-keeping gene of 
glyceraldehyde 3-phosphatedehydrogenase (GAPDH) and HS6ST1 gene (VHBio).  
PCR procedure was optimized by changing temperatures and incubation times as 
well as concentrations of template DNA and primers. The best conditions for 
thermal cycler (Hybaid) are summarized in table 2.3. 
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Table 2.3. Thermal cycler conditions for conventional PCR.  
Whereas the optimal concentrations for master mix and primers were as follows for 
20 µl reaction tubes (Table 2.4):  
 
 
Table 2.4. Optimal concentrations of PCR mix components. 
A plasmid encoding HS6ST1 DNA was used as a positive control (Gene Services) 
and PCR products were visualized on 1% agarose gel in TAE buffer. 
2.5.8.1 Oligo nucleotide primers  
Oligo primers were designed considering many conditions such as:   
 Length between 18-30 bp. 
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 Primers must not be complementary to each other. 
 Melting temperature is between 50oC and 65oC. 
 They should bind specifically at the beginning of the target DNA. 
 They should have sequence homology with the target DNA. 
 CG contents should be around 50-55% of whole nucleotide content. 
 Primers for GAPDH and HS6ST1 were designed according to the above 
conditions and ordered from (VHBio), (Table 2.5).   
 
Table 2.5. Primer sequences for conventional PCR amplification. 
2.5.9   Quantitative PCR (qPCR) 
Real time PCR (RT-PCR or qPCR) is a method developed for quantifying DNA that 
allows detection of amplified DNA at higher sensitivity compared to conventional 
PCR.  Herein, in qPCR the amount of quantified DNA is linked to fluorescence 
intensity by binding to a fluorescent reporter molecule.  In conventional PCR the 
amplified DNA is detected at the end of the reaction whereas the quantitative PCR 
(qPCR) measures the fluorescence at each cycle as the amplification is still in 
progress (exponential phase) before the consumption of the reagents and the 
accumulation of inhibitors.  Fluorescence reporter molecules such as double-
stranded DNA binding-dye or dye-labelled probes are used for monitoring the 
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progress of amplification reaction.  The cycle number where the amplification 
crosses a definite threshold of fluorescence level is known as threshold cycle (CT).  
The probes used in this study were hydrolysis probes (TaqMan) which are sequence 
specific comprised basically of oligonucleotides labelled with FAM dye and 
TAMRA quencher.  TaqMan primers generally contain additional sequence to the 
primer known as the probe.  This probe anneals to the same strand of targeted 
sequence closely downstream the primer site.  The fluorescence reporter dye (FAM) 
is attached to the 5’ end whereas the quencher is attached to the 3’ end of the probe.  
Fluorescence from the reporter is quenched as long as the reporter and the quencher 
stay close together (Figure 2.2).  When polymerization extends, the Taq DNA 
polymerase encounters the 5’ end of the probe.  Taq polymerase then degrades the 
5’ end of the probe releasing the reporter dye and the quencher which results in 
fluorescence activity.   
  
Figure 2.2. Diagram showing primer probes fluorescence during real time PCR.  
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Real time PCR experiments were performed in 96 well plates using master mix 
(Stratagene) with high Rox while primer-probes were ordered from TaqMan Gene 
Expression Assay with FAM dye-labelled probes.  Rox dye provides a passive 
reference dye that helps in fluorescence normalization relating to pipetting errors 
and instrument limitations. 
One tenth of cDNA (2µl) was used as template in each reaction (20µl).  QPCR 
experiments were run in Applied Biosystem Prism 7000 machine with the following 
conditions (Table 2.6):  
 
Table 2.6. Real time PCR conditions. 
Each well had a 20 µl reaction volume as follows: 10 µl of 2x master mix (high 
ROX), 1 µl of primer probe (20 x), 2 µl of cDNA and the volume was completed to 
20 µl with RNase free water (7 µl), (Table 2.7). 
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Table 2.7. Contents of qPCR tube reaction. 
2.5.9.1 Comparative CT method (ΔΔCT) 
For DNA quantification and data analysis, the comparative quantification method 
was used. This method was chosen to compare large number of targets with a house 
keeping gene without the need to run a standard curve for each assay.  In this 
method the house keeping gene served as a reference for comparison with a target 
gene.   
QPCR experiments were run in triplicates in 96 well plates and CT values were 
obtained.  ΔΔCT values were calculated for resting (non-stimulated) and stimulated 
cells for each of the targeted gene and endogenous gene in each experiment.  Fold 
change was expressed as the value of 2
-
 
ΔΔCT
 and ΔΔCT values were calculated as 
follows:  
ΔΔCT= ΔCT (calibrator) -ΔCT (unknown).   
ΔCT calibrator = (CTTa -CTRa) and  
 ΔCT unknown= (CTTa -CTRa).  Where CTTa is the CT value for targeted gene 
and CTRa is CT value for reference gene.    
ΔCT Data analysis was carried out using REST-2008 software. 
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2.5.9.2  Probes 
Human exon junction spanning probes do not detect any amplified genomic DNA.  
These primer probes were ordered from (Applied Biosystem, TaqMan Gene 
Expression assay, table 2.8). 
 
Table 2.8. Primer probes for RT-PCR (Applied Biosystem, TaqMan Gene 
Expression assay). 
2.5.9.3   Standard curve and Efficiency Test (Validation) 
A standard curve for the reference and targeted genes was made using the same 
concentration of cDNA.  Using 10-fold serial dilutions, the CT numbers and the 
logarithmic values of RNA concentration (ng) were calculated to express the slope 
equation and PCR amplification efficiency. The slope of standard curve was used to 
estimate the PCR amplification efficiency of a real time PCR reaction.  The 
efficiency was calculated from the equation: Exponential amplification=10
(-1/slope) 
Efficiency= [10
(-1/slope)
]-1, i.e. if the slope is -3.3 the amplification will be 2.0092 
and efficiency is 1.0092 which means 100% efficiency.  The efficiency of an 
optimal PCR should be between 90 and 110 % i.e. slope value between -3.1 and -
3.6.  Efficiency of qPCR can be affected by many factors such as amplicon length 
and primer designs.  To achieve valuable results efficiency of qPCR was 
investigated and the procedure was used only after achieving validity of amplifying 
of around 100% (Figure 2.3). 
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Figure 2.3. Efficiency of qPCR reaction for human GAPDH and HS6ST1 genes.  
Real time PCR experiment included template cDNA in 10-fold serial dilution in 
triplicates.  CT numbers were calculated and analyzed against logarithms of 
dilutions. A, efficiency for GAPDH gene. B, efficiency for HS6ST1 gene.  (N=2) 
2.6 Protein chemistry 
2.6.1 Protein extraction 
Protein was extracted from cells using a lysis buffer (50mM Tris, 150mM NaCl, 
0.5-1% NPO4, phosphatase inhibitor) which was supplemented with one tablet of 
protease inhibitor (Complete Mini Protease Inhibitor Cocktail, Roche) for each 10 
ml.  Cells were grown in 25 cm
2
 flasks till 70-80% confluency and medium was 
removed, cells were washed in PBS and detached by EDTA-Trypsin.  Then cells 
were centrifuged and pellets were treated with 200µl lysis buffer, mixed well and 
left on ice for 15 minutes. These lysates were sonicated till frothing and centrifuged 
at 20,000 g for 20 minutes.  The supernatant was removed to clean Eppendorf tubes 
where they were used for protein assay.   
2.6.2 Protein assay  
Protein concentration was estimated by using Bicinochoninic Acid (BCA) kit 
(Pierce).  The assay basically depends on detecting protein by the Biuret reaction.  
In this reaction, peptides bind to cupric ions and form a coloured chelate complex 
under alkaline condition where Cu
+2
 is reduced to Cu
+
.  Then one Cu+ ion reacts 
with two molecules of BCA forming a purple-coloured product that exhibits 
absorbance at 562nm wavelength.  Protein concentration was estimated in reference 
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to protein standard curve made using serial dilutions of a known concentration of 
BSA protein. 
2.6.3 SDS-PAGE  
SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis, is a 
procedure that separates different proteins depending on molecular weight instead 
of negative charge. SDS allows all proteins to have high negative charge so they 
travel according to their molecular sizes when an electrical field is applied.  SDS-
PAGE consists of resolving component and stacking component which are prepared 
as shown in table 2.9.  The gel was set up in a running tank with vertical 
electrophoresis apparatus (Bio-Rad).  
 
Table 2.9. Components of 10% resolving and stacking acrylamide gels. 
Acrylamide gel (10%) was used to fractional proteins of molecular sizes between 15 
and 170 kD.  After sample loading, the gel was immersed in running buffer (25 mM 
Tris, 250 mM glycine and 0.1%SDS with pH: 8.3) and electrical current of 80-120V 
was applied. A protein marker (Fermentas) was run with the proteins as a size 
reference.  Equal concentrations of protein samples (10-30µg) were loaded after 
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being mixed with 1x SDS loading buffer (50mM Tris, 100mM dithiotheritol DTT, 
2% SDS, 10% glycerol and 0.1 % Bromophenol blue) and boiled at 100
o
C for 5 
minutes. 
2.6.3.1 Coomassie staining 
Gels were stained with Coomassie blue to visualize the protein bands.  Coomassie 
stain consists of 10% acetic acid (v/v), 10 % isopropanol (v/v) and 0.1 % Coomassie 
blue powder (w/v).  
2.6.4 Western blotting 
After running the proteins on acrylamide gel, protein bands were transferred to 
polyvinylidene difluoride (PVDF, Amersham) membrane by a procedure known as 
gel transfer.  First, the PVDF membrane was immersed in methanol for 30 seconds 
followed by distilled water for 1-2 minutes.  Electrophoresed gel was immersed in 
transfer buffer which consists of 3.03 g Tris-base, 14.4 g glycine, 200 ml methanol 
and the mix was made up to 1000 ml in distilled water.  The electro-blotting cassette 
was preassembled in the transfer buffer and PVDF membrane was put over the gel 
that allows transfer of proteins from the gel to the PVDF membrane.  The cassette 
was then put in transfer tank, immersed with transfer buffer and an electrical field 
was applied with 30V overnight with the cassette cooled by running water.  
The membrane was removed and blocked in 5% non-fatty milk (Marvel) or 5% 
BSA in TBS-T (5mM Tris, 150mM NaCl, 0.1% Tween-20 with pH: 7.4) for one 
hour. Primary antibody was added in blocking buffer for at least one hour at room 
temperature or at 4
o
C overnight.  Then, the membrane was washed three times with 
TBS-T and incubated with secondary antibody conjugated by horseradish 
peroxidase (HRP), (Sigma-Aldrich), in blocking reagent for one hour at room 
temperature.  The membrane was then washed in blocking buffer for three times on 
shaking incubator.  The bound antibody was visualized by incubating the membrane 
with enhanced luminol-based chemiluminescence (ECL) substrate (Pierce, Thermo 
Scientific).  A working reagent was prepared by mixing one volume of reagent A 
with one volume of reagent B.  Appropriate volume (5 ml) of the working reagent 
was put on the membrane for 5 minutes.  This substrate allows the oxidation of 
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luminol by HRP which results in emission of light.  The membrane was then sealed 
in an appropriate cassette for exposure to X-ray film (Kodak). 
2.6.4.1 Staining of PVDF membrane 
Protein bands on PVDF membrane were visualized after membrane development by 
staining with copper-phthalocyanine (0.05% copper in 12m HCl). 
2.7 Flow Cytometry 
2.7.1 General principles 
Flow cytometry (FACScan, Becton Dickinson) measures cells quantitatively and 
qualitatively as the machine recognizes cell numbers and cell types.  The cells are 
forced into a narrow stream so they are counted one at a time.  At this point cells are 
intercepted by a laser beam of known wavelength (generally 488nm) that stimulates 
the cells to emit light. This light may be scattered at two levels known as forward 
scatter (FSC) and side scatter (SSC).  FSC light is scattered at low angle with laser 
beam that generates a signal which is proportional to the cell size.  SSC light is 
scattered at 90
o
 angle with the laser beam proportional to the granularity of the 
cytoplasm.  Data from deflected light are collected by a computer unit for each cell 
which allows determination of cell’s number and type.  In case of fluorochrome 
labeling, for example with a FITC-conjugated antibody, light of a different wave 
length will be emitted after exposure to the laser beam.  The emitted light is 
measured by photomultiplier tubes equipped with filters to measure light at a correct 
wavelength only.  The photomultiplier converts fluorescence into electrical signals 
which are proportional to the number of excited molecules. 
2.7.2 Immunofluorescence antibody labelling 
Flow cytometry (BD Biosciences) was used for examining cell fluorescence after 
using FITC/TRITC-conjugated factors for labelling the molecule of interest.  Cells 
were labelled for intracellular or extracellular antigens.  In case of intracellular 
antigens, cells were treated with detergents such as TritonX-100 (Sigma-Aldrich) to 
increase permeability allowing dye entry through pores in the plasma membrane.   
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For labelling cell-surface antigen, cells were detached by incubating with cell 
dissociation solution (Invitrogen) for 5-10 minutes at 37
o
C.  These cells were then 
centrifuged at 500g for 5 minutes and pellets resuspended in PBS and counted.  
Cells were then suspended in 2% BSA-PBS (at 4x10
6
 cell/ml) and a definite number 
of cells (2x10
5
) was transferred to Eppendorf tube (50 µl volume).  An appropriate 
volume of primary antibody was added (1:50/100), mixed and incubated on ice 
(4
o
C) for 30 minutes.  Appropriate isotype-matched control with an irrelevant 
antibody was used to detect non-specific binding of primary antibody.  Unbound 
antibody was removed by washing the cells for 3 times in PBS.  Cells were 
resuspended in 2%BSA-PBS and fluorochrome-conjugated (FITC) secondary 
antibody was added for additional 30 minutes and incubated on ice.  Secondary 
antibody is usually produced in different species i.e. rabbit anti mouse and it is 
specific for the primary antibody.  Cells were then washed twice in PBS and 
resuspended in 200-300 µl of 2%BSA-PBS where they were ready for flow 
cytometry measurement.  Steps that included fluorochrome labelling were 
performed in the dark.  Non-viable cells were excluded by using propidium iodide 
(PI) at concentration of 5 µg/ml.  PI was added immediately to each sample prior to 
flow cytometry and dead cells were gated out accordingly.  Data were analyzed 
depending on median fluorescence intensity (MFI) measured by flow cytometry.  
MFI values were determined statistically using WinMDI 2.9 software. 
2.7.3 Cell stimulation and phenotyping 
Cells were investigated for the expression of specific antigens in order to define 
their phenotype and examine the activity of stimulators.  Endothelial and epithelial 
cells were examined for the expression of MHC II antigens following stimulation by 
IFN-γ (R&D).  Flow cytometry was used to measuring the expression of MHC II 
antigens after stimulating cells with interferon gamma IFN-γ (R&D) for different 
time points.  Endothelial and epithelial cells were stimulated with IFN-γ (25 ng/ml) 
for three and seven days respectively.  These cells were detached by trypsin/EDTA, 
washed three times with PBS and incubated with monoclonal mouse anti-human 
HLA-DP, DQ, DR, (DAKO Clone CR3/43, FITC-conjugated) for 30 minutes at 
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4
o
C.  Cells were washed twice, resuspended in 2% BSA- PBS and examined by 
flow cytometry. 
2.7.4 Antibody labelling  
Monoclonal antibody 10E4 (Seikagaku-#370255) was used as an anti HS sulphation 
antibody.  Cells were detached using cell dissociation solution (Sigma-Aldrich), 
washed twice with PBS, counted and suspended in 2% PBS-BSA.  10E4 antibody 
(mouse anti-human IgM) was added at 1:100 ratios, tubes were then incubated at 
4
o
C for 60 minutes, washed twice with PBS and incubated with FITC-conjugated 
anti-mouse antibody for additional 30 minutes.  Cells were then washed twice with 
PBS, suspended in 2% PBS-BSA and examined by flow cytometry.  Mouse anti-
human IgM antibody was used as an isotype. 
2.7.5 Phage display antibody 
Phage display antibodies are produced in bacteria (generous gift from Prof. T.V. 
Kuppevelt); these antibodies have the ability to bind to specific epitopes in HS 
structure.  They have been used recently for examining the changes in HS structure 
over a wide range (table 2.10).  For staining with these antibodies, cells were 
detached using cell dissociation solution (Sigma-Aldrich), washed twice with PBS, 
counted and suspended in 2% PBS-BSA.  Cells were then blocked with 2% BSA-
PBS for one hour and incubated with phage display antibody at 1:10 overnight at 
4
o
C.  The cells were washed with PBS and incubated with anti-VSV cy3-conjugated 
antibody (Sigma-Aldrich) at 1:200 on ice for further 30 minutes.  Cells were then 
washed twice with PBS, suspended in 2%PBS-BSA and examined by flow 
cytometry.  Mouse anti-human IgG2 antibody was used as an isotype. 
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Table 2.10. Epitopes of HS antibody specific antibodies.  
2.8 Statistical analysis 
Data were statistically analyzed using Student’s (two paired/unpaired) T-test for 
data with normal distribution.  ANOVA for comparing three or more independent 
groups was used with Tukeys and Bonferroni post tests. Software such as Windows 
Excel, Prism 3/4, WinMDI 2.9 and REST-2008 were used.  P values less than 0.05 
were considered significant. 
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3.1 Introduction 
Heparan sulphate has a wide range of interactions with a variety of materials such as 
growth factors, cytokines, viruses, enzymes (Sarrazin et al., 2011).  The sulphation 
of HS undergoes changes in accordance with its involvement in biological activities 
in health and disease.  HS regulation includes sulphation changes at specific 
sulphate groups by increasing or decreasing the sulphate transferase activities.  For 
example, the stimulation of endothelial cells with cytokines such as IFN-γ resulted 
in increased expression of NDST1 and NDST2 genes at mRNA level.  This increase 
was shown to enhance the ability of HS to interact and present chemokines such as 
CCL5 (Carter et al., 2003).   
3.1.1 HS6ST modifying enzyme 
The HS6ST enzyme transfers sulphate group to the 6-O position of glucosamine of 
the HS repeated disaccharide units.  This enzyme has three isoforms, each with a 
specific substrate and a different tissue distribution (Habuchi et al., 2000).  Changes 
in sulphation patterns of heparan sulphate can be examined by generating cell lines 
which overexpress or knock-out a definite sulphate group (Pikas et al., 2000; Do et 
al., 2006).  Overexpression of HS6ST isoforms, for instance, was previously studied 
by transfecting the human embryonic kidney cell line (HK293) with mice HS6ST 
isoforms.  Structural disaccharide analysis of HS from these cells shows a high 
concentration of 6-O sulphate groups at GlcA-GlcNS6S and GlcA-GlcNAc6S 
residues.  Additional changes included decreased sulphation at N- and 2-O 
positions.  The HS chains following HS6ST overexpression exhibit further changes 
in domain distribution including gradual changes from NS, NA/NS and NA 
domains toward more NS and NA domains along with changes in polyanionic 
properties and increased chain length (Do et al., 2006). 
3.1.2 HS detecting antibodies 
Interaction between heparan sulphate and proteins such as growth factors is 
mediated by specific HS domains.  Structural diversity of these domains is often 
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investigated using the specific HS antibody, 10E4 (David et al., 1992) and 
additional antibodies produced using phage display technology because of the poor 
immunogenicity of HS (Dennissen et al., 2002).  
Several phage display antibodies are used for the investigation of changes in HS in 
the context of inflammation, development, carcinogenesis and fibrosis (Gomes et 
al., 2006; Tatrai et al., 2010).  For example, HS4C3 antibody was shown to target a 
specific HS epitope containing highly sulphated disaccharide of GlcNS3S6S-Ido2S 
in rat kidney cells (van Kuppevelt et al., 1998; Ten Dam et al., 2006).  Incubating 
cells with FGF2 could inhibit the HS4C3 binding by about 60 % (Lensen et al., 
2005).   
Staining of renal sections with phage display antibodies showed specific binding to 
basement membrane epitopes in different renal structures including glomerulus, 
Bowman’s capsule and cortical tubules (Lensen et al., 2005).  The RB4EA12 
antibody targets an HS epitope composed of IdoA-GlcNS6S (Dennissen et al., 
2002).  This antibody was used for examining changes in HS in fibrogenesis and 
carcinogenesis.  Interestingly, the HS epitopes for RB4EA12 and HS4C3 were both 
increased in liver cirrhosis compared to normal liver (Tatrai et al., 2010).  However, 
the fine individual and relative modifications of HS are still a big challenge to 
resolve (Smits et al., 2006; Rops et al., 2008). 
3.1.3 HS6ST function and physiological role 
Heparan sulphate is involved in a wide range of biological activities via interaction 
with many proteins including cytokines, growth factors, morphogens and ECM 
proteins (Whitelock and Iozzo, 2005).  These interactions depend to a large extent 
on the sulphation pattern of HS including the 6-O position (Esko and Selleck, 
2002).  HS6-O sulphation is regulated during embryonic development (Allen and 
Rapraeger, 2003), aging (Feyzi et al., 1998; Huynh et al., 2012) and carcinogenesis 
(Jayson et al., 1998).   
Heparan sulphate interaction with growth factors is dependent on the presence of 
specific sulphate groups.  The role of 6-O sulphation in modulating of HS fine 
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structure and FGF signalling has been the topic of extensive study.  Although 6-O 
sulphation is not an absolute requirement for FGF2 binding, it constitutes an 
essential requirement for FGF2-FGFR signalling and mitogenic activity (Sugaya et 
al., 2008).  For example, addition of selective 6-O desulphated heparin blocked the 
induction of mitogenic activity in vitro following FGF2 stimulation (Guimond et 
al., 1993; Walker et al., 1994).  Similarly, disaccharide analyses show that 
mitogenic activity of FGF2 is correlated with 6-O sulphate content (Pye et al., 
1998).  Furthermore, Guimond et al. showed that addition of 2-O desulphated 
heparin, which retains 6-O sulphate groups, has the capability to bind FGF2 with 
less affinity compared to native heparin.  However, removing the 6-O sulphate 
groups had no effect on FGF2 binding (Guimond et al., 1993).  A recent result has 
shown that GAGs exhibit an age-dependent decrease in FGF2 binding parallel to 
decreases in N- and 2-O sulphate groups even with increased 6-O sulphate (Huynh 
et al., 2012).  The 6-O sulphate group constitutes an essential component for HS 
binding with HGF (Lyon et al., 1994a), PDGF (Feyzi et al., 1997), lipoprotein 
lipase (Parthasarathy et al., 1994) and, interestingly, FGFR1 (Schlessinger et al., 
2000). 
Additional roles have been reported for 6-O sulphate groups in the inflammatory 
response.  For example, this group is required for HS interaction with L- or E-
selectins.  This facilitates leucocyte rolling and adhesion to endothelial cells (Wang 
et al., 2002; Celie et al., 2005).  
 
 
 
 
 
 
 
The Effect of HS6ST1 on HS Structure and Biological Activity 
 
65 
 
 
3.1.4 Specific aims 
Definition of the role of HS sulphation is an issue of vital importance due to the 
involvement of HS in several biological activities in health and disease.  This part of 
the research aims to shed light on changes in HS sulphation.  In particular, the role 
of 6-0 sulphate groups in interaction with cytokines involved in chronic rejection.  
For further understanding the HS structure modulation and its effect on HS biology, 
these specific aims are addressed: 
 To examine the expression of HS modifying enzymes in human kidney cell lines  
 To investigate the changes in sulphation of HS by HS6ST enzyme following 
cytokine stimulation 
 To generate HS6ST1 overexpressing transfectants to: 
o Examine the changes in HS epitopes 
o Study the FGF2 binding to HS6ST1 transfectants 
o Investigate the effect of HS6ST1 overexpression on renal epithelial cell 
proliferation  
o Study the effect of HS6ST1 on pERK activation 
o Examine the effect of overexpression HS6ST1 on HS structure
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3.2 Specific materials and methods 
3.2.1 FGF2 binding assay 
In this study HS-FGF2 binding was examined using the Fluorokine Biotinylated 
human basic FGF2 kit (R&D).  Cells were detached using cell dissociation solution 
(Sigma-Aldrich), washed twice with PBS, counted and suspended at 4x10
6
 cells/ml 
in PBS containing 2% BSA.  In Eppendorf tubes, 10 µl of biotinylated FGF2 (final 
at 570ng/ml) were incubated with 25 µl of cells (1x10
5
cells) for 60 minutes at 4
o
C.  
Avidin-FITC (10 µl) was then added without wash and the tubes were incubated 
for another 30 minutes at 4
o
C in the dark.  Cells were then washed twice with PBS, 
resuspended in 200µl of PBS containing 2% BSA and investigated by flow 
cytometry.  Biotinylated protein (soybean trypsin inhibitor) to the same level of 
FGF2 was used as a negative control.  The specificity of the reaction was verified 
using blocking anti-human FGF2 antibody.  Negative and specificity controls were 
carried out with each assay.  Median fluorescence intensity (MFI) was used as an 
expression of fluorescence activity and ∆MFI refers to MFI of sample following 
subtraction of the control values.  Reference values were usually for cells incubated 
with Avidin-FITC conjugated substrate only (without adding biotinylated factors).  
The protocol was followed according to manufacturer’s instructions.   
3.2.2 CCL5 binding assay 
A chemokine binding assay (RANTES or CCL5) was developed in order to 
investigate the effects of sulphation changes of HS on human Fluorokine 
Biotinylated CCL5 (R&D) in a similar way to FGF2 assay. Fluorokine biotinylated 
CCL5 was added to 1x10
5
 cells at a final concentration of 100ng/ml and incubated 
at 4
o
C for one hour.  Avidin-FITC substrate was added without wash and the mix 
incubated for 30 minutes at 4
o
C.  Cells were washed and resuspended in 2% PBS-
BSA for flow cytometry analysis. Biotinylated protein (soybean trypsin inhibitor) 
to the same concentration as CCL5 was used as a negative control.  Anti-human 
CCL5 antibody was used as a blocking control to verify specificity of CCL5 
binding.  Protocol was followed according to manufacturer’s instructions.   
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(www.rndsystems.com/pdf/nfrn0.pdf)  
3.2.3 Proliferation assay 
Cell proliferation assays are widely used for studying growth factors or media 
components that affect cell division and cell biology.  In this study, proliferation 
assay was performed to investigate whether changes in GAG sulphation alter cell 
proliferation.  A non-radioactive, colorimetric proliferation assay (Promega) was 
used to determine the number of viable cells in proliferation assays.  This assay 
contained a tetrazolium compound (MTS) and electron coupling reagent phenazine 
methosulphate (PMS).  The assay depends on cell bio-reduction of MTS 
tetrazolium into a formazan product which is soluble in tissue culture medium and 
can be measured at 490nm. This reduction is performed by dehydrogenase enzymes 
essentially found in metabolically active cells.  Formazan products are proportional 
to the number of viable cells.  The working reagent was prepared in the hood by 
mixing 2ml of MTS with 0.1 ml of PMS (20:1 ratio) at room temperature.  
Cells were harvested, counted and seeded in triplicate in 96 well plates at 5x10
3 
cells/well and cultured with 5% FCS media overnight. The next day, medium was 
removed and fresh medium with 0.5% FCS was added and the cells were left to 
grow in normal condition.  To examine the effect of FGF2 on proliferation, FGF2 
was added at 10ng/ml in separate wells alongside wild type cells. Cells were left to 
grow according to experimental design for 0, 24, 48, 72 and 96 hours in the same 
conditions.  At the time of assay, medium was removed, 100 µl of fresh 0.5% FCS 
medium was added with 20 µl of working reagent (MTS/PMS) and mixed gently.  
The plate was incubated at 37
o
C and 5% CO2 incubator for 1-4 hours.  Readings 
were taken at 490nm wavelength by spectrophotometer at 0, 60,120, 180 and 240 
minutes.  Wells containing 100 µl of medium only with 20 µl of working reagent 
(MTS/PMS) were considered as negative controls.  Readings were analyzed using 
Windows Excel and Prism 4.  
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3.2.4 Isotope 35S labelling 
Renal epithelial cells transfected with HS6ST1 and appropriate mock transfectants 
were labelled with 
35
S to determine the structure changes of HS.  The cells were 
grown in 25 cm
2 
flasks until subconfluent, 5 ml of fresh medium containing 
200µCi/ml of Na2
35
SO4 (PerkinElmer Life Sciences) was added at 37
o
C for 24 
hours.  The cells were washed twice with cold PBS and treated with 3 ml of 
solubilization buffer at 4
o
C for 60 minutes in a shaking incubator.  The 
solubilization buffer was prepared in advance and contained 1% Triton X-100, 50 
mM Tris, 0.15 M NaCl, pH 7.4 and protease inhibitor (Complete Mini Cocktail, 
Roche).  Lysates were centrifuged at 500g for 15 minutes and the supernatant was 
transferred into fresh tubes.  100 µl of the supernatant was used for protein 
estimation by BCA kit (Pierce).  The supernatant was used for purification of 
labelled GAGs.   
3.2.4.1 GAG isolation 
GAGs were isolated by treating supernatants from 
35
S labelled lysates with 
Diethylaminoethyl (DEAE) Sephacel (Sigma-Aldrich).  DEAE is a weak anion 
exchange resin based on beaded cellulose.  DEAE remains charged and 
consistently maintains a high capacity in the working range (pH: 2-9).  DEAE 
columns were prepared at least 30 minutes before use.  First, the tubes (disposable 
2ml polystyrene columns; Thermo Scientific) were set up and washed 2-3 times 
with equilibration buffer (0.05M Tris/HCl pH: 8.0, 0.15 NaCl and 0.1% TX-100).  
The liquid inside each tube was held by the bottom cap and a porous floating disc 
was added on top of the liquid and pushed down avoiding gas bubbles.  500 µl of 
degassed DEAE slurry was then added and washed 3 times with equilibration 
buffer; the tube was left for 30 minutes to allow the gel to settle.  Labelled 
supernatant was diluted with equilibration buffer to a final concentration of 0.15 M.  
The supernatant was then applied to the prepared DEAE column and washed 3 
times with 5 ml of equilibration buffer.  An additional wash by acetate buffer 
(0.15M NaCl, 0.05 acetate, 0.1% TX-100, protease inhibitor and pH 4) was 
performed.  The pH was then increased to 7.4 by adding washing buffer (0.05M 
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Tris pH: 7.4, 0.15 M NaCl, 0.1% TX-100 plus protease inhibitor) and finally the 
labelled material was eluted by applying high salt elution buffer (0.05 M Tris/pH 
7.4, 1.5M NaCl, 0.1%TX-100 and protease inhibitor).   
3.2.4.2 Sample Desalting 
The labelled material containing GAGs were desalted using PD-10 columns (GE 
Healthcare).  PD-10 columns are packed with Sephadex G-25 which allows 
efficient separation of high molecular weight substances from those with low 
molecular weight such as NaCl.  In this study a protocol was used where the liquid 
was passed through the column by gravity.  The PD-10 columns were prepared in 
advance by decanting the column storage solution and washing with 25 ml of 
equilibration buffer (0.5M ammonium bicarbonate).  The sample was then applied 
in a 2.5 ml volume of elution buffer.  The sample was collected in the void volume 
flow through.  The samples were then freeze-dried and sent to Prof. Marion 
Kusche-Gullberg in Norway for further structural analyses. 
3.2.4.3 Experiments performed by Marion Kusche-Gullberg, Bergen, Norway 
The samples were treated with alkaline to release GAGs from the core protein.  The 
GAG chains were then recovered by PD-10 gel filtration and evaporated to smaller 
volumes.  These samples were run on Superose 12 columns before and after 
degradation of chondroitin sulphate (CS) with ABC chondroitinase to evaluate the 
HS/CS ratio.   
The remaining samples were treated with nitrous acid (pH 1.5) which cleaves the 
glucosaminidic linkage at GlcNS units.  Samples were then reduced by treating 
with NaBH4 and deamination products (aManR: 2, 5 anhydro-D-mannitol) were 
fractionated by gel chromatography on Sephadex G-15 equilibrated with 0.2M 
NH4CHO3.  Fractions related to di-saccharides and higher saccharides were 
collected and lyophilized repeatedly.  Disaccharides were further separated by high 
performance anion-exchange liquid chromatography (HPLC). 
The 
35
S-labelled disaccharides were analyzed twice on a Partisil-10 SAX column 
and eluted at a rate of 1ml/minutes with KH2PO4 solutions of stepwise increasing 
concentration. 
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Mono-O sulphated and di-O sulphated disaccharides were eluted with 0.026 M and 
0.15 M KH2PO4 respectively.  These disaccharides are GlcA-aManR6S (GMS), 
IdoA-aManR6S (IMS), IdoA2S-aManR(ISM) and IdoA- aManR6S (ISMS).  These 
correspond to the following disaccharides in the intact chain respectively GlcA-
GlcNS6S, IdoA-GlcNS6S, IdoA2S-GlcNS and IdoA2S- GlcNS6S.   
3.2.5 HS-Heparitinase III treatment  
Heparitinase III is a hydrolysis enzyme produced by Flavobacterium heparinum 
(Sigma-Aldrich).  The powder was reconstituted in 20 mM Tris-HCl (pH 7.5) 
containing 0.1 mg/ml BSA with 4mM CaCl2 according to manufacturer’s 
instructions.  Cells were incubated with Heparitinase III at 10 Sigma Unit/ml (one 
IU=600 Sigma Unit) for 60 minutes at 37 
o
C. 
3.3 Results 
3.3.1 Cell Phenotyping 
3.3.1.1 Expression of E-cadherin  
E-cadherin is a cell-cell adhesion molecule which is considered a characteristic 
marker of epithelial cells.  Renal epithelial cell phenotype was verified by 
examining the expression of E-cadherin by immunofluorescence.  Cells were 
stained with anti E-cadherin antibody followed by FITC-conjugated secondary 
antibody.  As shown in figure 3.1, epithelial cells express E-cadherin and show 
increased fluorescence activity compared to those with secondary antibody only.   
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Figure 3.1. HK2 cells stained with anti E-cadherin antibody.  A: Cells with no 
primary antibody (control).  B: Cells with E-cadherin antibody and FITC 
conjugated secondary antibody. Images were taken by scanning fluorescence 
microscope.  The figure is representative of two independent experiments. (Scale 
bar is 47.62µm)   
3.3.1.2 Expression of MHC-II  
Class-II major histocompatibility complex antigens (MHC-II) are expressed 
constitutively on the surfaces of antigen presenting cells (APCs) such as 
macrophages, B cells and dendritic cells.  MHC-II antigens are necessary for the 
presentation of exogenous antigens to CD4+ lymphocytes.  These antigens were 
shown to be upregulated in somatic cells as a consequence of proinflammatory 
cytokines such as IFN-γ and TNF-α in the context of graft rejection (Pober et al., 
1996).  IFN-γ is a key proinflammatory cytokine which is upregulated in chronic 
graft rejection.  To investigate the ability of IFN-γ to induce MHC-II molecules in 
renal epithelial cells, these cells were stimulated with IFN-γ for seven days at 
25ng/ml and investigated by flow cytometry.  The time and concentration 
dependency of the response to IFN-γ were optimised earlier within the group 
(Fritchley et al., 2000).  Specificity of antigen labelling was demonstrated by 
incubating stimulated cells with isotype-matched antibody.  As shown in figure 
3.2C and 3.3, IFN-γ stimulated cells show significantly increased (P<0.05) binding 
ability to MHC-II antibody compared to resting cells and isotype incubated cells.  
Epstein-Barr virus transformed lymphoblastoid cell lines (EVB-LCL), express 
MHC-II molecules, were used in experiments as positive control (Figure 3.2A).  
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Figure 3.2. Flow cytometric demonstration of MHC-II expression after stimulation 
with IFN-γ.  A, Epstein-Barr transformed virus lymphoblastoid cell lines (EVB) 
were used as positive control in resting condition. B&D, Endothelial cells (EAhy-
926 & HMEC1) were stimulated with IFN-γ (25ng/ml) (green histogram) for 3 
days whereas epithelial cells (HK2) were stimulated for 7 days (C).  Controls 
included unstimulated cells (red) and labelling with isotype-matched antibody 
(black).  The data shown is representative of 2 separate experiments (N=2).   
Endothelial cells were incubated with IFN-γ for 72 hours and examined for the 
expression of MHC-II molecules.  As shown in Figure 3.2B and D, IFN-γ 
stimulated EAhy-926 and HMEC-1 cells upregulated MHC-II antigen expression 
compared to non-stimulated cells.  This induction was investigated by flow 
cytometry with an IFN-γ concentration of 25ng/ml for 72 hours.  Median 
fluorescence intensity showed that MHC-II molecules were significantly 
upregulated in comparison to unstimulated cells.  EVB cells were used as a positive 
control (Figure 3.3). 
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Figure 3.3. Expression of class II MHC antigen after stimulation with IFN-γ.  
Median fluorescence intensity was measured for the expression of class II MHC 
antigen.  Endothelial cells (HMEC1 and EAhy-926) were stimulated with IFN-γ for 
3 days and epithelial cells (HK2) for 7 days. The MHC-II expression was 
visualized by FITC-conjugated secondary antibody.  Epstein-Barr virus 
lymphoblastoid cell lines (EVB-LCL) at resting condition was used as positive 
control.  Error bars represent the SEM of duplicate determinants (n=2), these data 
are representative of 2 idependent experiments (N=2).  
3.3.1.3 Expression of CD31 
Endothelial cells (EAhy-926 and HMEC-1) were phenotyped by investigating the 
expression of CD31 which is also known as platelet endothelial cell adhesion 
molecule (PECAM-1).  CD31 plays a key role in leucocyte transmigration through 
intracellular junctions.  CD31 is found between endothelial cells and considered as 
a characteristic marker of endothelial cells (Jimenez et al., 2003). 
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Figure 3.4.  EAhy-926 cells stained with anti CD31 antibody.  A: Cells with no 
primary antibody (control). B: Cells with CD31 antibody visualized by FITC 
conjugated secondary antibody.  Images were taken with scanning laser confocal 
microscope. IgG1 antibody (mouse) was used as a nonspecific binding isotype (not 
shown).  The figure is representative of two independent experiments.  (Scale bar is 
47.62µm) 
Staining of these cells with anti CD31 antibody showed that endothelial cells 
express significantly levels of CD31 compared to control.  Investigations were 
performed using immunofluorescence confocal microscope (Figure 3.4).   
3.3.2 Expression of HS6ST1 by conventional PCR 
3.3.2.1 RNA extraction and gel electrophoresis  
RNA was obtained following cell lysis and its integrity was examined by running 
defined amount on agarose gels along with RNA ladder.  Intact RNA was 
confirmed by the appearance of sharp bands corresponding to 28S and 18S 
ribosomal RNA on agarose gel electrophoresis with a ratio of 2:1 respectively. 
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Figure 3.5. Agarose gel electrophoresis of RNAs from different cell lines.  For each 
cell line 0.5 µg of total RNA was loaded on 0.5% agarose gel to examine the 
integrity of RNA. RNA from HK2, EAhy.926 and HMEC1 were in lanes 2, 3 and 4 
respectively. 
RNA samples from each of the cell lines used in this study produced well defined 
28S and 18S bands with no smearing, indicating little or no degradation (Figure 
3.5). 
3.3.2.2 Conventional PCR 
Expression of the HS6ST1 gene was investigated in three cell lines (HK2, 
EAhy.926 and HMEC1) using the reverse transcription PCR protocol.  RNA was 
obtained from resting cell lines and after stimulation with IFN-γ (25ng/ml) for 24 
hours.  GAPDH was used as a house keeping gene.  Primers for HS6ST1 and 
GAPDH were designed with product amplicons at 463bp and 590 bp respectively.  
Plasmid encoding DNA of the HS6ST1 gene was used as a positive control.  PCR 
products were examined by electrophoresis on agarose gels.  
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Figure 3.6. Agarose gel electrophoresis of HS6ST1 expression by reverse 
transcription PCR.  PCR was carried out using cDNA from resting and IFN-γ 
(25ng/ml for 24 hours) stimulated cells.  All cells show the expression of GAPDH 
and HS6ST1 positive control (plasmid encoding HS6ST1).  A, Lane-1 (L1) 
contains 100 bp ladder, L2: PCR mix only, L3: HK2-HS6ST1 (empty), L4: HK2-
GAPDH, L5: positive control HS6ST1 plasmid, L6: HK2-HS6ST1 (empty), L7: 
PCR mix only, L8: EAhy.926-GAPDH, L9; EAhy.926-HS6ST1 (empty), L10: 
PCR mix only, L11: HMEC1-GAPDH, L12: HMEC1-HS6ST1 (empty). Panel B is 
the same as A but with IFN-γ stimulated samples. 
In figure 3.6 (left panel) the PCR products of resting cells show transcripts for 
positive control of plasmid HS6ST1 in lane 5 and GAPDH in lanes 4, 8 and 11 
from cell lines HK2, EAhy.926 and HMEC1 respectively.  No transcripts were seen 
for HS6ST1 in lanes 6, 9 and 12 that represent HK2, EAhy-926 and HMEC1 
respectively.  In a similar way the right panel shows lack of expression of HS6ST1 
following stimulating with IFN-γ.  
3.3.2.3 Expression of HS6ST1 using quantitative PCR (qPCR) 
Expression of HS6ST1 gene was further investigated by real time PCR which is a 
more quantitative procedure compared to conventional PCR.  HK2, EAhy-926 and 
HMEC1 were shown to express constitutive levels of HS6ST1.  This expression 
was examined in resting cells and after stimulation with factors such as PMA and 
cytokines such as TNF-α, IFN-γ and TGF-β.  Cytokine concentrations and 
incubation times were optimised earlier by the group (Fritchley et al., 2000).  For 
HK2 cells, no significant changes in HS6ST1 expression were noticed following 
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cytokine stimulations for 24 hours.  However, IFN-γ significantly (P<0.05) 
downregulated HS6ST1 expression in HMEC1 cells by about 60 % compared to 
control (Figure 3.7, B). 
  
Figure 3.7. Stimulation of HS6ST1 expression by cytokines.  A, renal epithelial 
cells (HK2) were stimulated with TGF-β (10ng/ml) and IFN-γ (25ng/ml) for 24 
hours. RNA was extracted and cDNA synthesized and used for qPCR.  Each 
column represents fold change expression of HS6ST1 normalized to control (1). B, 
endothelial cells HMEC1 were stimulated and screened for HS6ST1 expression 
after stimulation with TGF-β (10ng/ml) and IFN-γ (25ng/ml) for 24 hours.  (N=2, 
*P<0.05). 
3.3.3 Cell stimulation and FGF2 binding 
To examine the binding of FGF2 to renal epithelial cells, an assay for binding 
biotinylated FGF2 was designed.  Renal epithelial cells (HK2) were shown to bind 
to FGF2 at a significant level.  This binding was further investigated following cell 
stimulation for 24 hours with cytokines such as IFN-γ and TGF-β.  Stimulation of 
renal epithelial cells with these cytokines produced no significant change (P > 0.05) 
in their binding to FGF2.  Unstimulated cells were used as a control (Figure 3.8).  
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Figure 3.8. Binding of FGF2 following cytokine stimulation.  HK2 cells were 
stimulated with IFN-γ (25ng/ml) and TGF-β (10ng/ml) respectively for 24 hours.  
Cells were then investigated for their potential to bindFGF2.  Flow cytometric 
results were expressed as median fluorescence intensity (∆MFI) values and 
statistics were performed using ANOVA.  Stimulated cells were compared to 
resting cells; error bars show the SEM (N=3, P>0.05). 
3.3.4 Cell stimulation and 10E4 binding 
To examine the expression of HS on renal epithelial cells, an HS-specific 
monoclonal antibody was used and cells were investigated by flow cytometry.  The 
10E4 antibody is a mouse anti-human HS antibody which targets an epitope 
containing N-acetyl and N-S positions in the structure of HS.  Renal epithelial cells 
(HK2) were shown to bind to 10E4 antibody.  This binding ability showed no 
significant change after stimulation with cytokines such as IFN-γ and TGF-β 
compared to unstimulated cells as control (Figure 3.9).  
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Figure 3.9.  Binding of 10E4 antibody to HK2 cells after cytokine stimulation.  
HK2 cells were stimulated with IFN-γ (25ng/ml) and TGF-β (10ng/ml) for 24 
hours.  The cells were then investigated for the binding of 10E4 by flow cytometry.  
The reaction was visualized using a FITC-conjugated secondary antibody.  
Stimulated cells were compared to resting cells and ∆MFI values were expressed.  
Error bars show the SEM (N=3, P>0.05). 
3.3.5 Generating of stable HS6ST1 transfectants 
3.3.5.1 Cloning of HS6ST1  
The mammalian expression vectors pcDNA3.1/Zeo+ and pCR-Blunt II-Topo 
coding HS6ST1 were digested with restriction enzymes Pst I and BamH I to 
provide unique and specific overhang ends.  As a result of digestion, the 
pcDNA3.1/Zeo vector size was 5 kb and the insert HS6ST1 size was 1321 bp.  
Both plasmids were analysed by agarose gel electrophoresis (Figure 3.10A).  
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Figure 3.10. Agarose gel electrophoresis of restriction digested plasmids.  A, 
plasmid (PCR-Blunt II-Topo) carrying HS6ST1 and vector pcDNA3.1/Zeo+ were 
digested with PstI and BamHI.  Both the insert and vector were cut out of the gel 
and purified.  Lane 1: 1 kb ladder, lane 2: Blunt II-Topo + PstI, lane 3: Blunt II-
Topo +BamHI, lane 4: Blunt II-Topo + PstI & BamHI, lane 6,7 : vector 
pcDNA3.1/Zeo with PstI & BamHI.  B, Purified HS6ST1 insert and 
pcDNA3.1/zeo+, digested with PstI & BamHI and run on the gel.  HS6ST1 insert is 
in lanes 2 and 3 whereas vector pcDNA3.1/Zeo lanes 5 and 6. Lane 1 contains 1kb 
DNA ladder.    
Gel slices were cut out and purified.  Purified DNAs for each of the insert 
(HS6ST1) and the vector were ligated and the resulting vector/insert was amplified 
and sequenced.  The purified DNA was additionally run on the gel for further 
confirmation of digestion reaction and sizes (Figure 3.10, B).  
3.3.6 Transfection procedure  
3.3.6.1 Transfection optimisation 
The transfection procedure involves insertion of DNA within a cell, allowing 
protein expression.  A lipid based transfection protocol was used in this project.  
The transfection procedure was optimised using different ratios of DNA 
concentration to Effectene reagent (ER).  To obtain best results for transfection 
efficiency and minimum cell toxicity due to transfection reagents, HK2 cells were 
The effect of HS6ST1 on HS structure and biological activity 
 
81 
 
transfected with vector encoding green fluorescent protein (GFP) with different 
plasmid DNA concentration (µg) to ER (µl) ratios (Table 3.1).  The efficiency of 
transfection was measured by flow cytometry. 
  
Table 3.1. Optimization of transfection procedure. 
Highest transfection efficiency was achieved at a DNA: ER ratio of 1:50 and DNA 
concentration at 0.4 µg for six well plates (Figure 3.11).  
3.3.6.2 Antibiotic killing curve 
Incubating HK2 cells with different concentrations of antibiotic (Zeocin) showed 
that the lowest concentration that caused killing of HK2 was 400 µg/ml.  Therefore 
HS6ST1 transfectants were selected in a medium with Zeocin at 400µg/ml and 
maintained at 300µg/ml, data not shown. .  
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Figure 3.11. Determination of the transfection efficiency for HK2 cells transfected 
with GFP.  Plasmid expressing GFP was transfected into HK2 cells. GFP was 
transfected at a ratio of 1:50 of DNA to Effectene Reagents respectively. Resting 
cells showed no fluorescence activity (red histogram) whereas transfected cells 
showed high fluorescence activity (black line).  Investigation was carried out by 
flow cytometry and data were analysed by WinMDI 2.9.   
3.3.6.3 Generation of HS6ST1 transfectants 
The HS6ST1 insert was ligated to pcDNA3.1/zeo+ and the resultant plasmid was 
sequenced (see appendices).  The HS6ST1 expression vector was transfected into 
renal epithelial cells using optimised conditions for transfection.  Stable clones 
were created and selected with 400µg/ml Zeocin.  Stable clones were grown and 
screened for the expression of HS6ST1 by real time qPCR.  The clones expressing 
the highest level of HS6ST1 mRNA were selected for further investigation (Figure 
3.12).  These clones were named as HS6ST1 transfectants and given the initials “T” 
with a reference number.  The highest expressing clones (T4 and T7) were 
maintained with Zeocin 300µg/ml and used for further investigations.  Stable mock 
transfectants were generated by transfecting HK2 cells with the pcDNA3.1/zeo+ 
plasmid without the insert.  These transfectants were cultured under the same 
condition as HS6ST1 transfectants (Zeocin, 400µg/ml). 
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Figure 3.12. HS6ST1 expression of HK2 stable transfectants using qPCR.  Total 
RNA was reverse transcribed and levels measured by qPCR.  Values were 
normalized to GAPDH and reported in relation to wild type HK2 cells.  
Experiments were performed in duplicate and data represents two independent 
experiments.  
3.3.7 Interactions of HS6ST1 transfectant 
3.3.7.1  Binding to 10E4 antibody (Ab) 
To examine the changes in HS epitopes after HS6ST1 overexpression, renal 
epithelial transfectants (T7) were investigated for 10E4 antibody binding by flow 
cytometry.  These transfectants were examined in comparison to mock 
transfectants.  HS6ST1 transfectants (T7) showed less binding to 10E4 antibody 
compared to mock transfectants stained with an isotype-matched control antibody 
(Figure 3.13).   
This reaction was quantified by median fluorescence intensity using flow 
cytometry.  Reaction specificity was examined by incubating cells with isotype 
(IgM) antibody of the same species (mice).  The reduction in 10E4 antibody 
binding by HS6ST1 transfectants was shown to be statistically significant (Figure 
3.14). 
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Figure 3.13. Representative HS6ST1 transfectant binding to 10E4 antibody. Left 
panel represents gated viable cells counted by forward scatter compared to side 
scatter in flow cytometry.  Right panel represents histogram of T7 (blue line) 
binding to 10E4 in reference to mock transfectants (green line), isotype incubated 
cells (black line) and cells with secondary antibody only (red histogram). 
 
Figure 3.14. Binding of HS6ST1 transfectants to 10E4.  2x104 cells of mock and 
HS6ST1 transfectants were incubated with 10E4 (1:100) for 60 minutes at 4
o
C 
followed by anti-mouse FITC-conjugated antibody.  The same number of cells was 
incubated with IgM isotype antibody.  Median fluorescence intensity was measured 
by flow cytometry. Error bars show the SEM (N=3, **: P < 0.01). 
3.3.7.2 Phage display antibody binding 
A series of experiments was designed to examine the changes in sulphation pattern 
after HS6ST1 overexpression using HS4C3, RB4EA12 and HS3A8 phage display 
antibodies (a generous gift from Dr. Van Kuppevelt).  Investigations were carried 
out using flow cytometry. 
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3.3.7.2.1 Binding to HS3A8 Ab 
The HS3A8 antibody targets specific epitope including sulphate groups at N-, 6-O 
and 2-O positions.  As shown in figure 3.15, HS6ST1 transfectants increased the 
binding of (T7) to HS3A8 antibody compared to mock transfectants (M.HK2).  
This increase was statistically significant (P<0.05). 
 
Figure 3.15.  Binding of HS3A8 phage display antibody to HS6ST1 transfectants.  
Cells of mock and HS6ST1 transfectants were incubated on ice with HS3A8 
antibody at 1:10 followed by Cy3 labelled anti-VSV secondary antibodies.  
Fluorescence was investigated by flow cytometry and experiments were performed 
in duplicates (N=4, P<0.05).  
3.3.7.2.2 HS4C3 binding 
The HS4C3 phage display antibody targets N-S, 6-OS, 2-OS and 3-OS in the HS 
structure.  Sulphation changes due to HS6ST1 overexpression were investigated by 
HS4C3 binding with reference to mock transfected cells.  Cells with HS6ST1 over 
expression showed noticeable upregulation of HS4C3 binding compared to mock 
cells (Figure 3.16).  This increase was statistically significant (P<0.05) (Figure 
3.18). 
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Figure 3.16. Representative histogram showing the binding of HS4C3 to HS6ST1 
transfected cells.  A, Mock transfectants were incubated with HS4C3 on ice for 60 
minutes at 1:10 followed by Cy3 labelled secondary antibody.  B, T7 binding to 
HS4C3 phage display antibody (black line) to T7 transfectants was compared to 
cells with secondary antibody only (red histogram).  Median fluorescence intensity 
was measured by flow cytometry and the data were analyzed by WinMDI2.9.  
3.3.7.2.3 RB4EA12 
For further clarification of HS sulphation changes, HS6ST1 expressing 
transfectants were investigated for the binding of phage display antibody 
RB4EA12.  This antibody targets specifically the N-acetyl, N-S and 6-OS positions 
on the HS structure.  HS6ST1 transfectants showed increased binding to RB4EA12 
compared to mock transfectants (Figure 3.17).   
HS6ST1 transfectants were shown to upregulate RB4EA12 binding in a significant 
manner (P<0.05), (Figure 3.18). 
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Figure 3.17.  Representative histogram of HS6ST1 transfectant binding to 
RB4EA12.  A, Mock transfectant were incubated with RB4EA12 on ice for 60 
minutes at 1:10 followed by Cy3 labelled secondary antibody.  B, T7 binding to 
HS4C3 phage display antibody (Black line) compared to T7 cells incubated with 
secondary antibody only (red line).  Median fluorescence intensity was measured 
by immunofluorescence flow cytometry and data were analyzed by WinMDI2.9.  
 
Figure 3.18. Analyses of HS4C3 and RB4EA12 binding to HS6ST1 transfectants.  
HS4C3 and RB4EA12 antibodies were incubated with mock and HS6ST1 
transfectants (T7) for one hour at 4
o
C followed by addition of monoclonal Cy3-
labelled anti-VSV antibody (mouse IgG1 isotype) in 1:200 and incubated for 45 
minutes at 4oC. Columns represent mean of median fluorescence intensity of mock 
and HS6ST1 transfectants (N=2).  Error bars represent SEM,*P<0.05. 
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3.3.8 HS6ST1 transfectant binding with FGF2 
3.3.8.1 Optimisation of FGF2 binding 
3.3.8.1.1 PBS-BSA and RDF1 solution buffer 
Biotinylated-FGF2 binding to cell surface HS was optimised in order to obtain best 
reaction conditions and results.  RDF1 is a buffered saline-protein solution 
provided with the biotinylated FGF2 assay kit.  This solution is specifically 
designed to minimise background staining and stabilise specific binding.  Cells 
were washed and resuspended in PBS-BSA 2% and/or RDF1.  Results show that 
cells washed and suspended in PBS-BSA  achieved better binding ratios compared 
to those with RDF1 (Figure 3.19).  
 
Figure 3.19. Representative histograms showing optimization of the FGF2 binding 
assay. A, Mock transfectant binding to FGF2 in case of RDF1 (black line) and 
PBS-BSA (green line) whereas red line represents cells with Avidin-FITC only. B, 
HS6ST1 transfectants (T4). C, T7 binding to FGF2. 
Statistical analysis of MFI values for mock and HS6ST1 transfectants show that 
PBS-BSA significantly enhanced the binding of FGF2 to all cell lines compared 
with RDF1(Figure 3.20). 
The effect of HS6ST1 on HS structure and biological activity 
 
89 
 
 
 
Figure 3.20. Optimization of the biotinylated FGF2 binding assay.  Mock HK2 and 
HS6ST1 transfectants (T4 and T7) were incubated with biotinylated FGF2 
followed with the avidin-FITC substrate.  Cells were then washed and resuspended 
in either RDF1 or PBS-BSA2%.  Cells were investigated by flow cytometry (N=2, 
**P<0.01). 
This experiment showed that incubation of the FGF2 reaction in RDF1 or PBS-
BSA gave similar results in term of specificity (Figure 3.21).  No changes were 
noticed in negative control and anti-FGF2 antibody when using RDF1 or PBS-
BSA.  This indicates that PBS-BSA has no negative effect on reaction specificity.  
This result was confirmed in tubes containing mock and two HS6ST1 transfectant 
clones (T4 and T7).that gave similar results  
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Figure 3.21. Optimization of FGF2 and effect on specificity. A, FGF2 binding 
assay using RDF1.  Negative control appears in black line and blocking with anti 
FGF2 antibody appears in green. B, FGF2 binding assay with PBS-BSA 2% where 
negative control appears in black line and blocking antibody in green.  Cells were 
analysed by flow cytometry, N=2. 
3.3.8.2   HS binding to 10E4 in presence of sodium chlorate 
To examine the role of HS in binding the 10E4 antibody, a series of experiments 
was performed after desulphation of HS by incubating cells with up to 150 mM 
sodium chlorate for three days.  Sodium chlorate inhibits heparan sulphate 
sulphation by competing with 3’-phosphoadenosine-5’phosphosulphate (PAPS) 
which constitutes an essential sulphation donor for HS (Safaiyan et al., 1999).  
Sodium chlorate concentration was optimised in this study for renal epithelial cells, 
and the higher concentration with viable cells was 150 mM (data not shown).  Cells 
were examined for the 10E4 binding and investigated by flow cytometry.  Treating 
cells with with sodium chlorate will deprive them from sulphation and will give an 
example of changes of HS sulphation on 10E4 binding epitope following HS6ST1 
overexpression.  HS6ST1 transfectants in sodium chlorate were examined against 
wild type and mock transfectants.  As shown in figure 3.22, sodium chlorate 
reduced HS6ST1 transfectants and mock transfectants binding to 10E4 anibody.  
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This reduction reached up to 50% and 20% respectively compared to non-sodium 
chlorate treated cells.   
    
Figure 3.22. Analysis of 10E4 binding to chlorate-treated wild-type and HS6ST1 
transfected cells. Cells were incubated with sodium chlorate (150mM) for 72 hours.  
Cells were then incubated with 10E4 antibody alongside wild type transfectants 
(without sodium chlorate) at 1:100 at 4
o
C for 60 minutes.  Cells were washed and 
incubated with FITC-conjugated secondary antibody.  Cells were washed and 
resuspended in PBS containing 2%BSA and examined by flow cytometry.  (N=2 
with 4 replicates, *: P<0.05) 
3.3.8.3 HS binding to FGF2 
To examine the role of HS in binding FGF2, an assay was designed including wild 
type Chinese hamster ovary cells (WT-CHO) and 2 mutant cell lines which do not 
express HS.  The mutant cell line CHO-745 lacks the xylosyltransferase activity 
required to transfer xylose to the core protein (serine); this is necessary to initiate 
GAG synthesis (Esko et al., 1985).  Mutant CHO-677 cells lack HS due to 
deficient acetyl glucosaminyltransferase and glucorunyltransferase activities; these 
are vital for HS synthesis (Murphy-Ullrich et al., 1988).  Wild type CHO, CHO-
745 and CHO-677 were used to examine FGF2 binding to HS and GAGs.  The 
FGF2 assay was carried out by flow cytometry.  As shown in figure 3.23, wild-type 
CHO cells bound more FGF2 than either the CHO mutant cells.  This change in 
FGF2 binding was statistically significant (P<0.01). 
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Figure 3.23. FGF2 binding to WT-CHO, CHO-745 (GAG mutant) and CHO-677 
(HS mutant) cells.  Cells were incubated with biotinylated FGF2 followed by 
Avidin-FITC and investigated by flow cytometry. A, a representative flow 
cytometric result showing FGF2 binding to WT-CHO and B, a representative 
histogram of HS-mutant (CHO-745) cell binding to Bio-FGF2.  C, FGF2 binding 
ability was expressed as ∆MFI.  Mean ∆MFI values are shown and error bars 
represent the SEM. (N=3, **= P<0.01). 
3.3.8.4 FGF2 binding in presence of sodium chlorate 
HS6ST1 transfectants (T7) were incubated with different concentrations of sodium 
chlorate in a time course of 72 hours followed by FGF2 binding assay.  Sodium 
chlorate was added at 30, 50, 100 or 150 mM.  The MFI values for FGF2 binding 
to the T7 transfectants were markedly decreased at a sodium chlorate concentration 
of 30 mM compared to mock transfectants.  At a sodium chlorate concentration 
150mM, FGF2 binding was completely inhibited for both mock and HS6ST1 
transfectants, with ∆MFI values of around 20 (Figure 3.24).  
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Figure 3.24. FGF2 binding in presence of sodium chlorate.  Mock HK2 and 
HS6ST1 transfectants were incubated with different concentrations of sodium 
chlorate for 72 hours.  Cell viability was determined by Trypan blue.  Cells were 
investigated for FGF2 binding by flow cytometry.  The error bars show the SEM 
(N=3, P<0.05). 
These results were shown to be statistically significant, with the greatest difference 
between the cell lines observed at a sodium chlorate concentration 30 mM 
(P<0.05). 
3.3.8.5 FGF2 binding with Heparitinase III 
Heparitinase III is an enzyme known to degrade heparin/HS by cleaving the N-
sulphated (NS) domains near iduoronic acid residues (Lohse and Linhardt, 1992).  
In order to verify the specificity of FGF2 binding to HS, mock and HS6ST1 
transfectants were treated with heparitinase III.  Figures obtained by flow 
cytometry showed that ∆MFI values of heparitinase III-treated (mock and HS6ST1 
transfectants) were decreased by more than 75% compared to resting cells.  
Statistical analysis showed that heparitinase III significantly decreased FGF2 
binding by both mock and HS6ST1 transfectants (P<0.05), (Figure 3.25). 
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Figure 3.25. FGF2 binding after incubation with heparitinase III.  Binding of mock 
HK2 cells and HS6ST1 overexpressing cells to biotinylated FGF2 before and after 
application of heparitinase III.  Mock and HS6ST1 transfectants were incubated 
with heparitinase III (10 Sigma unit/ml) for 60 minutes at 37
o
C.  The cells were 
then incubated with biotinylated FGF2.  The results were referenced to cells with 
no heparitinase III.  The error bars show the SEM (N=3, P<0.05). 
3.3.8.6 FGF2 binding with HS6ST1 transfectants  
To examine the effect of HS6ST1 overexpression on HS biology, HS6ST1 
transfectants were examined for FGF2 binding and compared to mock 
transfectants.  These cells were incubated with biotinylated FGF2 and the bound 
factor was quantified by flow cytometry.  Flourescence intensity (∆MFI) values for 
FGF2 binding by HS6ST1 transfectants (T7) were approximately double those of 
mock transfectants (Figure 3.27 ).  Statistical analysis showed that HS6ST1 
transfection significantly increased the binding of FGF2 (P<0.05).  The specificity 
of this test was verified using a negative control that contains soya bean protein 
which had been biotinylated to the same extent as FGF2. Additional controls 
included treating cells with blocking anti-FGF2 antibodies.  Low ∆MFI values 
observed for control cells showed that binding is taking place mainly between HS 
and FGF2 specifically.  Both HS6ST1 clones show increased binding to FGF2 
compared to mock transfectants (Figure 3.26). 
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Figure 3.26. Representative histogram of flow cytometry for FGF2 binding to 
HS6ST1 transfectants.  Red histogram represents control cells with Avidin-FITC 
conjugated substrate, black histogram represents mock transfectants with FGF2, 
green and blue histograms represent HS6ST1 transfectants (T4 & T7) with FGF2.  
All cells were incubated with Avidin-FITC substrate, N=3. 
    
Figure 3.27. The effect of HS6ST1 overexpression on FGF2 binding. Mock HK2 
and T7 cells were investigated for binding of biotinylated FGF2, the reaction was 
verified by FITC-Avidin and fluorescence activity expressed as median 
fluorescence intensity (MFI) was investigated by flow cytometry. Negative control 
contained soya bean protein (non HS-binding) biotinylated to the same level as 
FGF2, whereas specificity was examined by incubating FGF2 with blocking 
antibodies.  Error bars represent the SEM (N=3, * P<0.05).  
3.3.8.7 FGF2 binding in presence of inhibitors 
FGF2 binding was further examined in the presence of competitors such as heparan 
sulphate, heparin, heparin de-O sulphate and heparin de-N sulphate.  De-N and de-
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O sulphated heparins lack sulphate groups at the N- and O- position respectively. 
Incubation of FGF2 with de-N or de-O sulphated heparins produced no changes in 
∆MFI values for HS6ST1 transfectants compared to control mock and HS6ST1 
transfectants (T7).  By contrast, incubation of FGF2 with heparin completely 
inhibited FGF2 binding to both mock and T7 transfectants.  Addition of soluble HS 
to FGF2 inhibited the binding to mock and HS6ST1 transfectant by 90% and 70% 
respectively.  As shown in figure 3.28, heparin and HS significantly competed with 
mock and T7 transfectants for the binding of FGF2 (P<0.05).   
 
Figure 3.28. FGF2 binding in presence of inhibitors.  Heparin de-O sulphate, 
heparin de-N sulphate, heparin and heparan sulphate were added to FGF2 for 10 
minutes prior to cell addition.  The assay was run in duplicates under normal 
conditions. All mediators were added at final concentration of 500µg/ml.  Error 
bars show the SEM (N=2, *: P<0.05). 
The concentration of heparin that causes 50% inhibition of the FGF2 binding (IC50) 
was determined by incubating mock and HS6ST1 transfectants with FGF2 in 
presence of various concentrations of heparin (Figure 3.29).  Heparin’s IC50 for 
mock transfectants was 0.01 µg/ml compared to 0.1 for HS6ST1 transfectants. 
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Figure 3.29. FGF2 binding in presence of heparin. Low concentrations of heparin 
were incubated with FGF2 for 10 minutes at room temperature.  Then mock HK2 
and T7 cells were added and FGF2 assay was carried out under normal conditions, 
(N=2). 
3.3.9 HS structural analysis 
3.3.9.1  Disaccharide structure 
HS sulphation was examined by using 
35
S as a source of sulphate to investigate 
sulphation pattern changes after HS6ST1 transfection.  HS structure was 
fractionated to mono and di-sulphated disaccharides which constitute substrates for 
the sulphate transferase process performed by HS6ST1 enzyme. 
HS6ST1 transfectants showed upregulation of heparan sulphate mono-O sulphated 
disaccharides such as glucuronic acid-N acetyl glucosamine 6S (GlcA-GNAc6S) 
and iduronic acid-N acetyl glucosamine (IdoA-GNAc6S) compared to mock 
transfectants.  These disaccharides are represented as GMS and IMS respectively 
(Figure 3.30).  In contrast, HS6ST1 overexpression resulted in decreased 
concentration of di-sulphated di-saccharides such as IdoA-GlcNS6S and IdoA2S-
GlcNS6S (ISM and ISMS) compared to mock transfectants (Figure 3.30).  These 
selective changes in saccharide concentration are statistically significant (P<0.05). 
 
The effect of HS6ST1 on HS structure and biological activity 
 
98 
 
 
Figure 3.30. HS disaccharide composition in HS6ST1 transfectants.  Mock and 
HS6ST1 transfectants were incubated with 
35
S at 200µCi/ml for 24 hours. Cells 
were lysed and GAGs were isolated using DEAE Sephacel columns. Samples were 
treated with nitrous acid and deaminated products were fractionated by gel 
chromatography on Sephadex G-15.  GAGs were separated using anion-exchange 
HPLC followed by running and eluting on Partisil 10 SAX columns.  
(N=2,**P<0.01,*P<0.05), data provided by collaboration with Prof. M. Kusche-
Gullberg (Norway) 
3.3.9.2   Sulphate distribution 
The distribution of 
35
S labelled monosaccharide fractions on the HS structure was 
examined to further explore the effect of HS6ST1 on the HS sulphation pattern. 
35
S 
labelled monosaccharides show that HS6ST1 overexpression changes the total 
sulphation distribution in the HS structure.  Sulphate groups at the 2-O position 
were downregulated by about 25% in HS6ST1 transfectants compared to mock 
transfectants.  Sulphation at the 6-O and N-S position was not significantly 
changed (Figure 3.31). 
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Figure 3.31. Sulphate group changes produced by HS6ST1 overexpression. 
Samples were isolated from 
35
S labelled HS chains which were obtained from 
solubilized cells of mock and HS6ST1 transfectants.  GAGs were depolymerized 
by low pH nitrous acid treatment followed by reduction with NaBH4.  Fractions 
were separated on a Partisil 10-SAX column alongside standard control. Error bars 
represent SEM, N=2 (4 replicates), **P<0.01). 
3.3.10  HS6ST1 and proliferation assay  
Measurement of cell proliferation is widely used to examine an increase in the 
number of viable cells.  Non-radioactive proliferation assays depend on the 
reduction of a tetrazolium substrate into a coloured compound.  This reaction takes 
place due to the effect of dehydrogenase enzymes found in active cells.  
Mitochondrial dehydrogenases in living cells reduce tetrazolium salts into a 
coloured formazan compound.  To examine the potential role of HS6ST1 in cell 
biology and proliferation, a series of experiments was set up to measure the 
proliferation of mock and HS6ST1 transfectants.  Proliferation was estimated using 
two different procedures; cell counting and colormetric proliferation assay.  Cell 
counting showed that cells with HS6ST1 overexpression have higher proliferation 
ratios than mock transfected cells after few days (Figure 3.32).  This result shows 
that HS6ST1 overexpression increased the number of HS6ST1 transfectants 
compared to mock transfectants at days 6 and 7 (P<0.05). 
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Figure 3.32. Representative figure showing a proliferation assay by cell counting. 
Equal cell numbers were seeded in 6-well plate with complete media in triplicates.  
Viable cells (using Trypan blue) were counted by using a Neubauer 
haemocytometer every 24 hours for 7 days. (N=3, P<0.05 between T7 and mock 
transfectant HK2 at days 6 and 7).  
A non-radioactive colourimetric proliferation assay showed that HS6ST1 
transfectants were more proliferative than mock transfectants (Figure 3.33, A).  To 
further examine the effect of FGF2 in presence of HS6ST1 overexpression, FGF2 
was added to the media and cells were investigated after 24, 48, 72 and 96 hours 
respectively.  FGF2 enhanced the proliferation of HS6ST1 overexpressing cells 
(Figure 3.33, B).  Addition of FGF2 to mock transfectants increased significantly 
the proliferation ratio compared to untreated mock transfectants.   
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Figure 3.33. Representative results of colourimetric proliferation assay for HS6ST1 
transfectants.  A, Cells were seeded in 96 well plates in triplicates with 0.05%FCS 
and incubated for 24, 48, 72 and 96 hours. B, cells were incubated in presence of 
FGF2 at 10ng/ml.  At the time of experiment, fresh medium was added with 
tetrazolium compound (MTS/PMS) and readings were taken at 490nm after 240 
minutes (N=3, P<0.001).  
3.3.11   HS6ST1 overexpression and ERK phosphorylation 
Binding of FGF2 to its specific receptor, FGFR induces signalling through the 
intracellular ERK pathway, resulting in phosphorylation of extracellular signal 
regulated kinase, ERK1,2 to produce pERK1,2 (Loo and Salmivirta, 2002).  These 
proteins are also known as mitogen activated protein (MAP) kinases and play a 
crucial role in cell proliferation and differentiation.  When FGF binds to FGFR, a 
signal from the cell surface activates several protein mediators and ends in the 
nucleus resulting in protein transcription or cell division (Klint et al., 1999).  
The sulphate group at the 6-O position of HS constitutes a major component in the 
FGF-FGFR signalling complex.  To further examine the role of HS6ST1 in this 
pathway, a series of experiments was carried out using western blotting to examine 
the expression of pERK1,2 in HS6ST1 and mock transfectants.  Mock and HS6ST1 
transfectants were incubated with FGF2 for short periods of time (5-10 minutes) as 
a stimulator of ERK activation.  Western blotting using anti-pERK1,2 antibodies 
showed that HS6ST1 overexpression increased the production of pERK1,2 in 
HS6ST1 transfectants compared to mock transfectants.  Densitometry of bands 
representing pERK1,2 showed that HS6ST1 transfectants expressed more than 
twice the amount of pERK compared to mock transfected cells (P<0.05).   
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FGF2 stimulation increased the ERK activation in mock transfectants which was 
proportional to the incubation time.  Althogh FGF2 stimulation caused a dramatic 
increase in pERK1,2 in mock transfectants, this factor had no significant change of 
pERK1,2 in HS6ST1 transfectants (P>0.05), (Figure 3.34). 
 
Figure 3.34.  Representative Western blot of pERK1,2 in HS6ST1 and mock 
transfectants.  A) Cells were incubated in 0.05% FCS medium for 24 hours.  The 
cells were then exposed to FGF2 (10ng/ml) in 0.05 %FCS media for 5 or 10 
minutes.  The cells were solubilized and proteins separated on 10% SDS-PAGE at 
10 µg protein/well.  Phospho-ERK 1,2 antibody (Millipore) was used overnight at 
1:1000 (4
o
C).  The same membrane was blotted for α-Tubulin antibody at 1:5000 
as a house keeping protein to demonstrate equal protein loading.  B) Analysis of 
densitometry of pERK bands normalized to α–tubulin.  These analyses were 
performed using Image-J and Prism 4 (N=3,*P<0.05).   
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3.4 Discussion  
HS is one of the most abundant GAGs on cell surfaces and within the extracellular 
matrix.  HS undergoes a series of modifications during and after synthesis.  These 
include transferring sulphate groups to specific positions on HS-GAG chains.  
Specific sulphate domains are required for HS-protein binding and signalling.  
Sulphate groups at the 6-O position are involved in a variety of interactions and 
signalling structures (Pye et al., 1998; Wang et al., 2002).  HS modifying enzymes 
have been upregulated following stimulation of endothelial cells with 
proinflammatory cytokines.  This change was accompanied with modulation of 
presentation and function of mediators such as chemokines (Ali et al., 2005a).   
3.4.1 Characterization of cell lines 
Phenotyping endothelial and epithelial cells provides a basis for further 
investigation of these cells.  Epithelial and endothelial cell lines in this study were 
characterized by expressing E-cadherin and CD31 respectively.  Epithelial and 
endothelial cells normally express these markers and can, under particular 
conditions, lose them for new markers in the context of a transformation process.  
For example, epithelial cells undergoing EMT can no longer express epithelial 
markers such as E-cadherin.  These cells alternatively express fibrogenic markers 
such as FSP-1 and α-SMA as signs of transformation (Zeisberg and Neilson, 2009).  
Similarly, endothelial cells lose the expression of CD31 as a sign of undergoing 
EndMT (Zeisberg et al., 2007a). 
HK2, HMEC1 and EAhy.926 cells were further phenotyped for expression of 
MHC-II molecules following stimulation with IFN-γ.  Induction of MHC-II 
molecules suggests potential involvement in the pathogenesis of the inflammatory 
response following graft transplantation.  This result supports a previous founding 
that endothelial and epithelial cells may act as antigen presenting cells in the 
context of inflammation (Cunningham et al., 1997). 
 
 
The effect of HS6ST1 on HS structure and biological activity 
 
104 
 
3.4.2 Observations of HS6ST1 expression 
This study shows that stimulation of endothelial cells (HMEC1 and Eahy.926) and 
epithelial cells (HK2) with proinflammatory cytokines has no effect on HS6ST1 
expression.  Investigation of HS6ST1 expression with conventional PCR exhibited 
no detectable bands of the agarose gel.  Whilst transcripts for HS6ST1 were 
detected by conventional PCR in HK2 cells they were not identified in HMECs.  
This is in contrast to the RT-PCR which found HS6ST1 expression in both cell 
lines.  The failure to detect HS6ST1 mRNA in HMECs using  conventional PCR 
may have been due to the relative poor efficiency of this primer combination or the 
possibility that one of the primer sites in HMECs were mutated.  Although using 
qPCR demonstrated clear expression of the gene in renal epithelial cells, no 
significant changes in the HS6ST1 gene expression were found following 
stimulation with cytokines such as IFN-γ or TGF-β.  However, IFN-γ caused a 
significant decrease in the gene expression in endothelial cells (HMEC1).  
Additionally, the current study shows that stimulation with these cytokines 
produces no changes in HS interaction with 10E4 Antibody or biotinylated FGF2.  
It also seems that treatment with IFN-γ or TGF-β has no effects on HS motif 
structure or polyanionic charge which are involved in interaction with 10E4 or 
FGF2.  Previously published results show that expression of HS6ST1 and HS6ST2 
was upregulated in glomerular endothelial cells following stimulation with TNF-α 
and/or IL-1β along with NDST1 and 2 on mRNA level (2 fold).   Interestingly, this 
was accompanied with increased 10E4 antibody binding which might be attributed 
to the increase in NDST1 expression which affects the 10E4 binding site (Rops et 
al., 2008).   
3.4.3 Observation of HS epitopes 
In order to examine the changes made by HS6ST1 enzyme on HS structure and 
biological activity, stable HS6ST1 transfectants were generated.  Stable 
transfectants were examined for HS6ST1 expression and the highest expressing 
clone (T7) was used for further investigations.  This study shows that HS6ST1 
transfectants significantly decreased the binding ability to 10E4 antibody compared 
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to mock transfected cells.  The epitope designed for interaction with 10E4 antibody 
contains a tetrasaccharide domain of N-sulphated and N-acetylated glucosamine 
(GlcA-GlcNS-GlcA-GlcNAc) (David et al., 1992; Leteux et al., 2001), whereas 
sulphates at the O-position are not required for this binding (van den Born et al., 
2005).  However, overexpression of O-sulphation might produce changes in the N-
sulphation process, N-acetyl distribution or even overall sulphation which affects 
10E4 binding.  Unpublished data have shown that overexpressing of NDST1 
increases the binding ability of HS-10E4 whereas knock-down of the gene shows 
the opposite effect (unpublished data by Dr. Spielhofer).   
This study shows that HS6ST1 transfectants exhibit a significantly increased 
ability to bind HS3A8 and HS4C3 antibodies compared to mock transfectants.  
These antibodies target HS epitopes consisting of trisulphated disaccharides, 
IdoA2S-GlcNS6S (Dennissen et al., 2002) and GlcNS3S6S respectively (van 
Kuppevelt et al., 1998).  Both epitopes are upregulated in chronic kidney rejection 
(unpublished data by Dr. Spielhofer, 2010); sections from human kidney 
undergoing chronic rejection have higher HS3A8 and HS4C3 epitope expression 
compared to normal, acute or moderately rejected kidney.  The increased binding 
ability of HS3A8 antibody might suggest the involvement of HS6ST1 enzyme in 
the etiology of renal fibrosis.  Similarity between FGF2 and HS4C3 epitopes was 
shown previously when FGF2-incubated cells blocked the interaction with HS4C3 
binding antibody by about 60% (van Kuppevelt et al., 1998).  Furthermore, 
previous addition of HS4C3 antibody completely inhibited the proliferation effect 
of FGF2 when added to human mesangial cells (HMC) in vitro (Lensen et al., 
2005).  The increased expression of HS4C3 epitopes in HS6ST1 transfectants can 
be classified in accordance with possible changes in HS sulphation such as 
increased FGF2 binding during fibrosis.  Similar correlation is shown during 
development, where cellular response to VEGF was increased with cells showing 
“higher binding affinity” to HS4C3 (Baldwin et al., 2008).  This is important due 
to the requirement for VEGF signalling (Tessler et al., 1994). 
Furthermore, investigations with RB4EA12 show that cells overexpressing 
HS6ST1 have a higher binding ability to RB4EA12 antibody compared to mock 
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transfectants.  This antibody recognizes an epitope consisting of: N-Acetyl, N-
sulphate and 6-O sulphate groups (IdoA-GlcNS6S), whereas 2-O sulphate is not 
required (Dennissen et al., 2002; Lensen et al., 2005).  This result is in line with a 
previous finding where SULF knock-out mice had higher 6-O sulphation 
(overexpression) accompanied with increased RB4EA12 binding (Lamanna et al., 
2006).  Interestingly, HS binding epitopes for HS4C3 and RB4EA12 have been 
markedly upregulated in human chronic fibrogenic disease (liver cirrhosis), (Tatrai 
et al., 2010).  These observations along with previous literature strongly suggest a 
possible role for 6-O sulphation in the etiology and development of chronic 
diseases.   
3.4.4 Observations with FGF2  
HS binding to FGF2 has been intensively studied from different points of view.  
HS binds FGF2 via a specific epitope which consists of tetrasaccharide domains of 
IdoA2S-GlcNS (Habuchi et al., 1992; Turnbull et al., 1992; Guglieri et al., 2008).  
The 6-O sulphate group is involved in a longer binding site and it is necessary also 
for receptor activation (Ornitz, 2000).  
In this study, biotinylated FGF2 was examined for HS binding using HS6ST1 
transfectants.  The reaction conditions were optimized and HS-FGF2 binding was 
investigated using HS and GAG deficient cell lines (CHO-677, 745 respectively) 
along with wild type CHO cells in a flow cytometric assay (Esko et al., 1985).  
Two clones of HS6ST1 transfectants were used in the investigations (T4 and T7) to 
confirm consistency. 
The current study shows that incubation with sodium chlorate (30mM) caused a 
dramatic drop in HS6ST1 transfectants binding to FGF2.  The decrease in FGF2 
binding is attributed to the HS O-desulphation which constitutes an essential 
component in HS-FGF2 binding (Kreuger et al., 2001).  This result is in agreement 
with literature where sodium chlorate caused selective O-desulphation (Safaiyan et 
al., 1999).  Indeed, this result shows that the main increase in FGF2 binding might 
be attributed to the upregulation in O-sulphation occurring due to HS6ST1 
overexpression.  Similarly, treatment with heparitinase III enzyme resulted in 
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downregulation of HS-FGF2 binding in both HS6ST1 and mock transfectants.  
Heparitinase III enzyme has the ability to cleave HS by removing N sulphated 
residues which is expected to disrupt the HS-FGF2 binding site (Lohse and 
Linhardt, 1992).   
The binding of biotinylated FGF2 was increased (2 fold) by HS6ST1 
overexpression compared to mock transfectants; this increase could be for various 
reasons.  Firstly, the 6-O sulphate group is not an essential component in the HS-
FGF2 binding epitope, which includes predominantly N-S and 2-OS groups 
(Guimond et al., 1993; Faham et al., 1996).  Although 6-O sulphate is not an 
essential component for HS-FGF2 binding, small amounts of this group were 
found in high affinity binding fractions (dp14), (Walker et al., 1994).  Secondly, 
earlier work showed that 2-O desulphated heparin, which retains 6-O sulphate 
groups, had the capacity to bind FGF2 but with lower affinity than native heparin 
(Guimond et al., 1993; Ishihara et al., 1997).  Thirdly, the increased FGF2 binding 
might be attributed to the effects of HS6ST1 overexpression on HS sulphation, 
including increased chain length, HS domain distribution and polyanionic 
properties (Do et al., 2006).  Furthermore, FGF2 increased binding might be 
attributed to changes in HS chain and overall O-sulphation following HS6ST1 
overexpression apart from 6-O sulphate group involvement in the HS-FGF2 
binding site in agreement with previous findings (Jastrebova et al., 2006; Mulloy 
and Rider, 2006).  In contrast, overexpression of NDST1 reduced the FGF2 
binding of NDST1 transfectants compared to wild type cells, although the N-
sulphates play an important role in HS-FGF2 binding epitope (unpublished data by 
Dr. Spielhofer).   
The current study shows that HS6ST1 overexpression has increased FGF-FGFR 
signalling leading to ERK activation and cell proliferation.  Cells with HS6ST1 
overexpression increased pERK activation in comparison to mock transfectants.  
This was noticed in the absence of FGF2; however, addition of FGF2 enhanced the 
ERK activation in mock transfectants but not in HS6ST1 transfectants.  It might be 
argued that overexpression of HS6ST1 has increased ERK activation to an upper 
limit in a way that could not be increased even in presence of a high concentration 
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of FGF2.  In agreement with pERK activation, HS6ST1 transfectants expressed 
higher proliferation ratios than mock transfected cells.  This result shows the 
important role of HS, particularly following HS6ST1 overexpressing in the 
mitogenic activity of renal epithelial cells.  This is in agreement with previous 
publication which showed involvement of HS in renal cell proliferation 
(Bokemeyer et al., 1997; Carey, 1997; Raats et al., 2000).  Additionally, the 
current study is in line with the previous notion that ERK activation is increased by 
HS oligosaccharides containing 2- and 6-O sulphate groups (Jastrebova et al., 
2010).  In further supporting experiments, an experimental mouse model with 
HS6ST overexpression exhibited increased FGF2-induced proliferation compared 
to wild type animals (Lamanna et al., 2006). 
3.4.5 Observation of HS structure 
Measurement of the expression of HS modifying enzymes has yielded important 
information in relation to HS structure, sulphation and activity.  Enforced 
expression of individual enzymes is also expected to affect not only the specific 
substrate but also the overall sulphation, domain distribution and HS chain length.   
In this study, disaccharide structural analysis shows that HS6ST1 transfectants 
exhibit upregulation of 6-O sulphation at mono-O-sulphated disaccharides 
containing GlcA-GlcNS6S and IdoA-GlcNS6S (GMS and IMS, Figure 3.30) as 
well as downregulation of heavily sulphated disaccharides GlcA2S-GlcNS6S and 
IdoA2S-GlcNS6S.  Interestingly, HK2 cells express a high level of trisulphated 
disaccharides (IdoA2S-GlcNS6S) which make these cells more similar to heparin 
than to HS structure.  These findings are in line with previous work which also 
shows that HS6ST1 overexpression had a relatively high concentration of 
monosuphated disaccharides GMS and IMS (Do et al., 2006).  The current study 
shows that HS6ST1 transferred sulphate groups to residues containing GlcA/IdoA 
rather than 2-O sulphated in agreement with previous finding (Habuchi et al., 
2000).  Furthermore, an increased concentration of 6-O sulphates at monosulphated 
disaccharides rather than trisulphated disaccharides is consistent with previous 
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finding which shows that HS6ST1 prefers low sulphated substrates (Habuchi et al., 
2007). 
This study shows that the overall sulphation at the 6-O position is not increased in 
HS6ST1 transfectants compared to mock transfectants.  This result can be 
attributed to the high concentration of trisulphated disaccharides (similar to 
heparin) including 6-O sulphate at the basal level in mock transfectants.  Taking 
into consideration that a highly sulphated substrate does not constitute the preferred 
substrate for HS6ST1 (Habuchi et al., 2007), it is not surprising that we do not see 
significant upregulation of 6-O sulphates.  This result does not agree with previous 
published data which showed that overexpression of HS6ST resulted in increased 
concentration of 6-O sulphation (Do et al., 2006).  
Further changes in HS from HS6ST1 transfectants in this study included 
downregulation of 2-O sulphation with no significant changes in N-sulphation.  
The decrease in 2-O sulphation was previously accompanied by HS6ST 
overexpression (Do et al., 2006).  The mechanism of compensation by which over-
sulphation at one position might affect sulphation at another position is not fully 
understood.  By contrast, it has been shown that double knock-out of sulphatase 
enzymes which resulted in increased 6-O sulphation was accompanied by an 
additional increase in 2-O sulphation (Lamanna et al., 2008).  It is possible that 
HS6ST1 overexpression can induce a loss of coordinated activity between HS 
modifying enzymes which normally function in concert within the gagosome. 
In conclusion, HS6ST1 transfectants increased the binding to FGF2 and 
proliferation of transfected cells.  These transfectants exhibited increased binding 
epitopes against phage display antibodies HS3A8, HS4C3 and RB4EA12.  These 
results show changes in HS sulphation and biological activities which are in line 
with transplanted kidney undergoing chronic rejection and interstitial fibrosis.  
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HS  
4.1 Introduction  
HS undergoes various modifications during synthesis in the Golgi system due to 
different modifying enzymes.  HS modifying enzymes such as NDST, HS2ST, 
HS6ST and HS3ST transfer sulphate groups to the HS chains (see section 1.6.4) 
which provides complexity and diversity that is needed for the HS function 
(Habuchi, 2000).  HS chains undergo additional modifications due to the effect of 
hydrolysis enzymes such as heparanase, SULF1 and SULF2.   These enzymes further 
modify the HS structure either by cleaving HS chains or by removing sulphate 
groups from specific positions (Lamanna et al., 2006).  This part of the research aims 
to shed more light on HS degradation enzymes and the effects on HS interaction and 
signalling with growth factors involved in the chronic kidney rejection.  
HS proteoglycans normally have a half-life of about 1-4 hours on cell surfaces 
(Yanagishita, 1992).  HSPGs are endocytosed or degraded by the action of protease 
enzymes and lipases.  In rat ovary cells for example, the HS chains are transferred 
after 25 minutes to lysosomes where they are degraded into inorganic sulphate and 
basic monosaccharides.  The HSPGs are recycled 10 times between cell surface and 
intracellular compartments before degradation in rat parathyroid tissue 
(Yanagishita, 1992).   
4.2 HS degradation 
HS chains are degraded after being synthesized, modified and exposed on cells 
surfaces and extracellular matrices.  This process is regulated by sulphatase and 
heparanase enzymes. 
4.2.1 Sulphatase enzymes  
Sulphation at the 6-O position is increased by transferring sulphate groups by the 
action of HS6ST enzymes.  However, 6-O sulphate groups can also be removed by 
the activity of sulphatase enzymes (Dhoot et al., 2001; Lamanna et al., 2007).  
There are 2 isoforms of relevant sulphatase termed SULF1 and SULF2; these 
enzymes are members of a family of 17 sulphatase enzymes in humans (Morimoto-
Tomita et al., 2002; Sardiello et al., 2005).  These members catalyze the hydrolysis 
of sulphated ester bonds in substrates such as sulpholipids and GAGs.   
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The endosulphatase enzymes (SULF1 and SULF2) interact with GAG chains via a 
unique hydrophilic domain (HD) located between N-catalytic domain and the C 
terminus.  The HD has a high content of basic amino acids and therefore a high 
positive charge at neutral pH which facilities the binding to the anionic heparin/HS 
structure, anchoring the enzyme to the cell surfaces (Frese et al., 2009).  SULF1 
was initially discovered in a molecular screen of the sonic hedgehog (Shh) gene in 
quail embryos; this enzyme is involved in the regulation of cellular differentiation 
by modulation of the Wnt signalling (Dhoot et al., 2001).   
SULF1 and SULF2 have an endosulphatase activity specific for glucosamine 
containing 6-O sulphate groups on the cell surface (Ai et al., 2006b).  These 
enzymes are considered the final HS modifying enzymes which exist in both cell 
surface-associated and soluble forms (Morimoto-Tomita et al., 2002).  Importantly, 
SULF2 has been shown to increase the expression of glypican 3 in hepatic cell 
carcinoma (HCC) and promotes FGF2 signalling (Lai et al., 2008a).  Glypican 3 
constitutes an important marker for hepatic cell carcinoma metastases (Ning et al., 
2012). 
4.2.1.1 SULF enzyme and HS structure 
The SULF enzymes have shown a substrate preference, with 6-O desulphation 
taking place at UA-GlcNS6S and UA2S-GlcNS-6S residues by 20% and 70% 
respectively.  No sulphatase activity was observed against UA-GlcNAc-6S residues 
(Lamanna et al., 2008).  Heparan sulphate obtained from SULF knockout mice 
shows various levels of 6-O disaccharide composition.  SULF1 knockout mice 
increase 6-O sulphation in all three HS domains (NS, NA/NS and NA) whereas the 
SULF2 knockout increases 6-O sulphates in NA only (Lamanna et al., 2007).  
Although sulphatase enzymes specifically remove 6-O sulphate groups from HS 
chains, SULF loss was shown to have additional changes on 2-O and N- sulphate 
groups on different types of HS (Lamanna et al., 2008).   
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4.2.1.2 The physiological role of sulphatase  
The interaction between proteins and HS depends on several factors, including 
chain length, polyanionic charge, and the pattern of sulphation.  However, 
accumulating evidence shows that loss of 6-O sulphation can modify protein 
binding (Dhoot et al., 2001; Ai et al., 2003a; Wang et al., 2004).  One example of 
the positive effect of sulphatase activity is the Wnt signalling system.  The 
expression of SULF1, by desulphation of the 6-OS group, increased Wnt binding to 
its cognate receptor Fizzled (Ai et al., 2003a).  However, in case of FGF2 the 6-O 
desulphation leads to deactivation of the signalling pathway (Wang et al., 2004).  
The removal of 6-O sulphate groups has also been shown to affect the binding of 
CXCL12 (stromal derived growth factor-1; SDF-1), VEGF and morphogens.  
These factors play significant roles in activities including development, 
differentiation and cell growth (Ai et al., 2003a; Wang et al., 2004; Uchimura et 
al., 2006; Lemjabbar-Alaoui et al., 2010).   
Sulphatase gene expression shows differential regulation during health and disease.  
For instance, the stimulation of human lung fibroblasts with TGF-β induces the 
upregulation of SULF1 expression.  Interestingly, it was suggested that SULF1 
might have negative effect on regulation of the fibrogenesis induced by TGF-β 
(Yue et al., 2008).  Expression of the SULF2 gene was increased in breast and lung 
carcinoma (Morimoto-Tomita et al., 2005; Lemjabbar-Alaoui et al., 2010). 
Sulphatase knockout results in mild changes in lung development, growth and 
viability (Rosen and Lemjabbar-Alaoui, 2007).  For example, SULF1 knockout 
mice show a nearly normal phenotype with higher mortality in the first few months 
of life whereas SULF2 knockout mice show only mild changes such as weight loss 
(Lamanna et al., 2006; Lum et al., 2007).  Importantly, double knockout of SULF 
genes results in neonatal lethality accompanied by defects in skeleton, kidney and 
the nervous system (Holst et al., 2007; Kalus et al., 2009).   
4.2.1.3 Heparanase enzyme (HSPE) 
Mammalian HPSE was first detected in human placenta and a hepatoma cell line 
(Hulett et al., 1999; Vlodavsky et al., 1999).  The HPSE gene was expressed in 
various cell types and tissues, with relatively high expression in placenta, lymphoid 
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organs, keratinocytes and carcinoma cells (Dempsey et al., 2000; Parish et al., 
2001; Vlodavsky and Friedmann, 2001).   
The HPSE is an endoglycosidase involved in HS degradation (Bame, 2001).  This 
enzyme hydrolyses the glucosidic bonds (β 1-4) within the HS chain producing HS 
fragments of 10-20 sugar units.  The suggested cleavage site for HPSE requires the 
presence of NS and 6-O-S groups in a specific orientation (Pikas et al., 1998; 
Okada et al., 2002).  It has been suggested that the minimum binding site is a 
trisaccharide domain of two glucosamine units and one UA (GlcN-UA-GlcN), 
(Okada et al., 2002).  
The HPSE enzyme plays important roles in biological activities such as 
angiogenesis, inflammation, carcinogenesis and metastases (Nasser, 2008). 
Interestingly, the action of HPSE allows the release of HS fragments, increasing 
FGF2 binding, dimerization and signalling (Elkin et al., 2001).  The HPSE enzyme 
might also affect the survival of transplanted organs by shedding the HS involved 
in the AT-III binding site.  This effect might be responsible for the intravenous 
coagulation and fibrin deposits in the graft (Ali et al., 2003).  Additionally, HPSE 
has an essential role in degradation of the vascular basement membrane.  This 
effect facilitates leucocyte passage through basement membrane by increasing 
barrier permeability during inflammation (Edovitsky et al., 2006).  Interestingly, 
HPSE can regulate syndecan 1 clustering and shedding from tumor cells (Yang et 
al., 2007).  The downregulation of syndecan 1 was shown to result in FGF2-
induced EMT (Kato et al., 1995).  Importantly, it has been shown recently that 
HPSE plays a crucial role in regulation and induction of EMT in renal tubular 
epithelial cells following FGF2 stimulation (Masola et al., 2012). 
The expression of HPSE is modulated during inflammatory processes.  For 
example, the expression of heparanase is increased during fibrotic liver disease 
(Tatrai et al., 2010).  The secretion of HPSE is also influenced by proinflammatory 
cytokines.  Stimulation of endothelial cells with proinflammatory cytokines such as 
TNF-α or IL-1β is known to promote the release of HPSE (Chen et al., 2004).   
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4.2.2 Aims  
Specific aims will be:  
 To examine the expression of heparan sulphate degrading enzymes such as 
sulphatase and heparanase in human kidney epithelial and endothelial cell 
lines. 
 To examine the modulation of sulphatase expression by a wide range of 
cytokines. 
 To generate stable transfectants of SULF2 in order to: 
o Examine the effects on FGF2 binding. 
o Examine the changes in sulphation pattern using phage display 
antibody. 
o Analyze the changes caused by SULF2 on HS structure using 35S 
uptake. (This work was carried out in collaboration with Prof. Kusche-
Gullberg in Norway)  
o Examine the effects of SULF2 overexpression on CCL5 binding 
o Investigate the effects of SULF2 on cell proliferation. 
o Investigate the effect of SULF2 on ERK activation. 
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4.3 Specific materials and methods 
4.3.1 SULF2 sequencing and alignment 
The plasmid was supplied by Addgene with an inserted SULF2 gene into the vector 
backbone (pcDNA3.1/Myc-His-).  The plasmid was transformed into the DH5-α 
bacteria for DNA amplification and seeded on agar plates with ampicillin.  The 
colonies were used for plasmid DNA isolation (Qiagen) and the DNA was cut by 
XhoI and HindIII enzymes which provide unique restriction sites (Figure 4.1).   
  
Figure 4.1. Drawing of plasmid pcDNA3.1/Myc-His- (vector) and SULF2 gene 
(insert).  
The restriction enzyme digestion produced two bands of 2600 bp and 5500 bp 
representing the SULF2 insert and the vector backbone respectively (Figure 4.2).  
The resultant insert was sequenced (Geneservice) and aligned with the SULF2 gene 
(Addgene plasmid-13004) in the PubMed-sequence site (see appendices).   
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Figure 4.2. Plasmid encoding SULF2 digested with XhoI and HindIII. The whole 
(pCDN3.1/his-) plasmid (including SULF2 insert) was digested with restriction 
enzymes XhoI and HindIII.  The digest reaction was performed at room 
temperature for 3 hours and the DNA was then run on 0.7% agarose gel alongside 
1kb DNA ladder (Lane 1).  Lane 2 contains the plasmid with XhoI, lane 3 contains 
plasmid with HindIII whereas the lanes 5 and 6 contain plasmid with both enzymes 
(XhoI and HindIII) in duplicate. 
4.3.2 Cell stimulation 
Renal epithelial cells were stimulated with cytokines and changes in HS sulphation 
were examined for gene expression (qPCR) and antibody interaction.  The cells 
were incubated with different cytokines separately and the RNA was extracted and 
used for cDNA synthesis and RT-PCR.  Renal epithelial cells (HK2) were seeded 
in six well plates in presence of complete DMEM-F12 medium overnight.  
Cytokines including IFN-γ, IL-17 or TGF-β were added to the medium in the 
absence of fetal calf serum (FCS) whereas BSA was added at 1%.  After 24 hours, 
the medium was removed and the cells were washed with PBS and used for RNA 
extraction by Trizol (Sigma).  The resting cells (non-stimulated cells) were 
considered as control.  The stimulated cells were also investigated for interaction 
with 10E4 antibody and FGF2. 
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4.3.3 RT-PCR 
4.3.3.1 Testing the efficiency of amplification 
Quantitative PCR was optimized at the beginning of gene expression experiments 
using specific primer probes (TaqMan) from Applied Biosystem.  The cDNA was 
synthesized and screened for HS degradation enzymes HPSE, SULF1 and SULF2 
using exon spanning primer probes (TaqMan) while the GAPDH was used as a 
house keeping gene.  In optimal PCR, DNA amplification should reach 100% when 
the slope is -3.32.  However, an amplification ratio of 90-110% is accepted.  For 
GAPDH, SULF1, SULF2 and HPSE the amplification efficiency (E) values were 
108%, 107%, 97.8% and 94.5 % respectively (Figure 4.3). 
 
Figure 4.3. RT-PCR efficiency with specific primer/probe combinations.  cDNA 
obtained from HKC8 renal epithelial cells was used as a template for RT-PCR 
experiment. cDNA was ten-fold diluted in 3 serial dilutions with primer probes of 
GAPDH, SULF1, SULF2 and HPSE. Cycle threshold (CT) numbers were 
calculated against logarithm of serial dilution.  Statistics were performed by using 
Excel regression.  
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4.3.3.2 PCR primer probes 
Human exon junction spanning probes do not detect any amplified genomic DNA 
(Applied Biosystem, TaqMan Gene Expression assay). 
GAPDH (Hs0099999905-m1) 
SULF1 (Hs00392834-m1) 
SULF2 (Hs00393644-m1) 
HPSE (Hs00395394-m1)  
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4.4 Results 
4.4.1 Cell stimulation and HS degradation enzymes 
The expression of HS degrading enzymes was investigated at the mRNA level by 
stimulating endothelial and epithelial cells with several cytokines.  These cytokines 
were TGF-β, IFN-γ and IL17 at concentrations which include 10ng/ml, 25ng/ml 
and 100ng/ml respectively; phorbol myristate acetate (PMA) was used at 
concentration 50ng/ml.  The concentrations and time points were optimized in the 
group earlier.  Investigations were performed by qPCR with specific codon-
spanning primer probes. 
4.4.1.1 Heparanase (HPSE) 
Heparanase is a glycosidase enzyme which acts as an endo β-D-glucuronidase of 
HS chain resulting in release of HS fragments of discrete sizes.  HPSE expression 
was investigated in resting cells and after cell stimulation. 
4.4.1.1.1 Endothelial cells and HPSE 
EAhy.926 cells were stimulated with TGF-β, IFN-γ and IL-17 for 24 hours; PMA 
was used for control.  Cytokine stimulation resulted in no significant changes in 
HPSE expression on mRNA level compared to resting cells.  Figure 4.4 shows that 
no significant changes were noticed using qPCR assay specific for HPSE (P>0.05).   
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Figure 4.4. Expression of heparanase (HPSE) by EAhy.926 after stimulation with 
cytokines.  Cells were incubated with IFN-γ (25ng/ml), TGF-β (10ng/ml), IL-17 
(100ng/ml) and PMA (50ng/ml) for 24 hours.  RNA was extracted and used (5µg) 
for cDNA synthesis.  QPCR experiments were performed in triplicates with gene 
expression assay with specific primer probes. CT values of stimulated cells were 
calculated and compared to those of resting cells in reference to GAPDH as a 
house-keeping gene.  Data were analysed by ∆∆CT method using REST-2009 
software.  No significant changes in HPSE expression were observed (N=3), error 
bars represent the SEM.  
4.4.1.1.2 Renal epithelial cells and HPSE 
Renal epithelial cells (HK2) were stimulated with cytokines such as TGF-β, IFN-γ 
and IL-17 for 24 hours whereas PMA was used for control.  Then cDNA obtained 
was examined for the expression of HPSE by real time PCR.  Data analyses show 
that IFN-γ and IL-17 stimulation resulted in no significant changes in HPSE 
expression compared to resting cells.  However TGF-β stimulation significantly 
downregulated the expression of HPSE by about 50% compared to unstimulated 
cells.  PMA also significantly downregulated HPSE expression by around 25% 
compared to unstimulated cells (Figure 4.5).  
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Figure 4.5. Expression of HPSE by HK2 cells after stimulation.  Cells were 
incubated with IFN-γ (25ng/ml), TGF-β (10ng/ml), IL-17 (100ng/ml) and PMA 
(50ng/ml) for 24 hours.  RNA was extracted and used (5µg) for cDNA synthesis.  
QPCR experiments were performed in triplicates with specific primer probes 
(TaqMan). CT analysis data were normalized to resting cells in reference to 
GAPDH as a house-keeping gene.  Data were analyzed by ∆∆CT method using 
REST-2009 software.  (N=3, *: P<0.05, **: P<0.01).  
4.4.1.1.3 Sulphatase 1 (SULF1) 
Sulphatase 1 constitutes a hydrolase enzyme that removes 6-O sulphate groups 
from the HS chains on cell surfaces.  SULF1 gene expression was examined using 
qPCR after stimulation with a set of cytokines in endothelial and epithelial cell 
lines.  Results were compared to resting cells.   
4.4.1.1.4 Endothelial cells and SULF1 
SULF1 gene expression in EAhy.926 was examined after stimulation with TGF-β, 
IFN-γ, and IL17 for 24 hours.  As shown in figure 4.6, IL17 stimulation has caused 
significant (P<0.05) downregulation of SULF1expression by around 60 % 
compared to resting cells (control).  In contrast, TGF-β stimulation has caused 
significant upregulation of SULF1 expression (P<0.05) by around 2.5 fold 
compared to resting cells.  Changes in SULF1 expression due to the effect of TGF-
β and IL17 proved to be statistically significant (Figure 4.6).  Stimulation with 
IFN-γ caused no significant changes on SULF1 expression. 
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Figure 4.6. Expression of SULF1 by EAhy.926 after stimulation.  Cells were 
incubated with IFN-γ (25ng/ml), TGF-β (10ng/ml) and IL-17 (100ng/ml) for 24 
hours.  RNA was extracted and used (5µg) for cDNA synthesis.  QPCR 
experiments were performed in triplicates with gene expression assay using 
specific primer probes.  CT values were calculated in reference to GAPDH and 
resting cells in ∆∆CT method using REST-2009 software.  (N=3, *: P<0.05).   
4.4.1.1.5 Renal epithelial cells and SULF1 
Renal epithelial cells (HK2) were stimulated with TGF-β, IFN-γ, IL17 and PMA 
for 24 hours and the expression of SULF1 gene was examined.  TGF-β and IL17 
had no significant effect on SULF1 expression compared to resting cells.  
Stimulation with IFN-γ, PMA and IL-17 resulted in remarkable downregulation of 
SULF1 by about 75%, 60% and 30% respectively compared to unstimulated cells 
(P<0.05).  These changes were shown to be statistically significant (Figure 4.7). 
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Figure 4.7. Expression of SULF1 by HK2 cells after stimulation.  Cells were 
incubated with IFN-γ (25ng/ml), TGF-β (10ng/ml), IL-17 (100ng/ml) and PMA 
(50ng/ml) for 24 hours.  RNA was extracted and used (5µg) for cDNA synthesis.  
QPCR experiments were performed in triplicates with specific primer probes 
(TaqMan).  CT values of stimulated cells were calculated and compared to those of 
resting cells with GAPDH as a house-keeping gene.  Data were analyzed by ∆∆CT 
method using REST-2009 software. (N=3, *: P<0.05).  
4.4.1.2 Sulphatase 2 (SULF2) 
Sulphatase 2 (SULF2) enzyme is an isoform of SULF1 that exists on the cell 
surface and also in soluble form that hydrolyses the 6-O sulphate of HS chains.  
SULF2 expression was investigated in endothelial and epithelial cell lines after 
cytokine stimulation using qPCR.   
4.4.1.2.1 Endothelial cells EAhy.926 and SULF2 
Endothelial cells EAhy.926 were stimulated with TGF-β, IFN-γ and IL17 for 24 
hours; PMA was used for control.  As shown in figure 4.8, TGF-β and PMA 
stimulation caused no significant changes on SULF2 gene expression compared to 
resting cells.  However, stimulation with IFN-γ resulted in upregulation of the 
SULF2 gene expression by about 3 fold compared to resting cells.  In contrast, IL-
17 stimulated cells exhibited downregulation of SULF2 by more than 50 % 
compared to resting cells.  Changes due to the effect of IFN-γ and IL-17 have 
proved to be statistically significant (Figure 4.8). 
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Figure 4.8. Expression of sulphatase 2 (SULF2) by EAhy.926 after stimulation. 
Cells were incubated with IFN-γ (25ng/ml), TGF-β (10ng/ml), IL-17 (100ng/ml) 
and PMA (50ng/ml) for 24 hours.  RNA was extracted and used (5µg) for cDNA 
synthesis.  QPCR experiments were performed in triplicates with specific primer 
probes. CT values were analyzed by using REST-2009 software.  (N=3, *: P<0.05). 
4.4.1.2.2 Renal epithelial cells and SULF2 
Renal epithelia cells (HK2) were stimulated with cytokines such as TGF-β, IFN-γ 
and IL17 for 24 hours; PMA was used for control. The expression of SULF2 gene 
was then examined.  Stimulation with IFN-γ, IL-17 and PMA showed no 
significant change in the SULF2 gene expression compared to resting cells.  
Interestingly, stimulation with TGF-β has resulted in gene overexpression of 
SULF2 by around 5 fold compared to resting cells.  This change has been shown to 
be statistically significant (P<0.01), (Figure 4.9).  
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Figure 4.9. Expression of SULF2 by HK2 cells after stimulation.  Cells were 
incubated with IFN- γ (25ng/ml), TGF-β (10ng/ml), IL-17 (100ng/ml) and PMA 
(50ng/ml) for 24 hours.   RNA was extracted and used (5µg) for cDNA synthesis.  
QPCR experiments were performed in triplicates with specific primer probes 
(TaqMan). CT values of stimulated cells were calculated and compared to those of 
resting cells in reference to GAPDH as a house-keeping gene.  Data were analyzed 
by ∆∆CT method using REST-2009 software.  (N=3, **: P<0.01).   
4.4.2 Generation of stable transfectants of SULF2  
Renal epithelial cells stimulated with TGF-β have shown upregulation of SULF2 
gene expression by 5 fold as seen above.  Due to the role of TGF-β in chronic 
allograft rejection and in order to shed more light on its role in the sulphation 
pattern of HS, stable transfectants with SULF2 overexpression were generated.  
These transfectants were used for further experiments in accordance to chronic 
rejection and sulphation pattern. 
4.4.2.1 Optimisation of transfection 
Transfection was optimised using a plasmid containing GFP.  Reporter plasmid-
GFP was transiently transfected into human kidney cell line HKC8 and 
investigated by flow cytometry.  A concentration of 0.4 µg of DNA was used with 
50 µl of Effectene reagent (Qiagen), (see 3.3.6.1).  24 hours later, cells expressing 
GFP formed about 70% of the total transfected cells.  This result means that 
transfection efficiency reached about 70% (Figure 4.10).  This ratio constitutes a 
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good basis for transfection by using the same protocol for transfecting SULF2-
containing plasmid into renal epithelial cells. 
 
Figure 4.10. Representative histogram of GFP transfection efficiency.  Renal 
epithelial cells were transfected with plasmid encoding GFP.  Transfection 
efficiency was investigated by measuring fluorescence intensity after 24 hours in 
comparison to non-transfected cells (red line).  GFP transfected cells (black line) 
represented about 70% of total cells.  Investigation was carried out by flow 
cytometry and data were analyzed by WinMDI 2.9.   
4.4.2.2 Antibiotic killing curve 
Incubating HKC8 cells with different concentrations of Geneticin (G418) showed 
that cells were killed at the lowest concentration starting from 600 µg/ml of G418 
in DMEM-F12 complete medium.  Transfectants (SULF2) were selected in a 
medium with G418 at 600µg/ml and maintained at 400µg/ml, data not shown. 
4.4.2.3 SULF2 cloning  
Renal epithelial cells were transfected with plasmid pcDNA3.1/Myc-his- (5500bp) 
containing SULF2 insert (2600bp).  Plasmid-insert was run on agarose gels 
following digestion with restriction enzymes in order to confirm the size of each 
component.  As shown in figure 4.2, plasmid was digested and run on the gel to 
confirm the SULF2 insert and vector sizes.  The plasmid was sequenced and the 
results were aligned with the original SULF2 gene sequence (appendices). 
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4.4.2.4 Generation of SULF2 transfectants 
A SULF2 expressing plasmid was generated. The sequence was then verified and 
used for transfecting renal epithelial cells.  Resulting clones were selected in 
presence of G418 (600µg/ml).  Selected clones were expanded and screened for the 
expression of SULF2 by qPCR.  Clones were given the initial “S” with a reference 
number and the highest expression clones (S5 and S11) were used for further 
investigations.  Mock transfectants were generated by transfecting renal epithelial 
cells with an insert-free plasmid.  Mock transfectants were selected and grown 
under the same conditions as for SULF2 transfectants (Figure 4.11).  
 
Figure 4.11. Expression of SULF2 in renal epithelial (HKC8) stable transfectants.  
QPCR experiments were carried out to screen the expression of SULF2 in HKC8-
SULF2 transfectants.  SULF2 transfectants were grown in presence of G-418 and 
total RNA was extracted and used for cDNA synthesis for qPCR.  GAPDH was 
used as a house-keeping gene and data were normalized to mock transfected cells.  
The highest SULF2 expressing clones (S-5 & S-11) were used for further 
investigations. (N=2)  
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4.4.3 Characterization of SULF-2 transfectants  
4.4.3.1 Antibody binding to the 10E4 epitope 
In order to investigate changes in HS structure after SULF2 overexpression, a 
series of experiments were performed to quantify 10E4 antibody binding.  These 
experiments were investigated by immunofluorescence and flow cytometry.   
4.4.3.1.1 Flow cytometry 
SULF2 transfectants were incubated with 10E4 antibody and the controls included 
cells incubated with isotype control primary antibody and secondary antibody only 
(with no primary antibody).  These cells were compared to mock transfectants.  
SULF2 transfectants show a trend to increased binding of the 10E4 antibody 
compared to mock transfectants (Figure 4.12, A).  However, this was not 
statistically significant (Figure 4.12, B). 
 
 
Figure 4.12. Characterization of HS sulphation of SULF2 transfectants binding to 
10E4.  SULF2 and mock transfectants were incubated with 10E4 antibody at 1:100 
for 60 minutes at 4
o
C followed by FITC-conjugated secondary antibody.  A, 
Histogram representing SULF2 transfectants (S-11) binding to 10E4 (blue) 
compared to mock transfectants (green), black line represents isotype IgM antibody 
incubated cells and red line represents cells with secondary antibody only. B, Mean 
values of median fluorescence intensity (∆MFI) measured by fluorescence flow 
cytometry (N=3).   
A 
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4.4.3.1.2 Immunofluorescence  
SULF2 transfectants were stained with anti HS antibody (10E4) by using 
immunofluorescence technique and investigated by confocal microscopy.  The 
figures produced by this method show that 10E4 binds at a higher level to cells 
with SULF2 overexpression compared to mock transfectants.  Transfectants with 
less SULF2 expression (S5) showed less antibody binding than cells expressing 
higher levels of SULF2  (S11).  Quantitative analysis by measuring MFI showed 
significant changes (P<0.05), (Figure 4.13, 4.14).  
 
Figure 4.13. Representative image of SULF2 transfectants stained with 10E4 
antibody.  Cells were seeded in 4 well chamber slides till confluency.  Then slides 
were fixed with cold acetone and blocked with PBS-BSA2% followed by 10E4 
antibody at 1:100.  FITC-conjugated secondary antibody was added and slides were 
examined by fluorescence inverted microscope.  Scale bar represents 47.62 µm. 
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Figure 4.14. Quantitative analysis of SULF2 transfectants stained with 10E4 
antibody.  Slides of mock and SULF2 transfectants (S5 and S11) were analyzed by 
Image J to measure mean fluorescence intensity.  Three slides from three 
independent experiments were quantified; each slide was screened for five random 
and equal areas.  (N=3, ***: P<0.001).   
4.4.3.2 Binding to phage display antibodies 
SULF2 removes sulphate group from 6-O position on cell-surface HS.  This may also 
influence the pattern of sulphation at the 3-O, 2-O and N- positions.  A series of 
experiments was carried out using phage display antibodies to investigate changes on 
HS epitope expression.  These experiments were evaluated by flow cytometry. 
4.4.3.2.1 Antibody binding to the HS3A8 epitope 
HS3A8 antibody targets specific sulphate groups at N-, 6-O and 2-O positions.  
SULF2 transfectants (S5 and S11) were shown to have a decreased ability to bind 
HS3A8 antibody compared to mock transfectants.  This downregulation was 
statistically significant (P<0.01) with S11 compared to mock transfectants (Figure 
4.15). 
 
132 
 
HS degradation 
  
 
Figure 4.15. Phage display antibody HS3A8 binding to SULF2 transfectants.  
Mock and transfectants were grown in presence of G-418 until 80% confluency.  
Cells were detached, washed and incubated with HS3A8 in 1:10 at 4
o
C for 60 
minutes.  Secondary anti-VSV-Cy3-conjugated antibody was added (1:200) for 
additional 30 minutes.  Cells were washed, resuspended in 2%FCS-PBS and 
investigated by flow cytometry.  A, representative histogram of SULF2 transfectant 
(green) binding to HS3A8 compared to Mock transfectant (black). B, Mean values 
of median fluorescence intensity (∆MFI) measured by fluorescence flow cytometry 
(N=3, **: P<0.01).  
4.4.3.2.2 Antibody binding to the HS4C3 epitope 
SULF2 transfectants and mock transfectants were incubated with HS4C3 phage 
display antibody.  This antibody targets sulphate groups at N- and O- positions.  
Data from flow cytometry show that cells with SULF2 overexpression had a 
decreased ability to bind this antibody compared to mock transfectants.  This 
decrease was shown to be statistically significant (P<0.05), (Figure 4.16). 
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Figure 4.16. Phage display antibody HS4C3 binding to SULF2 transfectants.  Mock 
and transfectants were grown in presence of G-418 until 80% confluent.  Cells 
were detached, washed and incubated with HS4C3 in 1:10 at 4
o
C for 60 minutes.  
Secondary anti VSV Cy3-labelled antibody was added (1:200) for additional 30 
minutes.  Cells were washed, resuspended in 2%FCS-PBS and investigated by flow 
cytometry.  Data were analysed using WinMDI 2.9 and Prism 4 software. A, 
representative histogram of SULF2 transfectant (green) binding to HS4C3 
compared to mock transfectant (black). B, Mean values of median fluorescence 
intensity (∆MFI) measured by fluorescence flow cytometry, error bars represent the 
SEM (N=3, *: P<0.05).   
4.4.3.2.3 Antibody binding to the RB4EA12 epitope 
The RB4EA12 antibody targets sulphate groups at the N- and 6-O positions.  An 
assay was designed to investigate the changes at sulphate groups following SULF2 
overexpression.  SULF2 transfectants showed a decreased ability to bind RB4EA12 
compared to mock transfectants.  This change was statistically significant (P<0.05), 
(Figure 4.17). 
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Figure 4.17. Phage display RB4EA12 binding to renal epithelial SULF2 
transfectants.  Mock and SULF2 transfectants were grown in 600µg/ml G-418 until 
80% confluent.  Cells were detached, washed and incubated with RB4EA12 in 1:10 
at 4
o
C for 60 minutes.  Secondary anti VSV-Cy3 labeled antibody was added 
(1:200) for additional 30 minutes.  Experiments were carried out in duplicates. A, 
representative histogram of SULF2 transfectant (green) binding to RB4EA12 
compared to mock transfectant (black). B, Mean values of median fluorescence 
intensity (∆MFI) measured by fluorescence flow cytometry.  Data were analysed 
using WinMDI 2.9 and Prism 4 software.  (N=2, *: P<0.05).  
4.4.3.3 Binding of FGF2 
To examine the effect of SULF2 overexpression on FGF2 binding, a series of 
experiments was carried out to assess the binding of FGF2.  Two clones of SULF2 
transfectants were used in the assay, one transfectant (S11) showed statistically 
significant results for binding biotinylated FGF2, whereas the S5 transfectant 
showed no significant results for FGF2 binding (data not shown).  Reaction 
specificity was verified by using negative control consisting of biotinylated Soya 
bean protein and anti FGF2 blocking antibodies to block unspecific binding.  The 
reaction was investigated by flow cytometry. 
The SULF2 transfectants showed a 30% decreased binding of FGF2 compared to 
mock transfectants.  This change was statistically significant (P<0.05), (Figure 
4.18). 
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Figure 4.18. Binding of FGF2 to SULF2 transfectants.  Mock-HKC8 and SULF2 
transfectants (S-11) were incubated with FGF2 on ice for 60 minutes followed by 
Avidin-FITC substrate for 30 minutes.  A, representative histogram of SULF2 
transfectant (purple) binding to FGF2 compared to mock transfectant (blue), black 
line represents negative control (Soya bean protein) and green line represents anti-
FGF2 containing tube whereas red histogram represents cells in incubated with 
secondary FITC-avidin substrate only. B, Mean values of median fluorescence 
intensity (∆MFI) measured by fluorescence flow cytometry, error bars represent the 
SEM (N=3, *P<0.05).  
4.4.3.4 Binding of CCL5 
A series of experiments were carried out to investigating the binding of SULF2 
transfectants to RANTES (CCL5).  Biotinylated CCL5 was incubated with a 
defined number of cells, the reaction was visualised by adding Avidin-FITC 
substrate and the reaction was investigated by flow cytometry.  Reaction specificity 
was verified by using Soya bean protein biotinylated to the same level as CCL5 as 
a negative control.  Anti CCL5 blocking antibody was used as an additional control 
to confirm the binding specificity.  Data analysis shows that SULF2 transfectants 
decreased the binding of CCL5 by about 40% compared to mock transfectants.  
This change is statistically significant (P<0.05), (Figure 4.19).  
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Figure 4.19. SULF2 transfectants binding to CCL5. Mock-HKC8 and SULF2 
transfectants (S-11) were incubated with CCL5 at 4
o
C for 60 minutes followed by 
Avidin-FITC for 30 minutes. These cells were investigated by immunofluorescence 
flow cytometry.  Fluorescence activity was expressed as ∆MFI and data were 
analysed by WinMDI 2.9 and Prism 4 software. A, representative histogram of 
SULF2 transfectant (green) binding to CCL5 compared to mock transfectant 
(black) whereas red histogram represents cells with secondary substrate only. B, 
Mean values of median fluorescence intensity (∆MFI) measured by fluorescence 
flow cytometry. Error bars represent the SEM, (N=3,*P<0.05).   
4.4.4 Analysis of the structure of 35S labelled HS 
Heparan sulphate from mock and SULF2 transfected renal epithelial cells were 
analysed to examine structural changes following SULF2 transfection.  Mock and 
SULF2 transfectants were incubated with 
35
S as a source of sulphate for 24 hours.  
The cells were lysed and heparan sulphate was separated by ion-exchange as stated 
in (3.2.4).  Samples were alkali treated and recovered GAGs were filtered by gel 
filtration.  GAGs were treated with nitrous acid and reduced to deaminated 
products.  Deaminated products were fractionated to disaccharides and further 
separated by anion-exchange HPLC.  
SULF2 transfectants show that sulphatase removes 6-O sulphate groups from not 
only highly sulphated IdoA2S-GlcNS6S (ISMS) but also from mono sulphated 
disaccharides of GlcA-GlcNS6S (GMS) and IdoA-GlcNS6S (IMS).  In contrast, 
SULF2 transfectants show remarkable increase (more than double) in IdoA2S-
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GlcNS (ISM) concentration compared to mock transfectants (P<0.001), (Figure 
4.20). 
 
Figure 4.20. HS disaccharides analysis of SULF2 transfectants.  Mock and SULF2 
transfectants were incubated with 
35
S 200µCi/ml for 24 hours. Cells were lysed and 
GAGs were isolated using DEAE Sephacel columns. Samples were treated with 
nitrous acid and deaminated products were fractionated by gel chromatography on 
Sephadex G-15.  GAGs were separated using anion-exchange HPLC followed by 
running and eluting on Partisil 10 SAX columns. (N=2, **: P<0.01,*: P<0.05) 
Sulphation changes following SULF2 transfection show that HS undergoes 
downregulation of sulphation at the N-position by about 10% compared to mock 
transfectants.  Sulphate groups at the 6-O position were also downregulated by 
about 25% in SULF2 transfectants compared to mock transfectants (P<0.01).  
However, sulphation at the 2-O position was upregulated by two-fold in SULF2 
transfectants compared to mock transfectants (Figure 4.21).  
Data analysis shows that 6-O containing disaccharides were decreased by about 
50% in SULF2 transfectants compared to mock transfectants. 2-O containing 
disaccharides were upregulated by 25% compared to mock transfectants (Figure 
4.21). 
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Figure 4.21. Sulphate group changes in SULF2 transfectants. Samples were 
isolated from 
35
S labelled HS chains from solubilized cells from mock and SULF2 
transfectants.  GAGs were depolymerized by low pH nitrous acid treatment 
followed by reduction with NaBH4.  Fractions were separated on Partisil 10-SAX 
column alongside with standard control.  (N=2, *P<0.05). 
4.4.5 Proliferation of the SULF-2 transfectants 
As stated in 3.3.11, sulphate groups at the 6-O position of HS have been implicated 
in regulation of the MAP kinase pathway that affects the proliferation of epithelial 
cells.  In this study, renal epithelial cells overexpressing SULF2 and mock 
transfectants were examined for proliferation by using a non-radioactive 
colorimetric proliferation assay.  As shown in figure 4.22, cells with SULF2 
overexpression have lower proliferation after 72 and 96 hours compared to mock 
transfectants.  Despite being small, this difference was found statistically 
significant (P<0.01).  Incubation of these cells with FGF2 enhanced the 
proliferation of both SULF2 and mock transfectants (Figure 4.22). In all cases, an 
equal number of cells was seeded into the assay wells at time 0. 
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Figure 4.22. Representative proliferation assay for SULF2 transfectants. Mock-
HKC8 and SULF2 transfectants were seeded in 96 well plates in triplicates with 
0.05%FCS and incubated for 24, 48, 72 and 96 hours.  The same mock-HKC8 and 
SULF2 transfectants were incubated with FGF2 at 10ng/ml.  Experiments were 
carried out by removing the medium and adding fresh medium with tetrazolium 
compound (MTS/PMS) and the plate was read at 490nm after 4 hours of incubation 
at 37
o
C. (N=3, P<0.001).   
4.4.6   SULF2 transfectants and ERK activation  
Sulphate groups at the 6-O position of HS have been implicated in FGF2-mediated 
activation of the ERK signaling pathway.  FGF2 increases phosphorylation of ERK 
into pERK.  In the previous chapter (3.3.11) it was shown that HS6ST1 
transfectants increase the phosphorylation of ERK1,2.  To further examine the role 
of 6-O sulphation on the ERK pathway, a series of experiments was carried out by 
Western blotting using a specific pERK antibody.  Cells were exposed to 
recombinant FGF2 as a stimulator of pERK activation for several time points.  As 
shown in figure 4.23, SULF2 transfectants demonstrate significantly (P<0.05) 
reduced pERK activation by about 30% compared to mock transfectants.  Addition 
of FGF2 for 3,5 and 10 minutes increases the pERK activation in both SULF2 and 
mock transfectants but there was a difference of approximately 30% between mock 
and SULF2 transfectants.  For equal loading, α-tubulin was used as a house-
keeping protein. 
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Figure 4.23. Western blotting of pERK1,2 for SULF2 transfectants in presence of 
FGF2.  Mock and SULF2 transfectants (S-11) were seeded in 6 well plates in 
0.05% FCS-DMEM-F12.  Cells were then incubated with FGF2 at 10ng/ml for 3, 5 
and 10 minutes.  Medium was removed and lysis buffer was added.  Lysates were 
run on 10% SDS-PAGE and transferred to PVDF membrane.  Protein bands were 
probed by anti pERK1, 2 at 1:1000 overnight at 4
o
C followed by HRP-secondary 
antibody.  The same membrane was blotted for anti-tubulin-α.  Bands were 
visualized by ECL substrate.  Densitometry analyses were performed using Image-J 
software. (N=2, p<0.05). 
  
 
 
 
 
 
141 
 
HS degradation 
  
4.5 Discussion 
Heparan sulphate undergoes a process of degradation and desulphation due to the 
effect of heparanase and sulphatase enzymes.  This process allows the HS to 
change its biological activities in accordance with novel roles to be played.  The HS 
sulphatase activity is influenced by proinflammatory cytokines during 
inflammation and chronic diseases.  Stimulation of specific cell lines with different 
cytokines mimics the environment of inflammation.  Building on stimulation 
results, stable transfectants of endosulphatase gene were generated in order to 
examine definite biological activities.  These transfectants provide a good model to 
examine the effect of endosulphatase on HS structure and the potential for 
interaction between HS and growth factors. 
4.5.1 Observation of gene expression following cytokine stimulation   
4.5.1.1 Heparanase (HPSE) 
Endothelial and epithelial cells were stimulated by several cytokines which are 
upregulated during inflammation.  The stimulated cells were analyzed using qPCR 
for the expression of specific genes encoding heparanase and sulphate enzymes.  
These genes were investigated on mRNA level using specific probes and qPCR.  
This study shows that the heparanase expression is significantly downregulated 
following stimulation by TGF-β and to a lesser extent by PMA.  This result 
contradicts with a former finding which shows that HPSE expression is upregulated 
in fibrotic liver disease (6-fold) (Tatrai et al., 2010).  The current result also 
contradicts with previous research which showed that cytokines such as TNF-α or 
IL-1β could increase HPSE secretion by endothelial cells (Chen et al., 2004).  
HPSE has been shown to play significant role in FGF2-induced EMT in association 
with syndecan accumulation and cleavage, thus the downregulation of the gene 
observed after stimulation by TGF-β might suggest an autocrine feedback 
mechanism of HPSE in the regulation of EMT (Masola et al., 2012).  However, 
further investigation including measurement of syndecan1 expression will be 
required for a better understanding of the consequences of HPSE regulation.  
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4.5.1.2 SULF1 and SULF2 
Epithelial and endothelial cells were stimulated by several cytokines in order to 
examine changes in sulphatase gene expression.  For the SULF1 gene, different 
levels of expression were found in endothelial and epithelial cells following 
cytokine stimulation.  The current study shows that SULF1 expression in epithelial 
cells was significantly downregulated following stimulation by IFN-γ or PMA 
whereas, in endothelial cells, it was significantly increased following the TGF-β 
stimulation (2.5 fold), (Figures 4.6, 4.7).  This result is consistent with previously 
reported results showing that stimulation of fibroblasts with TGF-β increased 
SULF1 expression in vitro and in vivo but with no significant changes in SULF2 
expression (Yue et al., 2008).  Accordingly, SULF1 expression was increased in 
chronic liver cirrhosis (6 fold) (Tatrai et al., 2010).   
Changes in HS sulphation are associated with the level of sulphotransferase and 
sulphatase enzymes (Tatrai et al., 2010).  HS sulphation undergoes various 
modulations following stimulation with pro-inflammatory cytokines.  This study 
shows that SULF2 expression was dramatically increased (5 fold) following 
stimulation of renal epithelial cells with TGF-β. This increase is expected to affect 
the role of HS in chronic inflammation and fibrotic disease.  Modulation of HS 
sulphation has been reported in inflammation and following cytokine stimulation. 
For example, stimulation of glomerular endothelial cells with TNF-α or IL-1β has 
produced changes in N- and 6-O sulphation (Rops et al., 2008).  Furthermore, 
stimulation of brain glia with TGF-β/TNF-α has resulted in upregulation of 2S 
sulphation and HS syndecan-1 synthesis (Properzi et al., 2008).  An increase in 
SULF2 gene expression was also reported in carcinoma cells in human breast 
cancer (Morimoto-Tomita et al., 2005).   
In order to further investigate the role of SULF2, stable transfectants of SULF2 in 
renal epithelial cells were generated.  These transfectants were grown under 
antibiotic selection alongside mock transfectants.  Fifteen clones were selected and 
two clones with the highest levels of SULF2 expression (S11 and S5) were used for 
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further investigations.  These clones were examined first for SULF2 expression on 
mRNA level by qPCR. 
4.5.2 Observation of changes in HS epitope expression 
Changes in the structure of HS produced by SULF2 overexpression were 
investigated by examining the interaction between SULF2 transfectants and the 
10E4 monoclonal antibody by immunofluorescence and flow cytometry.  This 
study shows that SULF2 transfectants had increased expression of the 10E4 epitope 
by immunofluorescence microscopy but not by flow cytometry.  The HS-10E4 
epitope includes a tetrasaccharide domain of N-sulphated and N-acetylated 
glucosamine (GlcA-GlcNS-GlcA-GlcNAc), (David et al., 1992; Leteux et al., 
2001).  The binding to 10E4 antibody is therefore influenced by N-sulphation, as 
this constitutes an essential component of the HS-10E4 epitope.  The increased 
expression of 10E4 epitope shown by immunofluorescence might be distributed 
between changes in extracellular HS compared to cell surface which is mostly 
affected following cell dissociation in the flow cytometry procedure.   It has been 
shown that a reduction in N-sulphation is accompanied by a reduction in 10E4 
antibody binding (Pankonin et al., 2005) and an increase in N-sulphation 
accompanied by increased 10E4 antibody binding (unpublished data by Dr. 
Spielhofer 2010), (van den Born et al., 2005).  However, a previously published 
work showed that SULF1 overexpression decreased the 10E4 epitopes in 3T3 cells 
(Ai et al., 2003b).   
The changes in HS sulphation following the SULF2 overexpression were further 
examined using phage display anti-HS antibodies.  These antibodies are widely 
used due to their interaction with specific sulphated saccharide domains in the HS 
structure.  The current study showed that SULF2 transfection significantly reduced 
HS3A8 antibody binding.  This antibody targets an HS epitope containing 
trisulphated disaccharides (IdoA2S-GlcNS6S), (Dennissen et al., 2002).  The 
reduction in antibody binding might be attributed to downregulation of the 6-S 
component in the binding epitope.  For example, TGF-β induced overexpression of 
SULF1caused different changes in HS sulphation, including a reduction in the 6-O 
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sulphate and increase in the N-S and 2-S groups in the human lung fibroblasts (Yue 
et al., 2008).  
To investigate the changes in HS in more detail, the interaction between SULF2 
transfectant cells and the HS4C3 antibody was examined.  This antibody targets 
trisulphated disaccharides with Iduronic acid and Glucuronic acid, i.e. GlcNS6S-
GlcA-GlcNS3S6S-IdoA2S-GlcNS3S6S (van Kuppevelt et al., 1998).  In the 
previous chapter, it was shown that cells overexpressing HS6ST1 significantly 
upregulated the HS4C3 binding epitope.  Therefore it is of great importance to 
determine whether 6-O desulphation has the opposite effect.  SULF2 transfectants 
showed a small but significant decrease in HS4C3 binding ability.  It has been 
previously reported that the binding of HS4C3 is correlated with FGF2 binding 
(Lensen et al., 2005).  Thus, the downregulation of HS4C3 binding observed with 
SULF2 transfectants in the current study suggests that reduction of 6-O sulphation 
might inhibit the binding to FGF2.   
Additionally, SULF2 transfectants showed increased expression of epitopes which 
interact with 10E4, whereas HS3A8 and HS4C3 epitopes were reduced.  This result 
is consistent with previously published literature showing that increased 10E4 
binding was accompanied by reduced binding to HS3A8 and HS4C3 in glomerular 
endothelial cells following stimulation by TNF-α (Rops et al., 2008).  The current 
study also showed that SULF2 transfection was associated with a marked reduction 
in expression of the RB4EA12 epitope.  This reduction is mainly attributed to the 
6-O content of the RB4EA12 binding epitope, which also contains NS or NAc 
residues (GlcNS6S/GlcNAc6S) (Dennissen et al., 2002; Lensen et al., 2005).   
4.5.3 Physiological changes after SULF2 transfection 
4.5.3.1 FGF2 binding 
Having generated stable SULF2 transfectants, the physiological role of HS was 
examined by investigating the binding of FGF2.  SULF2 transfected cells showed a 
significant reduction in their potential to bind FGF2 compared to mock 
transfectants.  Earlier results have shown that although 6-O sulphate is not essential 
for FGF2 binding, this group is crucial for FGF2-mediated receptor signalling and 
mitogenic activity (Guimond et al., 1993; Dai et al., 2005).  The current study 
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showed that SULF2 overexpression downregulated FGF2-mediated signalling via 
the ERK pathway as well as reducing cell proliferation.  This result is consistent 
with many previous studies which show a decrease in ERK activation following 
sulphatase overexpression (Dai et al., 2005; Kamimura et al., 2006).  Several 
researchers have found that SULF1 (but not SULF2) has the ability to reduce the 
intracellular signalling of many growth factors, including FGF2 (Lai et al., 2003; 
Lai et al., 2004a; Lai et al., 2004b; Wang et al., 2004).  However, it has been 
reported that SULF2 transfectants can show increased FGF2 binding and signalling 
in human hepatocellular carcinoma cells (Lai et al., 2008a). 
4.5.3.2 CCL5 presentation 
The current study shows that CCL5 presentation was downregulated following 
SULF2 overexpression.  Unpublished work from this group showed that 
overexpression of NDST1 increased both CCL5 presentation and binding of the 
10E4 antibody (Dr. Spielhofer 2010, PhD thesis).  The specific site on HS that 
binds CCL5 is poorly defined (Vives et al., 2002).  However, N- and O-sulphate 
groups seem to be involved in the binding motif (Shaw et al., 2004; Yamaguchi et 
al., 2006).  This suggests that changes in sulphation following SULF2 
overexpression will have a negative effect on CCL5 presentation.  An earlier study 
from this group showed that the presentation of CCL5 by endothelial cells is 
increased by increased N-sulphation of HS (Carter et al., 2003).   
4.5.4 Examination of HS structure  
Overexpression of the 6-O endosulphatase, SULF2 has biological effects on the 
interaction between HS and FGF2 and CCL5, as well as antibody binding to HS.  
This suggests that these changes in biological activity are accompanied with 
changes in HS structure.  To address this issue HS structure was examined by 
compositional analysis of disaccharides following deaminative cleavage (aManR) 
of 
35
S labelled HS.  This work was performed in collaboration with Professor 
Marion Kusche-Gullberg (Norway). 
This study shows that SULF2 overexpression produced significant changes in HS 
structure, including disaccharide concentration, domain distribution and sulphation 
pattern.  The disaccharide analysis showed a noticeable downregulation of residues 
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such as GlcA-GlcANS6S (GMS) and IdoA-GlcANS6S (IMS) and the trisulphated 
disaccharide Ido2S-GlcNS6S (ISMS).  By contrast, SULF2 overexpression 
increased the concentration of IdoA2S-GlcNS (ISM).  It is expected that the SULF 
enzymes target predominantly the HS-trisulphated disaccharide as a favorite 
substrate (Ai et al., 2006b).  Accordingly, the upregulation of ISM (predominant in 
the NA/NS domain) is consistent with a previously report of overexpression of 
SULF2 (in 293T cells) in vitro (Ai et al., 2006b).  This result is in agreement with 
previously reported changes in the distribution of HS domains following 6-O 
desulphation, which include greater expression of NA/NS domains than NS 
domains (Lamanna et al., 2007).  The resultant HS domain distribution might 
explain the changes in HS epitopes and physiological roles observed by interaction 
with phage display antibodies and FGF2 or CCL5 respectively.   
In the current study, the mode of HS sulphation following SULF2 overexpression 
showed a significant reduction in 6-O and N-sulphates but an increase in 2-O 
sulphate groups. Similarly, an increase in 2-O sulphation was reported in a previous 
study with SULF overexpression (Ai et al., 2006b).  However, this was not the case 
in SULF1 overexpression in Drosophila where no changes in 2-O sulphation were 
observed after 6-O desulphation (Kamimura et al., 2006).  Interestingly, SULF1 
and SULF2 knockout mice have shown that these enzymes can modulate the 
expression of sulphate groups at the N- and 2-O positions in cell surface and 
extracellular HS (Lamanna et al., 2008).  These non-substrate changes might 
explain a potential compensatory effect following SULF2 over-expression.  
However, following TGF-β induced overexpression of SULF1, no changes were 
found in the N- and 2-O sulphation alongside the 6-O desulphation (Yue et al., 
2008).  The level of overexpression might be responsible for this variance; in our 
study the increase in SULF2 gene expression following transfection is about 250-
fold.  
Although the total decrease in 6-O sulphate concentration was not remarkable, it 
was accompanied with significant changes in FGF2 and CCL5 binding activities.  
This can be justified by accompanying changes with additional sulphate positions 
including N- and 2-O positions. Furthermore, SULF2 overexpression was 
accompanied with low concentration of GlcA-Glc6S and IdoA-Glc6S which might 
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explain the reduced binding to FGF2 and CCL5.  This result is in agreement with 
previously shown changes in FGF2 biological activity following modulations of 
HS sulphation (Huynh et al., 2012). 
Taken together, these findings show that the SULF2 enzyme has an important role 
in regulation of the sulphation of HS which is accompanied by changes in 
physiological function by modification of the interaction with FGF2 and CCL5.  
The SULF2 transfectants also showed reduced proliferation and ERK activation 
compared to mock transfectants.  Analysis of the structure of HS isolated from 
SULF2 overexpressing cells showed decreased expression of substrate 
disaccharides such as GlcA-GlcANS6S (GMS), IdoA-GlcANS6S (IMS) and 
Ido2S-GlcNS6S (ISMS) along with increased IdoA2S-GlcNS (ISM).   
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Chapter Five 
5 HS Changes in UUO Mouse Model 
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5.1 Introduction 
Chronic rejection has been the major cause for loss of transplanted organs.  
Heparan sulphate has a wide range of interaction abilities with proteins, including 
cytokines and growth factors which are involved in the etiology of chronic fibrosis.  
Earlier unpublished work in our group has shown that heparan sulphate is 
upregulated in chronic rejection as well as in acute rejection compared to normal 
kidney.  Phage display antibodies were used in the two previous chapters in order 
to show modulation of HS sulphation after HS6ST1 or SULF2 overexpression.  In 
this chapter we followed up with an in vivo model of renal fibrosis to shed more 
light on changes in heparan sulphate sulphation.  This was performed by generating 
mice with a unilateral ureteral obstruction (UUO) of kidney.  Expression of 
specific HS epitopes in the UUO kidney will provide a better understanding of the 
modulations of HS structure during fibrosis.  
5.1.1 UUO kidney and chronic rejection 
The UUO kidney constitutes an in vivo model of experimental renal injury that 
leads to renal disease and fibrosis.  Mouse UUO constitutes an important model for 
examining renal fibrosis as well as experimental therapy (Chen et al., 2007).  
A series of events takes place 24 hours after UUO including reduced renal blood 
flow and glomerular filtration rate.  These changes are generally followed by 
hydronephrosis, interstitial inflammatory infiltration and tubular cell death 
(Vaughan et al., 2004).  Further changes include increased interstitial 
myofibroblasts (Hewitson et al., 2001), tubular atrophy (TA), (Gobe and Axelsen, 
1987), expansion of renal interstitium, increased ECM proteins and interstitial 
fibrosis (IF), (Eddy, 1996; Klahr and Morrissey, 2002).  Additional structural 
changes are expected to take place such as tubular dilation (Sunami et al., 2004).  
The UUO kidney in rabbits shows interstitial deposition of collagen I, III and IV, 
fibronectin and, interestingly, increased expression of HSPG (Sharma et al., 1993). 
Several mechanisms are involved in the etiology and development of IF in the 
UUO kidney.  Macrophage infiltration leads to proliferation and activation of 
fibroblasts in addition to production of cytokines leading to tubular cell death 
(apoptosis), (Misseri et al., 2005).  The second mechanism includes tubular cell 
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death by apoptosis and necrosis which may lead to TA.  This can be induced by 
factors including ischemia, hypoxia, oxidative stress and tubular dilation 
(Chevalier et al., 2009).  For example, oxidative radicals have a toxic effect on 
tubular epithelial cells which may cause apoptosis (Schaaf et al., 2002).  
Furthermore, oxidative radicals were shown to stimulate the expression of TGF-β1 
and the production of ECM proteins during IF (Yuan et al., 2003).  The third 
mechanism is the production of IF following activation of the EMT process.  Renal 
epithelial cells become motile fibroblasts and migrate into the tubular interstitium 
where they produce extracellular components (Iwano et al., 2002).  
5.1.2 Fibrosis markers 
Renal fibrosis is characterized by several pathological changes, as stated above, as 
well as increased expression of significant markers.  One of the key markers is the 
expression of fibroblast specific protein FSP1 (S100-A4).  Another marker is 
increased expression of α-SMA, which constitutes a key marker of myofibroblasts 
in both human renal IF and UUO models (Essawy et al., 1997; Roberts et al., 
1997).  Furthermore, accumulation of ECM proteins including fibronectin and 
collagen (types I, III, IV and V) is considered a good indicator of the fibrogenesis 
process (Okada et al., 2000).  In some cases the loss of expression is considered an 
indicator of potential changes during fibrosis.  For example, the loss of E-cadherin 
was found in TGF-β induced EMT which indicated a novel phenotype of the 
transformed cells (Zeisberg et al., 2003).  It seems clear that murine UUO provides 
the best model available for analysis of changes in the sulphation of HS during the 
development of a renal pathology analogous to the tubular atrophy with IF that is 
seen during chronic renal allograft rejection. 
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5.2 Aims 
The experiments described in this chapter examine changes in HS sulphation 
following the induction of murine UUO.  The following topics will be addressed: 
 Induction of the murine UUO model.  
 Immunocytochemical study of post UUO renal fibrosis. 
 Immunocytochemical study of changes in the expression of sulphation-dependent 
epitopes in the mRNA expression levels of HS using specific antibodies. 
 Quantitative examination of changes in the expression of HS modifying enzyme 
(NDST1, SULF1, SULF2 and HS6ST1) in UUO kidney. 
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5.3 Specific materials and methods 
5.3.1 Mice maintenance  
All animal handling was performed in accordance with the guidelines of the ethical 
committee of Newcastle University and Home Office Project License.  Wild type 
C57BL/6N male inbred mice (C57BL/6N, Supplier CRUK) were housed for one 
week prior to use (age 8-10 weeks).  Mice received water and standard mouse 
chow.  These mice were subjected to an abdominal incision where the left ureter 
was completely double ligated under general anesthesia with isoflurane and oxygen 
(Figure 5.1).  These animals were killed after 7 and 14 days of obstruction and both 
kidneys were removed.  Surgery was performed thankfully by Christopher Fox.  
The obstructed kidney was referred to as UUO kidney whereas contralateral right 
kidney was referred as the wild-type kidney.  For RNA isolation, one fifth of the 
kidney was excised and immersed immediately in liquid nitrogen and stored later at 
-80
o
C.   
 
Figure 5.1. Unilateral ureteral obstruction mice kidney.  The left ureter was double 
ligated and cut to generate UUO kidney.  Mice were killed after 7 or 14 days and 
both the kidneys were removed.  
For paraffin embedded sections, kidney was sectioned and immersed in Formalin 
Solution 10% Neutral Buffer (Sigma-Aldrich) for 24 hours before transfer to 70% 
ethanol.  Sections were then dehydrated, embedded in paraffin blocks and stored at 
room temperature.  For frozen sections, kidney sections were immersed 
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immediately in cold isopentane for few minutes, then in liquid nitrogen and later 
stored at -80
o
C.   
5.3.2 RNA extraction from mouse kidney 
Tissues taken from wild type and UUO kidney were stored in -80
o
C for RNA 
isolation.  For more productivity and purity, the SV total RNA isolation system 
(Promega) was used.  This system incorporates a DNase treatment step that reduces 
genomic DNA contamination.  This is necessary when using non exon-boundary 
spanning qPCR primer probes.  A ribonuclease free environment was created by 
cleaning all equipment, racks and surfaces with RNase-Zap (Sigma-Aldrich), 
diethylpyrocarbonate (DEPC) treated water and alcohol.  Tubes were autoclaved in 
advance and filter tips were used.  β-mercaptoethanol (BME) was added to the lysis 
buffer (Promega) as recommended in the manufacturer instructions.  
Kidney tissues were weighed under cold condition and the protocol for weights less 
that 30mg was followed.  This protocol is used for processing small tissue samples.  
Tissue was mixed with BME-added lysis buffer (175µl) in a clean glass mortar 
(pre-incubated on ice) and processed with a pestle till completely homogenized.  
Lysates were transferred to a clean tube, mixed with dilution buffer and incubated 
on a heat block at 70
o
C for 3 minutes.  The tubes were then centrifuged at 13000g 
for 10 minutes and supernatants were taken out, mixed with 95% ethanol and 
transferred to a spin column assembly.  The spin columns were centrifuged at 
13000g for one minute, ethanol-added RNA Wash Solution was added and the 
tubes were centrifuged for further 1 minute.  Each tube was then incubated with 
fresh DNase incubation mix (40
 µl Yellow Core Buffer, 40 µl 0.09M MnCl2 and 5 
µl of DNase enzyme) for 15 minutes at room temperature.  The reaction was 
stopped by adding 200 µl of DNase Stop Solution.  Tubes were then washed with 
RNA Wash Solution and the RNA was eluted by adding 100 µl of nuclease free 
water.  Tubes were centrifuged and the RNA was quantitated, electrophoresed at 
0.7% agarose gel and stored at -80
 o
C (Figure 5.2).   
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Figure 5.2. Representative gel photograph showing RNA extracted from frozen 
UUO kidney.  Three samples from three animal UUO kidneys were extracted and 
separated on 0.7% agarose gel. 
5.3.3 Frozen sections 
Frozen sections from wild type and UUO kidneys were cut into 5 µm thick-cross 
sections using cryostat at -20
o
C.  Frozen sections were stored at -20
o
C until needed.  
These sections were fixed with cold acetone at -20
o
C for 10 minutes and left for 
air-dry at room temperature.  Sections were then blocked with 2% BSA-PBS for 
one hour and incubated with phage display antibody at 1:10 overnight at 4
o
C 
(generous gift from Prof. van Kuppevelt).  Slides were then washed with TBS and 
incubated with anti-VSV Cy3-conjugated antibody (Sigma-Aldrich).  Nuclei were 
visualized by adding 4-6 diamine-2 phenylindol (DAPI) at 2 µg/ml final 
concentration (Sigma-Aldrich) and the slides were mounted in fluorescence 
mounting media (DAKO).  Slides were investigated using immunofluorescence 
microscopy.  Slides were prepared from five different animals with a UUO kidney.  
For each animal, at least three slides were stained and each slide was investigated 
by quantifying five equal squares (2.5uM)
2
 from tubular and interstitial spaces.  
Mean fluorescence intensity was expressed and compared between UUO kidney 
and normal kidney sections.  Slides were quantified using Image-J software. 
5.3.4 Primer probes 
Primer probes from TaqMan gene expression assay (Applied Biosystem) with 
FAM dye and TAMRA quencher were used for RNA analysis.  All probes except 
for HS6ST1 were exon boundary spanning preventing detection of genomic DNA.  
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The primer for HS6ST1 was not exon boundary spanning and could detect genomic 
DNA.  RNA samples were treated with DNase to increase specificity by removing 
any possible DNA contamination which might be detected by primer probes-s1.  
Pre-designed primer probes were purchased from Applied Biosystem: 
HPRT1 (Mm00446968-m1); m1 indicates that the probe spans an exon junction 
and it does not detect genomic DNA. 
HS6ST1 (Mm 01229698-s1); s1 indicates that the probe is derived from a genomic 
DNA sequence. 
SULF1 (Mm 00552283-m1) 
SULF2 (Mm 1248026-m1) 
NDST1 (Mm 00447005-m1) 
5.3.5 RT-PCR validity test 
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) was used as a house keeping 
gene in mice qPCR experiments.  Validity test was performed for investigating the 
qPCR condition and amplification efficiency.  Primers for HPRT1, SULF1, SULF2 
and HS6ST1 were investigated.  Validity values were calculated as stated before 
(4.3.3.1) and efficiency values were 106, 103 and 104.4% respectively (Figure 5.3). 
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Figure 5.3. Efficiency of qPCR reaction for murine HPRT1,SULF1and SULF2 
genes.  Real time PCR experiment included cDNA template in serial dilutions in 
triplicates.  Values at X axis represent the logarithm of the RNA concentration (ng).  
cDNA was synthesized in 5 µg RNA.  A, Represents efficiency for house-keeping 
gene HPRT1.  B, represents efficiency for SULF1 gene whereas C represents 
efficiency for SULF2 amplification. (N=2)  
5.3.6 Haematoxylin and Eosin staining (H&E) 
Frozen sections were fixed with acetone at -20
o
C for 10 minutes and left to air-dry 
at room temperature.  Sections were then immersed in haematoxylin for 3 minutes 
at room temperature, followed by washing with tap water.  Slides were dipped in 
Scott’s water for 30 seconds and washed with tap water.  In the next step, slides 
were immersed in eosin for one minute and washed with tap water.  Slides were 
then dehydrated in gradients of alcohol (50%, 75%, 95% and 100%), cleared with 
xylene, mounted with DPX and left to dry.   
5.3.7 Immunohistochemistry  
Frozen sections were stained for collagen-1 (Rabbit anti-mouse, Millipore) by 
immunohistochemistry.  Sections were fixed with acetone at -20
o
C for 10 minutes 
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and left for air-dry at room temperature before incubation with 0.3 % hydrogen 
peroxide in PBS-NaN3 for 10 minutes at room temperature.  Sections were then 
washed in TBS and blocked by Avidin for 15 minutes followed by Biotin for 15 
minutes (Vector Blocking Kit).  The slides were washed by TBS and blocked with 
20% normal swine serum (NSS) for one hour at room temperature. The primary 
antibody (Millipore) in NSS at 1:150 was added and the sections incubated 
overnight at 4
o
C.  After washing 3 times in TBS, biotinylated secondary antibody 
(Goat anti rabbit) in NSS at 1:200 was added and incubated at room temperature 
for one hour. The slides were then washed in TBS and incubated in ABC (Avidin 
Biotinylated HRP Complex) for 30 minutes (ABC Vector prepared 30 minutes in 
advance).  During incubation, 2.5 ml of 3, 3-diaminobenzidine (DAB) solution was 
prepared, mixed with 2 µl H2O2 and left in the dark.  Slides were covered with 
DAB solution for at least 2 minutes until they turned brown and washed with tap 
water. Slides were then counterstained with Mayer’s haematoxylin for 5 minutes 
and “blued” for few seconds in Scott’s water.  In the final step slides were 
dehydrated in gradients of alcohol (50%, 75%, 95% and 100%), cleared with 
xylene, mounted with DPX  and left to dry.  Images were taken with Leica LCM 
microscope and data were analyzed with Image-J software.  
5.3.8 Mouse on mouse (M.O.M) staining 
A mouse on mouse (M.O.M) kit (Vector) was used when staining murine tissues 
with murine antibodies as anti-mouse secondary antibodies do not distinguish 
between the mouse primary antibody and the endogenous mouse immunoglobulin 
(Ig).  This results in a high background staining which affects the specific binding.  
This problem was solved by using Avidin-Biotin blocking agents in the M.O.M 
protocol.  In brief, frozen sections were fixed with cold acetone at -20
o
C for 10 
minutes and left to air-dry at room temperature.  Slides were blocked in excess 
Avidin for 15 minutes followed by Biotin for a further 15 minutes at room 
temperature.  The slides were incubated for one hour in mouse immunoglobulin 
blocking reagent at room temperature.  The slides were then washed with TBS and 
incubated in primary antibody in M.O.M diluent (Protein concentrate in TBS) 
overnight at 4
o
C.  After washing, the slides were incubated with biotinylated 
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secondary anti-mouse IgG reagent for 10 minutes at room temperature.  Then the 
sections were washed and fluorescein Avidin DCS was applied for 5 minutes 
followed by TBS washing.  Finally the slides were incubated with DAPI and 
mounted with Vectashield mounting medium (Dako). 
5.3.8.1 Data analysis  
Data were statistically analyzed by using Student’s unpaired T-test for data with a 
normal distribution.  ANOVA for comparing three or more independent groups 
with Tukeys and Bonferroni post tests was also used.  Software including Windows 
Excel, Prism 4, Image-J and REST2008 were used. P values < 0.05 were 
considered significant. 
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5.4 Results 
5.4.1  Haematoxylin and eosin staining (H&E) 
Haematoxylin stains basophilic structures a deep purple or blue colour.  Eosin is an 
acidic stain of a red colour which stains acidophilic structures in the cytoplasm a 
red or pink colour.  Frozen sections were stained by H&E to show the pathological 
changes after UUO.  Dilation of the tubule’s lumen with increase in ECM spaces 
was noticed in UUO sections compared to intact kidney sections (Figure 5.4). 
5.4.2 Fibrosis markers  
Fibrosis is a major consequence of UUO kidney.  Several fibrosis markers are 
upregulated following UUO, including fibronectin, collagens, α-SMA and 
increased depositions of ECM proteins (Sunami et al., 2004).  In order to verify the 
fibrosis in kidney after 7 days of UUO incidence, the frozen sections were stained 
with antibodies against collagen-1 and α-SMA.  
5.4.2.1 Staining collagen-1  
Chronic fibrosis is usually accompanied by pathological changes including 
epithelial cell proliferation, EMT and deposition of collagen in extracellular spaces 
(Misseri et al., 2004). Collagen I deposition in the interstitial space is considered a 
diagnostic marker for tissue fibrosis.  Collagen I was observed in the basement 
membrane and interstitial spaces. 
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Figure 5.4.  Staining of mice kidney sections with haematoxylin and eosin (H&E). 
Frozen sections from wild type and UUO kidney were fixed with cold acetone and 
stained with haematoxylin followed by eosin. Sections were then immersed in a 
gradient of alcohol and xylene.  The scale bar represents 100 µM.   
Frozen sections were stained with anti-collagen-1 antibody using the 
immunohistochemistry procedure.  Sections show that collagen-1 is upregulated in 
UUO kidney compared to intact wild type kidney.  Data were analyzed by 
quantitation of stained sections at the tubular and interstitial spaces.  These 
analyses show that collagen-1 was significantly upregulated in interstitial spaces in 
UUO kidney compared to wild type (P<0.001), (Figure 5.5, 5.6). 
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Figure 5.5. Staining of mice kidney sections with Collagen-1.  Sections from 
normal and UUO kidneys were blocked with Avidin-Biotin and incubated with 
Collagen-1 (1:150) overnight at 4
o
C followed by incubation with biotinylated 
secondary antibody.  Sections were incubated with Vector ABC and developed 
with DAB-H2O2.  Brown color represents collagen-I activity.  Scale bar represents 
200 µM.   
  
Figure 5.6. Quantitative analyses of tubular collagen-1 staining of UUO mice 
kidney.  Results represent data from three UUO mice and three normal kidneys.  At 
least three sections from each kidney were screened (n=15).  Frozen sections were 
stained with collagen-1 by immunohistochemistry.  Random areas (five for each 
section) from tubules were quantified and analyzed by Image-J software. (N=3, 
***P<0.001). 
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5.4.2.2 Staining with α-SMA 
Upregulation of α-smooth muscle actin depositions constitutes an additional 
diagnostic marker of myofibroblasts.  In normal kidney, a very limited number of 
cells with α-SMA is found in the vascular walls.  Increasing numbers of α-SMA 
expressing cells are accompanied by renal disease.  Frozen sections were stained 
with α-SMA antibody in order to confirm the process of fibrosis in these UUO 
models.  Sections were stained with α-SMA antibody using the 
immunofluorescence technique and investigated by fluorescence microscopy.  
Results show that UUO kidney has a greater number of cells expressing α-SMA 
compared to normal kidney.  This increase was mainly localized around vascular 
structures (P<0.001), (Figure 5.7, 5.8).  
 
Figure 5.7. Representative image of UUO kidney staining with anti α-SMA 
antibody. Frozen sections from wild type and UUO kidney were fixed with cold 
acetone, blocked with PBS-BSA 2% and incubated with anti α-SMA antibody at 
4
o
C overnight.  Slides were washed with TBS and stained with FITC-conjugated 
secondary antibody.  Scale bars represent 100 µM. 
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Figure 5.8. Quantitative analysis of mean fluorescence intensity of UUO staining 
with.  Data were taken from three animal kidneys with UUO and compared to three 
normal kidneys.  Sections were taken from three different animals and five sections 
were screened from each one (n=15).  Mean fluorescence intensity was measured 
using Image-J software.  (N=3, ***=P<0.001). 
5.4.3 Staining with 10E4 antibody 
10E4 antibody targets heparan sulphate epitopes in Bowman’s capsule and tubules 
basement membrane (van Kuppevelt et al., 1998).  Frozen sections from UUO and 
wild type kidney were stained with 10E4 antibody using a mouse on mouse 
(M.O.M) protocol and investigated by fluorescence microscopy.  10E4 antibody 
was bound mainly within the tubular basement membrane with increased 
deposition in UUO sections compared to normal sections.  Data analysis using 
tubular mean fluorescence intensity, show that binding of 10E4 antibody is 
significantly upregulated (P<0.001) in UUO sections compared to wild type 
(Figure 5.9, 5.10).  
5.4.4 Staining with phage display antibodies 
Phage display antibodies have been widely used for investigation of changes in HS 
structure.  These antibodies show selectivity against kidney structures including 
glomerular basement membrane (GMB), tubules and the interstitium.  Three phage 
display antibodies were used in this study (generous gift from Dr. Van Kuppevelt).  
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Sections were further examined by fluorescence microscopy.  These antibodies 
were optimised recently in the group by (Dr. Julia Spielhofer). 
 
Figure 5.9. Representative staining of mice kidney with 10E4 antibody.  Frozen 
sections from wild type and UUO kidneys were stained with 10E4 antibody by 
using mouse on mouse (M.O.M) protocol.  Sections were fixed by cold acetone and 
blocked by Avidin-Biotin.  Then slides were incubated with mice IgG blocking 
antibody followed by incubation with 10E4 (1:100) overnight at 4oC.  Biotinylated 
secondary anti-mouse antibody was added and followed by fluorescein Avidin 
DCS.  Slides were visualized by Leica Fluorescein microscopy.  Scale bar 
represents 100 µM. 
 
Figure 5.10. Quantitative analyses of UUO sections staining with 10E4 antibody.  
Frozen sections from three normal and UUO kidneys were stained with 10E4.  
Sections from each kidney (5 areas, n=15) were analyzed by measuring the density 
of tubular and interstitial areas randomly by Image-J software.  (N=3, ***: 
P<0.001) 
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5.4.4.1 HS3A8 
HS3A8 antibody reacts with highly sulphated oligosaccharides including 6-O and 
N- sulphate groups (GlcNS6S) and sulphated iduronic acid (IdoA2S) (van de 
Westerlo et al., 2002).  A series of experiments was performed to stain frozen 
sections from UUO and wild type kidney with HS3A8 antibody for 
immunofluorescence analysis.  The UUO sections show that HS3A8 antibody was 
most predominant in tubular basement membrane and interstitial spaces (Figure 
5.11).  Data analysis included mean fluorescence intensity of tubular and interstitial 
structures and showed that the upregulation of HS3A8 deposition was significant 
(P<0.001), (Figure 5.12). 
 
Figure 5.11. Representative staining of murine kidney with phage display HS3A8 
antibody.  Frozen sections from wild type and UUO kidneys (from animals 4, 6 and 
8) were stained with HS3A8 antibody.  Sections were fixed by cold acetone and 
blocked by 2% BSA-PBS.  Slides were incubated with HS3A8 antibody at 1:20 
overnight at 4
o
C.  Slides were visualized by adding secondary Cy3-labelled anti 
VSV antibody (1:200).  Slides were examined with Leica fluorescence microscopy.  
Scale bar represents 100 µM.   
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Figure 5.12. Quantitative analyses of UUO section staining with phage display 
HS3A8 antibody. Three sections from each kidney were analyzed by measuring the 
density of tubular and interstitial areas (5 areas, n=45) randomly by Image-J 
software.  Three animals were investigated (N=3, ***: P<0.001). 
5.4.4.2   HS4C3 
Phage display antibody HS4C3 targets the IdoA2S-GlcNS3S6S domain on the HS 
structure.  In kidney, HS4C3 predominantly stains peritubular capillaries and GMB 
(van Kuppevelt et al., 1998).  Frozen sections stained with HS4C3 antibody show 
that glomerular staining was predominant in both wild type and UUO sections.  
Tubules and interstitium show increased staining in UUO sections compared to 
wild type (Figure 5.13).  These changes were shown to be statistically significant 
(P<0.001) by measuring mean fluorescence intensity of selective tubular and 
interstitial structures (Figure 5.14). 
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Figure 5.13. Representative staining of mice kidney with phage display HS4C3 
antibody. Frozen sections from wild type and UUO kidneys were stained with 
HS4C3 antibody.  Sections were fixed by cold acetone and blocked by 2% BSA-
PBS.  Then slides were incubated with HS4C3 antibody at 1:20 of 2% BSA-PBS 
overnight at 4
o
C.  Secondary Cy3-labelled anti VSV antibody was added. Slides 
were visualized with Leica fluorescence microscopy.  Scale bar represents 100 µM. 
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Figure 5.14. Quantitative analyses of UUO sections stained with HS4C3 antibody.  
Frozen sections from normal and UUO kidneys were stained with phage display 
HS4C3 antibody.  Sections from each kidney were analyzed by measuring the 
density of tubular and interstitial areas (n=30) randomly by Image-J software.  
(N=3, ***: P<0.001) 
5.4.4.3 RB4EA12 
The RB4EA12 antibody recognizes mainly IdoA-GlcNS6S on the HS structure, 
RB4EA12 most strongly stains cortical tubules in kidney structure (Dennissen et 
al., 2002).  Frozen sections stained with RB4EA12 show predominant staining in 
tubules and to a lesser extent the interstitium or glomerulus (Figure 5.15).  Tubular 
fluorescence intensity shows significant changes (P<0.01) between UUO and wild 
type sections (Figure 5.16). 
 
 
169 
 
HS changes in UUO mouse model 
 
Figure 5.15. Representative mice kidney sections stained with RB4EA12 phage 
display antibody.  Frozen sections from wild type and UUO kidneys (from animals 
2 and 6) were stained with RB4EA12 antibody.  Sections were fixed by cold 
acetone and blocked by 2% BSA-PBS.  Then slides were incubated with RB4EA12 
antibody at 1:20 of 2% BSA-PBS overnight at 4
o
C.  Secondary Cy3-labelled anti 
VSV antibody was added. Slides were visualized by Leica fluorescence 
microscopy.  Scale bar represents 100 µM.   
 
Figure 5.16. Quantitative analyses of UUO section staining with phage display 
RB4EA12 antibody. Sections from each kidney were analyzed by measuring the 
density of tubular and interstitial areas (n=30) randomly by Image-J software.  
(N=3, ***: P<0.001)   
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5.4.5 Gene expression of HS modifying enzymes   
5.4.5.1 Efficiency test for murine qPCR 
To shed more light on changes taking place in UUO kidneys on the mRNA level, a 
series of RT-PCR experiments were performed.  Using RNA from UUO and wild 
type kidney, cDNA were synthesized and used for RT-PCR.  These experiments 
were designed to examine the changes on HS gene expression such as mouse 
NDST1, HS6ST1, SULF1 and SULF2.  HPRT1 was used as a house keeping gene.  
Data analysis using CT numbers and ΔΔCT method show that UUO kidney had 
significantly (P<0.01) upregulated the SULF1 gene expression by about three fold 
compared to wild type kidney.  By contrast, expression of SULF2 gene was 
downregulated by about 40% in UUO kidney compared to wild type kidney 
(p<0.01).  Gene expression of NDST1 and HS6ST1 showed no significant changes 
(Figure 5.17). 
 
Figure 5.17. Quantitative RT-PCR analyses of gene expression in UUO kidney.  
cDNA was synthesized following DNase treated RNA from normal and UUO mice 
kidneys.  Expression of genes was investigated using TaqMan gene expression 
assay in reference to house-keeping HPRT1 gene.  Data were analyzed by using 
ΔΔCT method and REST2008 software.  (N=3, **: P<0.01)   
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5.5 Discussion 
This chapter aims to compare in vitro findings of HS sulphation changes resulted in 
modulation of interaction with biotinylated FGF2 and phage display antibodies 
with an in vivo model of renal fibrosis.  The UUO kidney model was created by 
double ligation of the left ureter for 7 and 14 days.  Changes in UUO kidney were 
studied using H&E staining, immunofluorescence and immunohistochemistry.  
Furthermore, expression of HS modifying genes during UUO was examined with 
qPCR. 
5.5.1 Observation on fibrosis markers 
Fibrotic markers were investigated in this study in UUO kidney to confirm that 
fibrosis is induced by day 7 after induction of UUO.  In this study, investigation of 
collagen I and α-SMA showed significant upregulation in UUO kidney compared 
to normal kidney.  The increased expression of collagen I in UUO kidney is 
considered an indication of fibrosis and renal scarring (Kelynack et al., 1999).  The 
current result is consistent with previous research showing increased collagen 
deposition in the context of UUO fibrosis (Wright et al., 1996).   
Another example of fibrosis development in the UUO kidney was shown by 
investigation of α-SMA.  Results show that UUO kidney significantly increased the 
expression of α-SMA compared to wild type kidney.  This result is in line with 
previously reported interstitial fibrosis (Alpers et al., 1994).  Additionally, this 
result is in agreement with the involvement of myofibroblasts in the synthesis of α-
SMA during interstitial fibrosis (Badid et al., 2002).   
5.5.2 Observation on HS changes 
The 10E4 monoclonal antibody was used in frozen sections to determine the 
abundance of N-sulphated epitopes in normal and UUO kidney.  This study shows 
that the 10E4 epitope was significantly increased in the UUO kidney compared to 
wild type kidney, mainly located in basement membrane and peritubular spaces.  
The 10E4 antibody targets N-acetyl/N-sulphate domains of HS structure (David et 
al., 1992).  This result is in agreement with literature showing that the 10E4 
antibody and N-sulphation epitope were associated with biological activities of 
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chronic disease such as wound healing and proliferation of epithelial cells (Celie et 
al., 2008).  Furthermore, Morita et al. found that in renal interstitial fibrosis (unlike 
glomerulosclerosis), the 10E4 epitope was increased alongside FGF2 binding 
epitope in the expanded peritubular interstitium (Morita et al., 1994a).  However, 
earlier work in our group showed increased expression of 10E4 antibody in acute 
and moderate rejection of kidney whereas no significant increase in chronic 
rejection was noticed (Unpublished data from Dr. Spielhofer 2010).   
Phage display antibodies were used to increase understanding of HS changes in the 
UUO model.  Frozen sections were stained with HS3A8, HS4C3 and RB4EA12 
antibodies.  This study showed significantly increased expression of these HS 
epitopes in UUO kidney compared to wild type kidney.  The HS3A8 antibody 
targets a complex HS epitope composed mainly of trisulphated disaccharides 
IdoA2S-GlcANS6S (Dennissen et al., 2002), whereas HS4C3 antibody targets a 
domain of IdoA2S-GlcNS3S6S (van Kuppevelt et al., 1998).  This result is in line 
with earlier unpublished work in our group which showed increased expression of 
HS3A8 and HS4C3 epitopes in chronic rejection of liver and kidney grafts (Dr. 
Spielhofer).  Importantly, it has been shown recently that HS deposition in liver 
cirrhosis is correlated with changes in HS modification machinery; the HS4C3 
epitope was accumulated in chronic liver disease as well as in rat liver fibrogenesis.  
This deposition includes in addition to blood vessels, basement membrane and 
epithelial bile ducts (Tatrai et al., 2010).   
Targeting the HS4C3 epitope using a specific antibody resulted in inhibition of the 
stimulatory effect of FGF2 on human mesangial cell (HMC) proliferation, 
suggesting a similarity between FGF2 and HS4C3 epitope binding domains of HS 
(Lensen et al., 2005).  Conversely, addition of FGF2 antibodies inhibited the 
binding of HS4C3 by about 60% (Lensen et al., 2005).  These findings support the 
hypothesis that upregulation of HS4C3 in UUO kidney is an indicator of the 
regulation of effector factors, such as FGF2, which have a crucial role on graft 
fibrosis.   
The targeting of tubular basement membrane by both FGF2 and the phage display 
antibodies might indicate increased FGF2 binding alongside increased synthesis of 
antibody epitopes.  FGF2 binding was linked to tubulointerstitial injury in human 
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kidney, suggesting a further involvement of the effector in tubular epithelial cell 
growth and proliferation (Morita et al., 1994b).  The increased expression of 
HS4C3 indicates to a potential role of the 3-O sulphate groups in the HS 
involvement in fibrosis pathology.  This is in agreement with previously reported 
high expression of the HS3ST1 gene in failed grafts compared to non-failed graft or 
normal kidney (Einecke et al., 2010).  
Furthermore, this study shows that staining frozen sections with the RB4EA12 
antibody showed increased deposition of a related HS epitope in UUO kidney 
compared to wild type kidney.  The RB4EA12 antibody targets an HS epitope 
composed of disaccharide with N-Acetyl/N-sulphate with 6-O sulphate (IdoA-
GlcNS6S) (Dennissen et al., 2002).  The RB4EA12 epitope was mainly localized 
in the thickened basement membrane and peritubular spaces of dilated ducts in 
UUO kidney (Figure 5.15).  It has been reported that RB4EA12 stains proximal 
tubules in human kidney (Lensen et al., 2005).  The current upregulation reflects a 
moderate increase in HS 6-O sulphation in UUO kidney.  This is in agreement with 
increased expression of RB4EA12 in human fibrogenic disease including liver 
cirrhosis and focal nodular hyperplasia (Tatrai et al., 2010).  In fact, this increase 
seems consistent with suggested roles of N- and 6-O sulphation changes in HS 
regulation during fibrogenic renal disease.   
5.5.3 Observation on mRNA level 
To further investigate changes in HS in renal fibrosis, additional experiments were 
performed to measure the expression of HS modifying enzymes at mRNA level 
using qPCR.  Genes encoding NDST1, HS6ST1, SULF1 and SULF2 were 
investigated in reference to the HPRT1 housekeeping gene.  Results show that 
expression of the 6-O endosulphatase SULF1 and SULF2 are significantly changed 
by UUO.   
The SULF2 gene was downregulated by about 40% whereas SULF1 was 
upregulated by 3-fold in UUO tissue compared to wild type (Figure 5.17).  The 
sulphatase enzymes remove 6-O sulphate group from a substrate containing Ido2S-
GlcNS6S (Dhoot et al., 2001; Ai et al., 2006a).  The current result is also in 
agreement with recent data showing that SULF1 expression is increased (6 fold) in 
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chronic liver cirrhosis (Tatrai et al., 2010).  Interestingly, this study shows no 
changes in NDST1 and HS6ST1 expression in UUO mice at mRNA level despite 
the increase in N- and 6-O sulphate epitopes noticed in UUO staining.   This can be 
justified by the presence of three isoforms for HS6ST and four isoforms for NDST 
which catalyze the same reaction.  
Heparan sulphate was shown to undergo changes during acute and chronic 
diseases.  Several publications have reported changes in HS modifying enzymes 
following cell stimulation by proinflammatory cytokines.  For example, stimulation 
of glomerular endothelial cells with IFN-γ caused increased expression of NDST1 
on mRNA level which increased sulphation at the N- position and , thereafter, 
enhanced the chemokine presentation and leucocyte migration (Carter et al., 2003). 
The current study shows differential regulation of SULF1 and SULF2 in the UUO 
kidney.  This is in agreement with a previous research which showed also that each 
enzyme has independent expression in the same tissue (Lai et al., 2004a; Lai et al., 
2008b).  These data are further supported by HS regulation in lupus nephritis, 
where SULF2 expression was decreased by 2 fold with no detectable changes in 
SULF1expression (Rops et al., 2008).   
Taken together, these findings confirm the importance of HS modifying enzymes 
and demonstrate several manners of regulation of HS biology in health and disease.  
Although the mechanism of HS regulation is not clear, this molecule exhibits a 
range of modifications which enhance its cytokine binding and presenting 
activities.  The SULF2 expression following TGF-β stimulation of HK2 cells along 
with increased SULF1 expression in UUO kidney suggests a potential role for these 
enzymes in the pathology of kidney fibrosis.   
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6.1 Summary of findings 
6.1.1 Introduction 
Heparan sulphate is involved in a variety of biological activities including 
development, carcinogenesis and inflammation.  It is involved in interaction with a 
wide range of proinflammatory cytokines and growth factors which play essential 
roles in the inflammatory response and graft rejection.  Interestingly, HS undergoes 
several modifications during embryonic life, carcinogenesis and inflammation 
(Hacker et al., 2005; Lai et al., 2008a; Huynh et al., 2012).  In chronic rejection, 
for instance, modification to HS sulphation enhances the binding, concentration 
and activity of TGF-β, IFN-γ, chemokines and FGF2. The interaction between 
proteins and HS requires to a large extent specific binding motifs on HS with 
unique sulphation patterns (Lindahl, 2007).  Sulphation of HS undergoes 
significant changes during acute kidney rejection (Ali et al., 2005a) and chronic 
liver cirrhosis (Tatrai et al., 2010). 
6.1.2 Effect of HS6ST1 on FGF2 binding 
Fibroblast growth factor 2 plays a key role in the pathology of renal fibrosis and 
EMT.  This factor stimulates the proliferation of fibroblasts and mesangial cells and 
induces the secretion of TGF-β, which stimulates the EMT process (Strutz and 
Zeisberg, 2006).   
Many enzymes are involved in HS synthesis and modification.  For FGF2 binding, 
the binding motif on HS must include N-sulphate and 2-O sulphate groups 
(Guimond et al., 1993; Faham et al., 1996).  The HS6ST enzymes transfer 6-O 
sulphate to the C6 position of glucosamine within the HS structure.  This 6-O 
sulphate plays a significant role in the binding of a variety of cytokines and growth 
factors to HS (Lyon et al., 1994b; Feyzi et al., 1997).  This group is also essential 
for FGF2-FGFR signalling and subsequent mitogenic activity (Pye et al., 1998).   
HS6ST1 is a highly expressed isoform of the HS6ST enzyme (Habuchi et al., 2003; 
Smeds et al., 2003).  Stable transfectants of renal epithelial cells with HS6ST1 
overexpression were generated to investigate the changes in HS structure and 
biological activity produced by this enzyme.  These transfectants show for the first 
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time that overexpression of HS6ST1 significantly increases the binding of FGF2 to 
these cells.  This was accompanied with an increase in ERK activation and 
proliferation.  Although 6-O sulphate is not a major component of the FGF2 
binding motif, which also contains NS and 2-OS modifications (Ishihara et al., 
1994; Kreuger et al., 2001), the increase in FGF2 binding represents a novel and 
interesting result.  
Despite intensive study of the heparin/HS binding motif for FGF2, no unique 
binding sequence has been completely described (Esko and Selleck, 2002).  In the 
FGF2 binding domain, the N- and O-sulphate groups are located in a way that 
allows HS-protein interaction to take place.  The location of N- and 2-O sulphate 
groups along with chain length and overall O-sulphation seems more important for 
HS interaction than the specific distribution of sulphate groups (Jastrebova et al., 
2006).  In conclusion, the HS-FGF2 binding does not depend completely on any 
single unique sequence but on the combination of several components (Mulloy and 
Rider, 2006).  
The increase in FGF2 binding was accompanied with increased expression of HS 
epitopes specific for the HS3A8, HS4C3 and RB4EA12 monoclonal antibodies.  
Earlier results have shown competition between HS4C3 antibody and FGF2 
binding to HS.  Treatment of human mesangial cells (HMC) with the HS4C3 
antibody also resulted in inhibition of the stimulatory effect of FGF2 on HMC 
proliferation.  Similarly, treatment of these cells with FGF2 inhibited the binding of 
HS4C3 (Lensen et al., 2005).  Therefore, the increased binding of HS4C3 by 
HS6ST1 transfectants indicates that the function of HS can change following 
HS6ST1 overexpression during renal fibrosis.   
Upregulation of the HS3A8 and RB4EA12epitopes on the HS6ST1 overexpressing 
cells suggests that additional changes in HS chemistry can occur following 
HS6ST1 overexpression during renal fibrosis.  An increase in RB4EA12 binding 
has also been reported in chronic liver cirrhosis and suggests a potential role for 
increased expression of the 6-O sulphate group in fibrogenesis (Tatrai et al., 2010).   
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6.1.3 The effect of HS6ST1 over-expression on HS structure 
The structure of HS was examined using 
35
S radioactive isotope and disaccharide 
analysis following deaminative cleavage (aManR) and HPLC (in collaboration with 
Prof. Marion Kusche-Gullberg in Norway).  The overexpression of HS6ST1 has an 
important effect on disaccharide structure and distribution.  This includes increased 
mono-O sulphated disaccharides (GlcA-GlcNS6S and IdoA-Glc-NS6S) and 
decreased trisulphated disaccharides (GlcA2S-GlcNS6S and IdoA2S-Glc-NS6S).  
This result is consistent with an earlier report describing specific substrates for 
HS6ST1 enzyme which prefers non-sulphated glucoronic acid (GlcA-GlcNAc) 
rather than 2-O sulphated iduronic acid residue (IdoA2S-GlcNS) (Habuchi et al., 
2000).   
The changes observed in HS structure include an increase in NA/NS domains 
following HS6ST1 overexpression; this is in agreement with earlier literature (Do 
et al., 2006).  Interestingly, no changes in the overall 6-O sulphation were found 
following HS6ST1 overexpression.  This may be attributed to the high degree of 
sulphation of HS produced by wild-type HK2 cells; hence the addition effect could 
not be seen. 
6.1.4 The biological effect of SULF2 overexpression 
Endosulphatase enzymes are the final modifying enzymes in HS synthesis 
(Lamanna et al., 2006).  These enzymes (SULF1 and SULF2) remove 6-O sulphate 
groups from the HS chain on the cell surface and the extracellular matrix.  In order 
to mimic the role of inflammatory cytokines on HS degradation, renal epithelial 
cells were stimulated with cytokines and investigated for the expression of HS 
degrading enzymes by qPCR.  Interestingly, stimulation with TGF-β increased the 
gene expression of SULF2 by 5 fold compared to resting cells.  This result is 
similar to literature previous report that stimulation with TGF-β can induce the 
expression of SULF1 in lung fibroblasts in vitro and in vivo (Yue et al., 2008).   
To shed more light on HS changes following SULF2 overexpression, stable SULF2 
transfectants were generated and investigated for changes in HS biology.  These 
transfectants were examined for binding to biotinylated FGF2.  Interestingly, 
SULF2 transfectants showed reduced FGF2 binding to their cell surface.  
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Consistently, SULF2 transfectants also showed reduced binding of the HS3A8, 
HS4C3 and RB4EA12 antibodies.  This is consistent with a previous report 
showing that changes in the expression of the HS4C3 epitope were paralleled by 
similar changes in FGF2 binding (Lensen et al., 2005).  Thus, the reduced binding 
of FGF2, HS3A8 and HS4C3 to SULF2 transfectants might be consistent with an 
anti-fibrotic effect of SULF2 overexpression; this is opposite to the effect of 
HS6ST1 overexpression (Table 6.1).   
 
Table 6.1. A summary of FGF2 and phage display antibody binding with HS6ST1 
and SULF2 transfectants FGF2 and phage display antibodies. 
In accordance with previous findings, SULF2 transfectants have less ERK 
activation compared to mock transfectants.  Removal of 6-O sulphate groups is 
expected to affect FGF-FGFR signalling and, consequently, ERK activation 
(Guimond et al., 1993; Dai et al., 2005).  The same can be said about the 
proliferation of SULF2 transfectants which showed a reduced proliferation rate 
compared to mock transfectants.  Previous researchers have found that 6-O 
endosulphatase enzymes have a negative effect on proliferation and mitogenic 
activity (Dai et al., 2005; Kamimura et al., 2006).   
HS changes following SULF2 overexpression also resulted in decreased binding 
and presentation of the chemokine CCL5.  Binding of CCL5 to HS depends on N- 
and O-sulphation.  Therefore, changes in HS sulphation can explain the modulation 
of CCL5 presentation (Shaw et al., 2004). 
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6.1.5  Effect of SULF2 overexpression on HS structure 
The effect of overexpression of SULF2 was examined by incubating SULF2 
transfectants with radioactive 
35
S and analyzing the disaccharide structure using 
deaminative cleavage (aManR) followed by HPLC.  These changes show that 
SULF2 removes 6-O sulphate groups from trisulphated disaccharides as a substrate 
target.  This is consistent with previous literature (Ai et al., 2003b; Ai et al., 
2006b).  Additionally, this result shows that the SULF2 enzyme removes the 6-O 
sulphate from disulphated disaccharides (GlcA-GlcNS6S and IdoA-GlcNS6S). 
Interestingly, SULF2 overexpression had a significant effect not only on 6-O 
desulphation but also on 2-O and N-sulphation.  Desulphation of the 6-O group was 
accompanied by upregulation of 2-O sulphation, which is consistent with previous 
results (Ai et al., 2006b).  This study also shows a mild downregulation of N-
sulphation following SULF2 overexpression.  By contrast, no significant changes 
in N- or 2-O sulphation were found in TGF-β induced SULF1 overexpression in 
vitro and in vivo in lung fibroblasts (Yue et al., 2008).  SULF1 overexpression in 
Drosophila produces no compensatory increase of 2-O sulphation (Kamimura et 
al., 2006).  The effect of 6-O desulphation on N- and 2-O sulphation might be 
related to the level of expression of the gene.  Changes in sulphation and structure 
are mostly responsible for the changes in physiological functions and antibody 
binding.  These changes explain the different roles that HS might have during 
inflammation processes and the mechanism which affects HS regulation. 
6.1.6 Changes of HS sulphation in the UUO mouse model 
UUO mice constitute an in vivo model of chronic fibrosis with increased expression 
of fibrosis markers such as α–SMA and collagen I.  UUO mice were generated 
after 7 days of double ligation of the ureter.  Frozen sections of the kidney were 
stained with phage display antibodies.  Results show significant upregulation of HS 
epitopes required for binding the 10E4, HS3A8, HS4C3 and RB4EA12 antibodies.  
Upregulation of the binding of these antibodies suggests changes in HS chemistry 
during kidney fibrosis.  HS3A8 and HS4C3 epitopes were also upregulated in 
fibrotic, rejected renal allografts, as shown earlier in this group (Dr. Spielhofer).  
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Interestingly, these changes were similar to those observed for HS6ST1 
transfectants, whereas the opposite was found in SULF2 transfectants (Table 6.1).   
In the case of the 10E4 antibody, UUO sections showed an increase in 10E4 
epitope expression whereas HS6ST1 transfectants expressed less of the 10E4 
epitope.  Earlier work showed that this epitope was upregulated in acute and 
moderate rejection but not in chronic renal allograft rejection (unpublished data by 
Dr. Spielhofer).  Expression of the 10E4 epitope in chronic fibrotic kidney with 
interstitial fibrosis (but not with glomerular sclerosis) has also been reported 
(Morita et al., 1994b).  
 
Figure 6.1. A summary of the effect of changes in HS sulphation on the biology of 
renal epithelial cells and the development of UUO pathology. 
Further investigations of the expression of HS modifying enzymes in UUO kidney 
were performed at the mRNA level by qPCR. These investigations show a 
significant increase in expression of SULF1 with a decrease in SULF2.  However, 
no significant changes were noticed for NDST1 or HS6ST1.  Again, upregulation 
                       General discussion  
182 
 
of SULF1 highlights the role of this enzyme in regulation of HS biology during 
chronic renal fibrosis.  It seems that tissues undergoing fibrosis have a different 
response to HS regulation.  Stimulation of renal epithelial cells with TGF-β 
increased the expression of SULF2 with no changes in SULF1 (chapter 4).  
Interestingly, it has been reported that SULF1 expression is increased following 
TGF-β stimulation of pulmonary fibroblasts in vitro and in vivo whereas SULF2 
expression did not show any significant changes (Yue et al., 2008). 
Therefore, these results suggest that HS undergoes significant changes following 
the overexpression of HS6ST1 and SULF2.  After HS6ST1 overexpression, HS 
shows an increased ability to bind FGF2 and phage display antibodies (HS3A8, 
HS4C3 and RB4EA12).  The increased expression of these epitopes might lead to a 
profibrotic environment which is enhanced by the increased anti-coagulant activity 
associated with the existence of the 3-OS component of the HS4C3 epitope (AT-III 
binding site), (Girardin et al., 2005).  Importantly, the SULF2 transfectants undergo 
reverse modifications including downregulation of binding to FGF2, HS3A8, 
HS4C3 and RB4EA12.  An in vivo model of kidney fibrosis showed significant 
upregulation of binding properties of HS3A8, HS4C3 and RB4EA12 antibodies 
accompanied with increased expression of SULF1 on mRNA.  These changes did 
not include HS6ST1 expression which might be related to an increase in alternative 
isoforms (HS6ST2 or HS6ST3).   
Taken together, these results suggest that the 6-O sulphation of HS has an 
important role in fibrogenesis associated with renal rejection..  
6.2 Implication of this study 
Specific targeting of HS6ST as a therapeutic intervention might have value for the 
prolongation of renal allograft survival.  For example, blocking the interaction of 
cytokines such as TGF-β or FGF2 with HS might allow the graft to escape a variety 
of profibrotic events.  HS targeting might include the use of soluble heparin-like 
molecules with limited anticoagulant activity but high affinity for pro-inflammatory 
and -fibrotic cytokines.  This requires knowledge of the specific HS sequences 
involved in cytokine binding.  Addition of such specific sequences might more 
potently delay (or even prevent) chronic renal allograft graft fibrosis.  This kind of 
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treatment might also complement the main immunosuppressive drugs which are 
used after transplantation. 
The same can be said for the phage display HS-specific antibodies.  Non 
immunogenic humanized antibodies might be used to block HS domains which 
bind FGF2; this may reduce FGF2-induced fibrogenic effects.  Recent data has 
shown that an anti-FGF2 antibody has the ability to inhibit the proliferation of 
hepatocellular carcinoma cells and the growth of carcinoma cell lines in nude mice 
(Wang et al., 2012).  
Exploring the changes in HS during chronic renal rejection could provide 
prognostic information of relevance for clinical therapy.  For example, regular 
examination of urine-secreted HS fragments in comparison to normal HS shedding 
might provide a non-invasive early warning of graft pathology. 
6.3 Future work  
There are a number of questions arising from this study.  Answers to these 
questions will certainly improve our understanding of the role of HS in renal 
fibrosis. 
1. Heparan sulphate undergoes a series of modifications due to the effect of several 
modifying enzymes.  These enzymes transfer sulphate groups to the HS chains 
which affects their biological activity.  This study examined the changes made by 
overexpression of HS6ST1 and SULF2.  Overexpression of additional enzymes 
will provide more information about HS structure and biological activities.   
2. Heparan sulphate plays a crucial role in inflammation and leucocyte migration.  6-
O sulphation is known to be crucial for cell adhesion mediated by L- and P-
selectin (Wang et al., 2002).  Cell lines with overexpression of HS6ST1, SULF1, 
SULF2 and other modifying enzymes could be used in leucocyte rolling assays 
under controlled shear pressure (using platforms such as the Cellix system) for 
examination of the effect of HS modification on leucocyte rolling and adhesion. 
3.  The effect of HS6ST1 and SULF2 on HS structure might be examined using 
additional procedures such as NMR and mass spectrometry (MS).   
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4. Increased expression of 6-O sulphate was shown in fibrotic UUO kidney and 
accompanied with increased FGF2 binding (Figure 5.11, 5.13 and 5.15).  Use of a 
soluble heparinoid or GAG mimetic with an ability to bind cytokines and growth 
factors should reduce the biological activity of these factors and inhibit allograft 
fibrosis.  A good example of this strategy is the use of low molecular weight 
heparin (Tinzaparin) to inhibit the binding between chemokine CXC12 and its 
receptor CXCR4, which reduced the metastatic spread of human breast cancer 
(Harvey et al., 2007). 
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 Appendices 
A. Verification of HS6ST1 sequence cloned in vector with HS6ST1 
transfectants using reverse BGH primers 
 Score = 1652 bits (859), Expect = 0.0, Identities = 917/933 (98%), Gaps = 5/933 
(0%)  Strand=Plus/Minus 
Que 570 ACTACATCACCCTGCTACGAGACCCCGTGTCCCGCTACCTGAGCGAGTGGCGGCATGTGC 629 
 |||||||||||  |||||||||||||   ||||| ||||||||||||||||||||||||| 
Sbj 986 ACTACATCACCN-GCTACGAGACCCCNNNTCCCGNTACCTGAGCGAGTGGCGGCATGTGC 928 
Que 630 AGAGGGGTGCCACGTGGAAGACGTCGTTGCATATGTGTGATGGGCGCACGCCCACGCCTG 689 
 ||||||||  |||||| ||||||||||||||||||||||||||||||||||||||||  | 
Sbj 927 AGAGGGTN--CACGNG-AAGACGTCGTTGCATATGTGTGATGGGCGCACGCCCACGNN-G 872 
Que 690 AGGAGCTGCCGCCCTGCTACGAGGGCACGGACTGGTCGGGCTGCACGCTACAGGAGTTCA 749 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 871 AGGAGCTGCCGCCCTGCTACGAGGGCACGGACTGGTCGGGCTGCACGCTACAGGAGTTCA 812 
Que 750 TGGACTGCCCGTACAACCTGGCCAACAACCGCCAGGTGCGCATGCTGGCCGACCTGAGCC 809 
 ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbj 811 TGGACTGCCCGTACAACCTGGCCAACAACCGCCAGGTGCGCATGCTGGCCGACNTGAGCC 752 
Que 810 TGGTGGGCTGCTACAACCTGTCCTTCATCCCCGAGGGCAAGCGGGCCCAGCTGCTGCTCG 869 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 751 TGGTGGGCTGCTACAACCTGTCCTTCATCCCCGAGGGCAAGCGGGCCCAGCTGCTGCTCG 692 
Que 870 AGAGCGCCAAGAAGAACCTGCGGGGCATGGCCTTCTTCGGCCTGACCGAGTTCCAGCGCA 929 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 691 AGAGCGCCAAGAAGAACCTGCGGGGCATGGCCTTCTTCGGCCTGACCGAGTTCCAGCGCA 632 
Que 930 AGACGCAGTACCTGTTCGAGCGGACGTTCAACCTCAAGTTCATCCGGCCCTTCATGCAGT 989 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 631 AGACGCAGTACCTGTTCGAGCGGACGTTCAACCTCAAGTTCATCCGGCCCTTCATGCAGT 572 
Que 990 ACAATAGCACGCGGGCGGGCGGCGTGGAGGTGGATGAAGACACCATCCGGCGCATCGAGG 1049 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 571 ACAATAGCACGCGGGCGGGCGGCGTGGAGGTGGATGAAGACACCATCCGGCGCATCGAGG 512 
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Que 1050 AGCTCAACGACCTGGACATGCAGCTGTACGACTACGCCAAGGACCTCTTCCAGCAGCGCT 1109 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 511 AGCTCAACGACCTGGACATGCAGCTGTACGACTACGCCAAGGACCTCTTCCAGCAGCGCT  452 
Que 1110 ACCAGTACAAGCGGCAGCTGGAGCGCAGGGAGCAGCGCCTGAGGAGCCGCGAGGAGCGTC 1169 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 451 ACCAGTACAAGCGGCAGCTGGAGCGCAGGGAGCAGCGCCTGAGGAGCCGCGAGGAGCGTC 392 
Que 1170 TGCTGCACCGGGCCAAGGAGGCACTGCCGCGGGAGGATGCCGACGAGCCGGGCCGCGTGC 1229 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 391 TGCTGCACCGGGCCAAGGAGGCACTGCCGCGGGAGGATGCCGACGAGCCGGGCCGCGTGC 332 
Que 1230 CCACCGAGGACTACATGAGCCACATCATTGAGAAGTGGTAGTGGCGGTGGTGGCCACGGG 1289 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 331  CCACCGAGGACTACATGAGCCACATCATTGAGAAGTGGTAGTGGCGGTGGTGGCCACGGG 272 
Que 1290 GAGGCCTCTTGGGGGGTGTGGGGGATAAAACAGGACAGACGACAGGTCCACCCAAGACTG 1349 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 271 GAGGCCTCTTGGGGGGTGTGGGGGATAAAACAGGACAGACGACAGGTCCACCCAAGACTG 212 
Quey 1350 TCAAGGGATGAGCATCCCAAACCTGCTCCACAGAGGTAGCTGCGTCCTGAAAAAAAACAG 1409 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjc 211 TCAAGGGATGAGCATCCCAAACCTGCTCCACAGAGGTAGCTGCGTCCTGAAAAAAAACAG 152 
Query 1410 AGCAGGGATGTAGTGGGGCTGGGCAGGGATGGGGGCTTGAGAAATCAACAGGTGCAGCCC 1469 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 151 AGCAGGGATGTAGTGGGGCTGGGCAGGGATGGGGGCTTGAGAAATCAACAGGTGCAGCCC 92 
Query 1470 AGTGGGTCAGAGGAAAGCGTGCTCGAAGGATGC 1502 
           ||||||||||||||||||||||||||||||||| 
Sbjct 91   AGTGGGTCAGAGGAAAGCGTGCTCGAAGGATGC 59 
CPU time:     0.05 user secs.     0.03 sys. secs     0.08 total secs. 
B.    Insert SULF2 align with human SULF2 using –bGHR  
Score = 1749 bits (947), Expect = 0.0, Identities = 998/1028 (97%), Gaps = 
13/1028 (1%) 
 Strand=Plus/Plus, >lcl|62673, Length=1071 
 
References  
217 
 
 
Que 2 GGGCCCCCCGAGCCTCGTGCTGTGCTTGCTGTCCGCAACTGTGTTCTCCCTGCTGGGTGG 61 
       |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 34 GGGCCCCCCGAGCCTCGTGCTGTGCTTGCTGTCCGCAACTGTGTTCTCCCTGCTGGGTGG 93 
Que 62 AAGCTCGGCCTTCCTGTCGCACCACCGCCTGAAAGGCAGGTTTCAGAGGGACCGCAGGAA 121       
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 94 AAGCTCGGCCTTCCTGTCGCACCACCGCCTGAAAGGCAGGTTTCAGAGGGACCGCAGGAA 153 
Que 122 CATCCGCCCCAACATCATCCTGGTGCTGACGGACGACCAGGATGTGGAGCTGGGTTCCAT 181        
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 154 CATCCGCCCCAACATCATCCTGGTGCTGACGGACGACCAGGATGTGGAGCTGGGTTCCAT 213 
Que 182 GCAGGTGATGAACAAGACCCGGCGCATCATGGAGCAGGGCGGGGCGCACTTCATCAACGC 241       
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 214 GCAGGTGATGAACAAGACCCGGCGCATCATGGAGCAGGGCGGGGCGCACTTCATCAACGC 273 
Que 242 CTTCGTGACCACACCCATGTGCTGCCCCTCACGCTCCTCCATCCTCACTGGCAAGTACGT 301 
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbj 274 CTTCGTGACCACACCCATGTGCTGCCCCTCACGCTCCTCCATCCTCACCGGCAAGTACGT 333 
Que 302 CCACAACCACAACACCTACACCAACAATGAGAACTGCTCCTCGCCCTCCTGGCAGGCACA 361 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 334 CCACAACCACAACACCTACACCAACAATGAGAACTGCTCCTCGCCCTCCTGGCAGGCACA 393 
Que 362 GCACGAGAGCCGCACCTTTGCCGTGTACCTCAATAGCACTGGCTACCGGACAGCTTTCTT 421 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 394 GCACGAGAGCCGCACCTTTGCCGTGTACCTCAATAGCACTGGCTACCGGACAGCTTTCTT 453 
Que 422 CGGGAAGTATCTTAATGAATACAACGGCTCCTACGTGCCACCCGGCTGGAAGGAGTGGGT 481 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sb 454 CGGGAAGTATCTTAATGAATACAACGGCTCCTACGTGCCACCCGGCTGGAAGGAGTGGGT 513 
Que 482 CGGACTCCTTAAAAACTCCCGCTTTTATAACTACACGCTGTGTCGGAACGGGGTGAAAGA 541 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 514 CGGACTCCTTAAAAACTCCCGCTTTTATAACTACACGCTGTGTCGGAACGGGGTGAAAGA 573 
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Que 542 GAAGCACGGCTCCGACTACTCCAAGGATTACCTCACAGACCTCATCACCAATGACAGCGT 601 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 574 GAAGCACGGCTCCGACTACTCCAAGGATTACCTCACAGACCTCATCACCAATGACAGCGT 633 
Que 602 GAGCTTCTTCCGCACGTCCAAGAAGATGTACCCGCACAGGCCAGTCCTCATGGTCATCAG 661 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 634 GAGCTTCTTCCGCACGTCCAAGAAGATGTACCCGCACAGGCCAGTCCTCATGGTCATCAG 693 
Que 662 CCATGCAGCCCCCCACGGCCCTGAGGATTCAGCCCCACAATATTCACGCCTCTTCCCAAA 721 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 694 CCATGCAGCCCCCCACGGCCCTGAGGATTCAGCCCCACAATATTCACGCCTCTTCCCAAA 753 
Que 722 CGCATCTCAGCACATCACGCCGAGCTACAACTACGCGCCCAACCCGGACAAACACTGGAT 781 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 754 CGCATCTCAGCACATCACGCCGAGCTACAACTACGCGCCCAACCCGGACAAACACTGGAT 813 
Que 782 CATGCGCTACACGGGGCCCATGAAGCCCATCCACATGGAATTCACCAACATGCTCCAGCG 841 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbj 814 CATGCGCTACACGGGGCCCATGAAGCCCATCCACATGGAATTCACCAACATGCTCCAGCG 873 
Que 842 GAAGCGCTTGCAGACCCTCATGTCGGTGGACGACTCCATGGAGACGATTTACAACATGCT 901 
        ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbj 874 GAAGCGCTTGCAGACCCTCATGTCGGTGGACGACTCCATGGAGACNATTTACAACATGCT 933 
Que 902 GG-TTGAGACGGGCGAGCT-GGACAACACGTACATCGTATACACCGCCGACCACGGTTAC 959 
        || |||||| ||||||||| ||| |  |||||||||||||||||||||||||||     | 
Sbj 934 GGNTTGAGANGGGCGAGCTNGGANAN-ACGTACATCGTATACACCGCCGACCACNNN--C 990 
Qu 960 CACATCGGCCAGTTTGGCCTGGTGAAAGGGAAATCCATGCCATATGAGTTTGAC ATCAG 1018 
          ||||| |    ||||     |  |||||| |||||||||||||||||||| ||  ||| | 
Sb 991 CACATNGNN--GTTTNNN--GN-GAAAGG-AAATCCATGCCATATGAGTT-GANNATCNG 1043 
Query 1019 GGTCCCGT 1026 
           |||||||| 
Sbjct 1044 GGTCCCGT 1051 
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C. HS structure analysis (S35) 
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 Disaccharide SULF2C SULF2+ 6OST1C 6OST1+  
     % of O-
35
S labeled disaccharides 
 
GMS   13 ± 1  1.5 ± 0.5 16 ± 2  27 ± 3 
IMS   10 ± 1  1.3 ± 0.2 8.5 ± 1.5 16.5 ± 3.5 
ISM   30 ± 2  68 ± 1  14 ± 1  8 ± 0 
ISMS   46.5 ± 3.5 29 ± 0.3 70.5 ± 6.5 49 ± 6 
 
    SULF2C  SULF2+     6OST1C  6OST1+ 
          % of O-35S labeled disaccharides 
 
2-O containing disaccharides 76     97     84       57 
6-O containing disaccharides 69     32              95       92 
 
C, mock transfected 
+, overexpressing cells 
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D. HS6ST1 transfectants binding to CCL5 
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